

BEFORE THE
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE
AND THE
APPLICATION REVIEW SUBCOMMITTEE
TO THE
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE
ORGANIZED PURSUANT TO THE
CALIFORNIA STEM CELL RESEARCH AND CURES ACT
REGULAR MEETING

LOCATION: OAKLAND MARRIOTT CITY CENTER
1001 BROADWAY
OAKLAND, CALIFORNIA

DATE: JULY 23, 2015
9 A.M.

REPORTER: BETH C. DRAIN, CSR
CSR. NO. 7152

BRS FILE NO.: 97739

BARRISTERS' REPORTING SERVICE

I N D E X

ITEM DESCRIPTION	PAGE NO.
REPORTS & DISCUSSION ITEMS	
1. CALL TO ORDER.	4
2. PLEDGE OF ALLEGIANCE.	4
3. ROLL CALL.	4
4. CHAIRMAN'S REPORT.	6
5. PRESIDENT'S REPORT.	15
PROPOSED CONSENT CALENDAR ITEMS 6-9	34
6. CONSIDERATION OF APPOINTMENT OF NEW SCIENTIFIC MEMBERS AND REAPPOINTMENT OF CURRENT SCIENTIFIC MEMBERS TO THE GRANTS WORKING GROUP.	
7. CONSIDERATION OF MINUTES FROM THE MAY ICOC BOARD MEETING.	
8. CONSIDERATION OF AMENDMENTS TO CIRM MEDICAL AND ETHICAL STANDARDS.	
9. CONSIDERATION OF AMENDMENTS TO THE CIRM CONFLICT OF INTEREST CODE.	
ACTION ITEMS	
10. CONSIDERATION OF AMENDMENTS TO CONCEPT PLAN FOR CLINICAL STAGE PROJECTS AND ALLOCATION OF ADDITIONAL FUNDING FOR CLINICAL STAGE PROJECTS FOR FY15/16.	35
11. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO PA 15-02 (PARTNERING OPPORTUNITY FOR CLINICAL TRIAL STAGE PROJECTS) AND PA 15-03 (PARTNERING OPPORTUNITIES FOR SUPPLEMENTAL ACCELERATING ACTIVITIES).	40

BARRISTERS' REPORTING SERVICE

I N D E X (CONT'D.)

12. CONSIDERATION OF CONCEPT PLAN FOR THE DISCOVERY STAGE PROGRAM ANNOUNCEMENTS.	53
13. CONSIDERATION OF CONCEPT PLAN FOR THE TRANSLATION STAGE PROGRAM ANNOUNCEMENTS.	121
14. CONSIDERATION OF CONCEPT PLAN FOR THE BRIDGES PROGRAM.	140
15. CONSIDERATION OF CONCEPT PLAN FOR THE SUMMER PROGRAM TO ACCELERATE REGENERATIVE MEDICINE KNOWLEDGE (FORMERLY CREATIVITY) PROGRAM.	151
16. CONSIDERATION OF AUGMENTATION TO THE REMCHO JOHANSEN & PURCELL, LLP CONTRACT.	156
CLOSED SESSION	---
17. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS FOR PA 15-02: PARTNERING OPPORTUNITY FOR CLINICAL TRIAL STAGE PROJECTS; PA 15-03: PARTNERING OPPORTUNITIES FOR SUPPLEMENTAL ACCELERATING ACTIVITIES. (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C)).	
DISCUSSION ITEMS	
18. SPOTLIGHT ON DISEASE	NOT REPORTED
19. COMMUNICATIONS REPORT	159
20. PUBLIC COMMENT.	30

BARRISTERS' REPORTING SERVICE

1 OAKLAND, CALIFORNIA; THURSDAY, JULY 23, 2015

2 9 A.M.

3
4 CHAIRMAN THOMAS: EVERYBODY PLEASE TAKE
5 YOUR SEATS. GOOD MORNING TO EVERYBODY FROM THE
6 DOWNTOWN OAKLAND MARRIOTT. WELCOME TO THE JULY
7 MEETING OF THE ICOC. MARIA, PLEASE LEAD US IN THE
8 PLEDGE OF ALLEGIANCE.

9 (PLEDGE OF ALLEGIANCE.)

10 CHAIRMAN THOMAS: MARIA, WILL YOU PLEASE
11 CALL THE ROLL.

12 MS. BONNEVILLE: DAVID BRENNER. KEN
13 BURTIS.

14 DR. BURTIS: HERE.

15 MS. BONNEVILLE: ANNE-MARIE DULIEGE. LEON
16 FINE.

17 DR. FINE: HERE.

18 MS. BONNEVILLE: ELIZABETH FINI.

19 DR. FINI: HERE.

20 MS. BONNEVILLE: MICHAEL FRIEDMAN. JUDY
21 GASSON.

22 DR. GASSON: HERE.

23 MS. BONNEVILLE: SAM HAWGOOD. DAVID
24 HIGGINS.

25 DR. HIGGINS: HERE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: STEPHEN JUELSGAARD.
2 SHERRY LANSING. KATHY LAPORTE. JACOB LEVIN.

3 DR. LEVIN: HERE.

4 MS. BONNEVILLE: BERT LUBIN. LAUREN
5 MILLER. LLOYD MINER. ADRIANA PADILLA.

6 DR. PADILLA: HERE.

7 MS. BONNEVILLE: JOE PANETTA. ROBERT
8 PRICE.

9 DR. PRICE: HERE.

10 MS. BONNEVILLE: FRANCISCO PRIETO.

11 DR. PRIETO: HERE.

12 MS. BONNEVILLE: ROBERT QUINT. AL
13 ROWLETT.

14 MR. ROWLETT: HERE.

15 MS. BONNEVILLE: JEFF SHEEHY.

16 MR. SHEEHY: HERE.

17 MS. BONNEVILLE: OSWALD STEWARD.

18 DR. STEWARD: HERE.

19 MS. BONNEVILLE: JONATHAN THOMAS.

20 CHAIRMAN THOMAS: HERE.

21 MS. BONNEVILLE: ART TORRES.

22 MR. TORRES: HERE.

23 MS. BONNEVILLE: KRISTINA VUORI. DONNA
24 WESTON. DIANE WINOKUR.

25 CHAIRMAN THOMAS: OKAY. THANK YOU VERY

BARRISTERS' REPORTING SERVICE

1 MUCH. WE'LL PROCEED NOW TO THE CHAIR'S REPORT.
2 NUMBER OF THINGS I WANTED TO TELL YOU FOLKS ABOUT.
3 I WANTED TO START OFF REITERATING AN E-MAIL YOU ALL
4 RECEIVED; BUT JUST IN CASE YOU DIDN'T GET A CHANCE
5 TO READ IT AND FOR THOSE IN THE AUDIENCE, I WANT TO
6 PERSONALLY CONGRATULATE OUR OWN VICE CHAIR SENATOR
7 ART TORRES FOR HIS CONFIRMATION BY THE STATE SENATE
8 TO BE A MEMBER OF THE HEALTH BENEFIT EXCHANGE BOARD,
9 WHICH IS THE BODY THAT'S SET UP TO OVERSEE OBAMACARE
10 ON BEHALF OF THE CITIZENS OF THE STATE OF
11 CALIFORNIA.

12 NOW, THIS WAS A RECENT NOMINATION AND
13 CONFIRMATION AND IS A GREAT THING FOR US TO HAVE
14 SENATOR TORRES THERE ON BEHALF OF US AND THE
15 CITIZENS. SENATOR TORRES, COULD YOU JUST PERHAPS
16 JUST SAY AN ADDITIONAL WORD ABOUT THE BODY?

17 MR. TORRES: WELL, FIRST, IT'S PRO BONO.
18 BUT THIS AGENCY WAS CREATED -- IT IS A STATE AGENCY
19 MUCH LIKE WE ARE WITH NO BUDGETARY IMPACT ON THE
20 STATE BUDGET; THEREFORE, IT'S VERY INDEPENDENT.
21 IT'S COMPOSED OF FIVE BOARD MEMBERS, ONE EACH FROM
22 EACH OF THE HOUSES OF THE LEGISLATURE WHICH WILL
23 OVERSEE OBAMACARE IN CALIFORNIA, COVER CALIFORNIA.
24 AND IT'S BASICALLY -- WE ARE THE LARGEST PURCHASER
25 OF HEALTHCARE IN THE STATE, AND MANY OF THE PLANS

BARRISTERS' REPORTING SERVICE

1 THAT WE'LL BE NEGOTIATING WITH, WHICH WILL BE
2 IMPORTANT, I BELIEVE, TO US, ESPECIALLY AS WE
3 PROCEED FURTHER INTO CLINICAL TRIALS AND AS
4 TREATMENTS BECOME AVAILABLE TO MAKE SURE THE
5 PATIENTS WILL BE ELIGIBLE FOR ASSISTANCE UNDER
6 OBAMACARE.

7 AND HERE IN CALIFORNIA WE HAVE SIGNED UP
8 ALREADY 1.8 MILLION PEOPLE TO BE COVERED UNDER COVER
9 CALIFORNIA. SO I'M PROUD TO BE PART OF THIS AND
10 LOOK FORWARD TO REPORTING BACK TO YOU PERIODICALLY
11 AS TO OUR PROGRESS AND HOW IT MAY VERY WELL IMPACT
12 WHAT WE ALL DO HERE. THANK YOU.

13 CHAIRMAN THOMAS: THANK YOU, MR. SENATOR.

14 IN EARLY JUNE I HAD THE PRIVILEGE OF
15 GIVING THE COMMENCEMENT SPEECH AT THE CEDARS-SINAI
16 GRADUATE PROGRAM IN BIOMEDICAL SCIENCE AND
17 TRANSLATIONAL MEDICINE. GOT TO PARTICIPATE WITH
18 DR. FINE AND DR. MELMED AND A HOST OF OTHER
19 DIGNITARIES FROM CEDARS. I WAS ABLE TO SPEND THE
20 ENTIRE DAY THERE REALLY DOING A DEEP DIVE INTO THAT
21 PROGRAM AND TO MANY OF THE THINGS THAT CEDARS HAS
22 GOING ON, AND IT WAS A FASCINATING DAY. I SPENT
23 BREAKFAST WITH THE GRADUATES. I MET WITH A NUMBER
24 OF OUR RESEARCHERS; CLIVE SVENDSEN, FOR EXAMPLE.
25 HAD LUNCH WITH ALL THE DEPARTMENT HEADS AT CEDARS,

BARRISTERS' REPORTING SERVICE

1 THEN HAD THE AFTERNOON CEREMONY, WHICH PERHAPS
2 DR. FINE COULD PROVIDE A BIT OF ADDITIONAL COLOR ON.
3 THEN A RECEPTION AND DINNER WITH DRS. FINE AND
4 MELMED, PRESIDENT TOM PRISELAC, AND OTHERS.

5 SO IT WAS A GREAT CHANCE TO REALLY SEE
6 IN-DEPTH THE QUALITY OF EVERYTHING THAT'S GOING ON
7 THERE, AND IT WAS A GREAT PRIVILEGE FOR ME.
8 DR. FINE, I DON'T KNOW IF YOU'D LIKE TO ADD A BIT ON
9 THAT.

10 DR. FINE: THEY HAVEN'T STOPPED TALKING
11 ABOUT HIS ADDRESS.

12 CHAIRMAN THOMAS: I HOPE THAT'S A POSITIVE
13 STATEMENT.

14 SO IN ADDITION TO THAT, I REPRESENTED CIRM
15 AT A NUMBER OF EVENTS THAT WERE FAR RANGING IN SCOPE
16 AND TYPE AND ATTENDANCE. WE HAD, AS YOU KNOW, THIS
17 YEAR'S MEETING OF THE INTERNATIONAL STEM CELL
18 RESEARCHERS, ISSCR. IT WAS IN HELD IN STOCKHOLM IN
19 LATE JUNE. AND I CAN REPORT, AS I ALWAYS DO, HAVING
20 GONE TO THESE MEETINGS, THAT IN SPEAKING WITH MANY
21 OF THE FOLKS THERE, EVERYBODY CONTINUES TO BE
22 GREATLY INTERESTED IN CIRM AND WHAT WE ARE DOING.
23 AND THE FEELING ALWAYS MAINTAINS, THAT COURTESY OF
24 THE WISDOM THE VOTERS OF CALIFORNIA, WE ARE THE
25 EPICENTER OF RESEARCH GIVEN THE GREAT FUNDING THAT

BARRISTERS' REPORTING SERVICE

1 WE HAVE. SO EVERYONE WANTS TO KNOW WHAT WE'RE
2 DOING, HOW THINGS ARE GOING, AND IT WAS ALWAYS A
3 PRIVILEGE, ALONG WITH A NUMBER OF OUR TEAM HERE, TO
4 REPRESENT CIRM AT THAT EVENT.

5 ONE OF THE THINGS WE DID, GEOFF LOMAX SET
6 UP A LUNCH WITH OUR COLLABORATIVE FUNDING PARTNERS
7 AND OTHER INTERESTED PARTIES. AND THE REASON FOR
8 SETTING THAT LUNCH UP, IN ADDITION TO UPDATING OUR
9 COLLABORATIVE PARTNERS, WAS TO MAKE THE POINT THAT
10 CIRM, UNDER DR. MILLS' LEADERSHIP AND CIRM 2.0, IS
11 ACTIVELY LOOKING TO ATTRACT THE BEST IN CLASS
12 PROJECTS FROM AROUND THE WORLD THAT COULD POSSIBLY
13 HAVE A NEXUS IN CALIFORNIA AND TO ENCOURAGE THEM TO
14 APPLY TO CIRM IN CONNECTION WITH WHATEVER THAT NEXUS
15 MIGHT BE, WHETHER IT'S RUNNING CLINICAL TRIALS IN
16 CALIFORNIA OR WHAT HAVE YOU.

17 THIS WHOLE NOTION OF LOOKING TO DO THAT IS
18 SOMETHING THAT GENERATED A LOT OF INTEREST AT ISSCR.
19 I SHARED SOME OF THIS WITH DR. MILLS, AND I BELIEVE
20 WE WILL BE GETTING SOME APPLICATIONS FROM FIRST-RATE
21 PROJECTS FROM OUTSIDE OF CALIFORNIA TO CIRM IN THE
22 FUTURE. SO I THINK THAT WAS A MEETING AND TIME VERY
23 WELL SPENT.

24 THE SPEAKERS, OF COURSE, AS ALWAYS, WERE
25 FASCINATING. THERE WERE MANY OF THE CIRM GRANTEES

BARRISTERS' REPORTING SERVICE

1 WHO WERE THERE AND EITHER SPOKE OR PARTICIPATED IN
2 THE PANELS AND ALL IN ALL A MOST INTERESTING EVENT.

3 FOLLOWING THAT, AN EVENT OF ANOTHER KIND,
4 I HAD THE PRIVILEGE OF SPEAKING TO THE HUNTINGTON
5 BEACH ROTARY CLUB AT THEIR LUNCH. THIS WAS A BIT OF
6 A DIFFERENT AUDIENCE, A BIT LESS SCIENTIFIC, BUT I
7 SHOULD SAY NONETHELESS INTERESTING. IN SPEECHES
8 LIKE THIS I TEND LESS TO SORT OF TALK CIRM AND
9 PORTFOLIO AND ALL THAT SORT OF THING, AND I TRY TO
10 GIVE THEM AN OVERVIEW OF CUTTING-EDGE DEVELOPMENTS
11 IN THE FIELD OF BIOLOGY OVER THE PAST 20 YEARS, SORT
12 OF STARTING WITH DOLLY THE SHEEP AND GOING FORWARD
13 AND FEATURING A NUMBER OF THE THINGS THAT OUR GREAT
14 RESEARCHERS HAVE DONE. IT'S A TALK THAT I THINK
15 GENERATES A LOT OF INTEREST. PEOPLE WANT TO HEAR
16 ABOUT SCIENCE, AND I THINK I HAD IT BROKEN DOWN IN
17 WHAT I HOPE IS SORT OF THE PLAIN ENGLISH WAY OF
18 SPEAKING.

19 IT'S SOMETHING THAT ADULTS, AND I'VE GIVEN
20 THIS TALK TO A NUMBER OF HIGH SCHOOL CLASSES AS
21 WELL, THAT IT'S ALL ABOUT TRYING TO GENERATE
22 INTEREST IN SCIENCE IN THE COMMUNITY EITHER WITH THE
23 ADULTS OR EVEN PERHAPS, MORE IMPORTANTLY, WITH
24 YOUNGER KIDS WHO ARE TRYING TO FIND THEIR WAY AND
25 ASSESS WHAT IT IS THAT THEY WOULD LIKE TO DO AS THEY

BARRISTERS' REPORTING SERVICE

1 MOVE THROUGH SCHOOL AND BEYOND.

2 WE HAD A NUMBER OF, DR. MILLS AND I AND
3 KEVIN MCCORMACK, HAD A NUMBER OF PATIENT ADVOCATE
4 TOWN HALLS UP AND DOWN THE STATE A COUPLE WEEKS AGO.
5 WE HAD SUCH MEETINGS IN SAN DIEGO. I SHOULD SAY
6 DR. HIGGINS, WHO WAS AT ALL OF THESE, GREAT
7 PARTICIPANT ON BEHALF OF THE BOARD AT SAN DIEGO. WE
8 HAD LOS ANGELES AND THEN WE HAD SAN FRANCISCO BACK
9 TO BACK TO BACK. THESE MEETINGS WERE DESIGNED FOR
10 DR. MILLS TO SORT OF PRESENT THE CURRENT STATE OF
11 PLAY WITH CIRM WITH A SPECIFIC EYE TOWARDS TALKING
12 ABOUT CONCEPTS THAT HE WOULD LIKE TO SEE
13 INCORPORATED INTO OUR STRATEGIC PLAN.

14 THESE MEETINGS WERE A GREAT OPPORTUNITY TO
15 HEAR FROM THE PATIENT ADVOCATES ABOUT CONCERNS THAT
16 THEY HAD, WHETHER IT HAD TO DO WITH THE STRATEGIC
17 PLAN OR OTHERWISE, AND I HOPE ARE BENEFICIAL TO
18 THOSE THAT ATTEND TO ALLOW THEM TO HEAR IN REAL-TIME
19 WHAT CIRM IS ABOUT AND HOW WE ARE PROCEEDING ALONG
20 PURSUING OUR MISSION. I THOUGHT ALL THE MEETINGS
21 WERE VERY INTERESTING. WE HAD A NUMBER OF FOLKS IN
22 SAN DIEGO WHO I BELIEVE ARE HERE TO SPEAK TO US AS
23 WELL, AND IT'S ALWAYS INSTRUCTIVE TO HEAR THEIR
24 COMMENTS.

25 ONE OF THE THINGS I WANTED TO HIGHLIGHT

BARRISTERS' REPORTING SERVICE

1 FROM THESE MEETINGS WAS AT THE LOS ANGELES MEETING,
2 WHICH WAS HELD AT USC, THEY HAD A NUMBER OF HIGH
3 SCHOOL KIDS WHO ARE GOING THROUGH THE CIRM-FUNDED
4 PROGRAM THERE WHO CAME TO HEAR DR. MILLS SPEAK, AND
5 I SPOKE TO A NUMBER OF THEM. AS IT HAPPENS, SOME
6 HAVE COME FROM THE HIGH SCHOOL WHERE MY KIDS ATTEND,
7 SO I KNEW A COUPLE OF THEM. AND IT'S ALWAYS
8 FASCINATING. AT THIS POINT THEY WERE TWO MONTHS
9 INTO THEIR PROGRAM, WHICH IS VERY INTENSE. AND IF
10 YOU LISTEN TO THESE KIDS, YOU'D THINK THEY WERE
11 SCIENTISTS. THEY'VE GOT THE LINGO DOWN, THEY WERE
12 TALKING ABOUT THE STUFF THEY'RE DOING IN THE LAB,
13 THEY'RE EXTREMELY ENTHUSIASTIC, ALL TO A PERSON VERY
14 APPRECIATIVE OF THE PROGRAM USC IS PUTTING AND CIRM
15 IS ENABLING THROUGH ITS FUNDING. JUST A DELIGHT TO
16 SEE THE LEVEL OF INTEREST AND ENTHUSIASM AND FURTHER
17 DRIVING HOME, I THINK, THE GREAT BENEFIT OF WHAT WAS
18 OUR CREATIVITY PROGRAM AND, AS YOU WILL HEAR TODAY,
19 IS NOW GOING TO BE RENAMED AS IS DESCRIBED TO THE
20 BOARD LATER IN THIS SESSION.

21 EQUALLY AS FANTASTIC WAS WE JUST HAD LAST
22 WEEK OUR ANNUAL MEETING OF THE BRIDGES STUDENTS,
23 WHICH SENATOR TORRES AND I ATTENDED. AND THIS, FOR
24 THOSE WHO'VE NEVER SEEN IT, IS A TWO-DAY SESSION
25 WHERE ALL THE BRIDGES STUDENTS ARE BROUGHT TOGETHER,

BARRISTERS' REPORTING SERVICE

1 AND THEY HEAR A NUMBER OF OUR PI'S GIVE TALKS ON
2 THEIR PARTICULAR ITEMS OF INTEREST. THEY HAVE A
3 CHANCE TO PRESENT THEIR POSTERS FOR THE WORK THAT
4 THEY HAVE BEEN DOING OVER THE COURSE OF THE YEAR.
5 AGAIN, IF YOU SAT AND LISTENED TO THEM, YOU'D THINK
6 THAT THEY'D BEEN IN THE FIELD OF REGENERATIVE
7 MEDICINE FOR QUITE SOME TIME.

8 DR. YAFFE PRESIDED OVER THIS MEETING AND
9 DID A WONDERFUL JOB IN PULLING IT ALTOGETHER, AS HE
10 DOES EVERY YEAR. THANK YOU, DR. YAFFE. ACTUALLY
11 COULD YOU JUST SAY A WORD OR TWO ON THIS, IF YOU
12 WOULD, BECAUSE IT'S SUCH A GREAT EVENT? I THINK
13 IT'S WORTH HEARING A BIT MORE DETAIL.

14 DR. YAFFE: THANK YOU, MR. CHAIRMAN.
15 WELL, WE HAD MORE THAN 200 PARTICIPANTS, STUDENTS,
16 FROM 16 DIFFERENT PROGRAMS FROM AROUND THE STATE,
17 FROM GEOGRAPHICALLY ALL OVER THE STATE FROM HUMBOLDT
18 TO SAN DIEGO AND CENTRAL VALLEY. AND IN BETWEEN WE
19 HAD SOME ARTISTS TALKS, NOT THE LEAST OF WHICH, I
20 THINK WAS AN INCREDIBLY INSPIRING TALK BY LAUREN
21 MILLER OF THIS BOARD ABOUT PATIENT ADVOCACY AND HER
22 OWN PERSONAL STORY. AND THEN SOME FABULOUS SCIENCE
23 TALKS. BUT, AGAIN, A KEY FOCUS IS MEETING THE
24 BRIDGES TRAINEES, HEARING ABOUT THEIR RESEARCH,
25 WHICH THEY PRESENT ON POSTERS, AND JUST HAVING AN

BARRISTERS' REPORTING SERVICE

1 OPPORTUNITY TO SEE THE INCREDIBLE POTENTIAL THAT'S
2 PRESENT IN THAT PROGRAM. AND REALLY APPRECIATE THE
3 SUPPORT OF CHAIRMAN THOMAS AND VICE CHAIRMAN TORRES
4 AND ALL OF YOU. I THINK THAT THIS HAS BEEN AN
5 INCREDIBLE EXPERIENCE FOR THE TRAINEES AND FOR ALL
6 OF US WHO PARTICIPATED.

7 CHAIRMAN THOMAS: THANK YOU, DR. YAFFE.
8 THANK YOU AGAIN FOR YOUR FINE WORK IN ADMINISTERING
9 THAT PROGRAM.

10 I DID WANT TO SHARE ONE ANECDOTE FROM ONE
11 EXCHANGE I HAD WHICH I THOUGHT YOU'D FIND KIND OF
12 NEAT. I WAS TALKING TO THREE KIDS WHO WERE STUDENTS
13 AT CAL STATE UNIVERSITY CHANNEL ISLANDS. THE THREE
14 ARE FROM INDIA. AND AS THEY DESCRIBED TO ME THE
15 REASON THAT THEY CAME FROM INDIA TO ATTEND CAL STATE
16 UNIVERSITY CHANNEL ISLANDS WAS SPECIFICALLY BECAUSE
17 THEY HAD THE BRIDGES PROGRAM. AND THEY HOPED TO BE
18 ABLE TO APPLY AND GET MEMBERSHIP IN IT AND TO GAIN
19 ACCESS TO ALL THE BENEFITS THAT THE PROGRAM
20 PROVIDES. SO I THOUGHT THAT WAS PRETTY COOL TO HAVE
21 KIDS FROM AROUND THE WORLD LITERALLY SEEKING OUT
22 COMING TO CALIFORNIA TO A PLACE THAT COULD GIVE THEM
23 THAT OPPORTUNITY. AND I THINK HE SPEAKS VOLUMES
24 ABOUT THE BENEFITS THAT THAT PROGRAM PROVIDES. IT,
25 TOO, WILL BE ON TODAY'S AGENDA FOR DISCUSSION AND

BARRISTERS' REPORTING SERVICE

1 CONSIDERATION OF RENEWAL.

2 SO IT'S BEEN A BUSY COUPLE MONTHS. I
3 THINK WITH THAT, I'M GOING TO TURN IT OVER TO DR.
4 MILLS TO GIVE THE PRESIDENT'S REPORT.

5 DR. MILLS: THANK YOU VERY MUCH, CHAIRMAN
6 THOMAS, MEMBERS OF THE BOARD, AND MEMBERS OF THE
7 PUBLIC WHO ARE HERE TODAY. I WILL GIVE MY
8 PRESIDENT'S REPORT AS I NORMALLY DO AND GO THROUGH A
9 FAIRLY EXTENSIVE REPORT STARTING WITH OUR MISSION.
10 I'M GOING TO PROVIDE AN UPDATE ON HOW OUR FOURTH
11 QUARTER IN 2015 WENT FROM A FINANCIAL PERSPECTIVE.
12 I'M GOING TO TALK A LITTLE BIT ABOUT HOW CIRM 2.0
13 CLINICAL IS DOING, AGAIN, JUST TO KEEP YOU GUYS
14 UPDATED AND TO MAKE SURE THAT WE'RE PROVIDING
15 REAL-TIME FEEDBACK ON WHAT WE LIKE AND WHAT WE DON'T
16 LIKE OUT OF THE PROGRAM.

17 WE HAVE A NEW HOME, WHICH I'LL BE
18 ANNOUNCING TODAY. I'LL BE INTRODUCING TO THIS BOARD
19 DR. RAMONA DOYLE, WHO IS OUR NEWEST MEMBER OF THE
20 CIRM LEADERSHIP TEAM. I'LL SAY A FEW BRIEF COMMENTS
21 ABOUT THE STRATEGIC PLAN AND THEN AN IDEA OF WHAT'S
22 COMING UP.

23 SO, AS ALWAYS, AS I PROMISED TO DO ALWAYS,
24 MAKE SURE THAT WE'RE ALL ON THE SAME PAGE WITH
25 REGARDS TO WHY WE'RE HERE AND WHY CIRM EXISTS. SO

BARRISTERS' REPORTING SERVICE

1 OUR MISSION IS TO ACCELERATE STEM CELL TREATMENTS TO
2 PATIENTS WITH UNMET MEDICAL NEEDS. AND I CONTINUE
3 TO PROMISE THAT EVERYTHING THAT WE DO AT CIRM WILL
4 BE ORIENTED TOWARDS ACCOMPLISHING THIS MISSION.

5 LET'S TAKE A BRIEF LOOK AT OUR FINANCIAL
6 FOURTH QUARTER. RECALL WE BASICALLY HAVE TWO
7 SEPARATE BUCKETS THAT WERE DESIGNATED UNDER
8 PROPOSITION 71. THE LARGER OF THOSE TWO BUCKETS IS
9 THE AWARD BUCKET. THAT'S THE \$2.75 BILLION BUCKET.
10 AND THEN A SMALLER BUCKET, THE ADMINISTRATIVE
11 BUCKET, WHICH WE FUND THE ACTUAL AGENCY OUT OF.

12 THE ADMINISTRATIVE BUCKET HAS MONEY FOR AT
13 LEAST ANOTHER FIVE YEARS, SPENDING OUT OF THAT
14 BUCKET AT THE ANTICIPATED RATE. THE CURRENT RATE IS
15 ABOUT 15 MILLION RIGHT NOW. WE DO EXPECT THAT TO
16 ACTUALLY COME DOWN A LITTLE BIT IN SOME OF THE
17 LATTER YEARS.

18 THE BIG BUCKET HAS \$1.97 BILLION, ABOUT
19 TWO BILLION OF IT THAT'S BEEN SPENT, LEAVING US
20 ABOUT 775 MILLION UNCOMMITTED. THE IMPORTANT THING
21 TO KNOW ABOUT THIS BUCKET IS THAT THAT UNCOMMITTED
22 NUMBER WILL FLUCTUATE AROUND AND EVEN SOMETIMES WILL
23 GO UP. AND THAT'S BECAUSE WHILE WE MIGHT MAKE A
24 COMMITMENT TO FUND A PROGRAM, IF THAT PROGRAM
25 ULTIMATELY TURNS OUT TO HAVE A PROBLEM OR STOPPED

BARRISTERS' REPORTING SERVICE

1 FOR SOME REASON, THAT MONEY COMES BACK OUT OF
2 UNCOMMITTED AND INTO THE AWARD BUCKET. SO IF WE
3 MAKE 190 TO \$200 MILLION A YEAR IN NEW AWARDS, WE
4 THINK THAT WOULD PUT US AT ABOUT \$107 MILLION NET
5 SPENDING, WHICH WOULD GIVE US THE OPPORTUNITY TO
6 FUND AT THAT RATE FOR ANOTHER FIVE YEARS OR THROUGH
7 FISCAL YEAR 2020. SO SORT OF THE TAKE HOME HERE IS
8 WE HAVE TWO THINGS, A LOT OF MONEY AND A LOT OF
9 TIME. AND SO WE NEED TO MAKE SURE THAT WE ARE DOING
10 EVERYTHING WE CAN TO USE THAT AS RESPONSIBLY AS WE
11 CAN.

12 SO HERE'S HOW IN THE FOURTH QUARTER,
13 TAKING AGAIN THE AWARD BUCKET, THESE NUMBERS MOVED
14 AROUND. SO WE MADE \$23 MILLION IN NEW AWARDS IN THE
15 FOURTH QUARTER, AND FORTUNATELY HAD NOT VERY MUCH IN
16 THE WAY OF REDUCTIONS, \$500,000 OF AWARD REDUCTION
17 AND 200,000 IN AWARD REPAYMENT.

18 IF YOU LOOK FOR THE YEAR, WE MADE \$130
19 MILLION IN AWARDS FOR FISCAL YEAR 2015. WE HAD \$28
20 MILLION OF REDUCTIONS AND ANOTHER MILLION IN
21 REPAYMENT. SO OUR NET COMMITMENT FOR THE YEAR WAS
22 ONLY 101 MILLION. SO WE'RE STILL NOT EVEN CLOSE TO
23 THE COMMITMENT RATE WHICH WE WOULD NEED TO GET TO OF
24 ABOUT 190 IN ORDER FOR US TO ACCOMPLISH OUR
25 FINANCIAL GOALS.

BARRISTERS' REPORTING SERVICE

1 HERE'S SOMETHING THAT I'M GOING TO SHOW
2 YOU. THIS IS AN EXAMPLE. THIS IS WHAT I WOULD LIKE
3 TO PROPOSE TO THE BOARD WE THINK ABOUT IN TERMS OF
4 FUNDING DECISIONS GOING FORWARD. WE'RE MOVING AWAY
5 FROM THE SORT OF POP-UP RFA'S THAT GET FUNDS GOING.
6 WE'RE MOVING MORE TOWARDS SUSTAINED PROGRAMS WHERE
7 THERE'S PREDICTABILITY. I'M GOING TO TALK A LOT
8 MORE ABOUT PREDICTABILITY WHEN WE TALK ABOUT THE
9 DISCOVERY AND TRANSLATIONAL ASPECTS. BASICALLY AT
10 CIRM WE FUND FIVE MAJOR PROGRAM AREAS: EDUCATION,
11 DISCOVERY, TRANSLATIONAL, CLINICAL, AND
12 INFRASTRUCTURE.

13 AND THIS IS JUST AN EXAMPLE. SO FOR 2016
14 THIS IS BASICALLY THE FUNDING THAT WE'RE ASKING FOR
15 FOR FISCAL YEAR 2016. ACTUALLY IF WE MAKE ALL THOSE
16 AWARDS, WE'LL ONLY GET OUR SPEND UP TO 150 MILLION
17 OUT OF 101. BUT YOU CAN SEE WHAT THIS ENABLES US TO
18 DO IS HAVE A CLEAR PICTURE OF OUR SPENDING GOING
19 FORWARD SO WE DON'T GET INTO A SITUATION AGAIN WHERE
20 WE'RE NOT SURE ABOUT THE FINANCIAL FUTURE OF THE
21 AGENCY OR WHERE WE STAND. WE'LL BE ABLE TO LOOK AT
22 IT VERY CLEARLY. IT WILL ALSO ENABLE THE BOARD TO
23 BE ABLE TO MAKE DECISIONS. SO SOMETHING MIGHT
24 HAPPEN AND WE MIGHT WANT TO SPEND MORE MONEY IN
25 EARLIER STAGE RESEARCH OR MORE MONEY IN LATER STAGE

BARRISTERS' REPORTING SERVICE

1 RESEARCH. SO WE CAN ADJUST THESE THINGS AND BE ABLE
2 TO HAVE A CLEAR PICTURE OF HOW THAT IMPACTS OUR
3 FUTURE GOING FORWARD. SO THAT'S ROUGHLY WHAT I
4 SAID.

5 THIS, BY WAY OF THAT EXAMPLE THAT I PUT
6 UP, WOULD BE ABOUT -- THAT WOULD BE A PRETTY TYPICAL
7 FUNDING SOLUTION FOR US. IF WE DID THAT AND SPENT
8 THE MONEY THE WAY THAT I PUT UP IN THE EXAMPLE, THAT
9 WOULD RESULT IN 193 NEW DISCOVERY AWARDS, 45 NEW
10 TRANSLATIONAL AWARDS, 50 NEW CLINICAL PROGRAMS, 50
11 NEW CLINICAL PROGRAMS, 1,125 STUDENTS TRAINED, AND A
12 SIGNIFICANT AMOUNT OF ACCELERATING INFRASTRUCTURE.
13 SO THE POINT OF THIS IS WE HAVE A LOT OF IMPACT LEFT
14 AT CIRM YET TO ACCOMPLISH.

15 SO TURNING NOW TO THE 2.0 REVIEW OF HOW
16 CLINICAL HAS GONE SO FAR. AGAIN, THE FIVE MAJOR
17 AREAS THAT WE FUND, INFRASTRUCTURE, DISCOVERY,
18 TRANSLATIONAL, CLINICAL, AND EDUCATION, THIS ONE IS
19 FOCUSING JUST ON THE CLINICAL SPAN OF THE BRIDGE
20 WITH CIRM 2.0 WHICH WE LAUNCHED. SO WE NOW THROUGH
21 JUNE HAVE HAD 17 APPLICATIONS COME IN UNDER THE
22 CLINICAL PORTION OF CIRM 2.0. THAT'S UP FROM ZERO
23 QUALIFIED APPLICATIONS LAST YEAR. SO FROM A DEMAND
24 STANDPOINT WE'RE DEFINITELY GETTING MORE DEMAND,
25 WHICH IS GREAT. I'M NOT GOING TO GO THROUGH EVERY

BARRISTERS' REPORTING SERVICE

1 ONE OF THESE APPLICATIONS HERE AND WHAT HAPPENED.
2 THEY'RE THERE.

3 THE SORT OF KEY POINTS I WANT YOU TO TAKE
4 AWAY ARE ONE IS THE DEMAND IS LEVELING DOWN MORE
5 CLOSELY TO WHAT WE THOUGHT IT WOULD BE. SO IN MAY
6 WE RECEIVED THREE APPLICATIONS, IN JUNE WE RECEIVED
7 TWO APPLICATIONS. THE REVIEW TEAM WAS VERY WORRIED
8 IN APRIL WHEN WE HAD FIVE APPLICATIONS BECAUSE
9 THAT'S MORE THAN WE ACTUALLY ANTICIPATED WE WOULD
10 HAVE, BUT IT SEEMS TO BE NORMALIZING DOWN AROUND THE
11 TWO OR THREE A MONTH AREA WHICH IS CLOSER TO WHAT WE
12 HAD PREDICTED.

13 ONE OTHER THING I WANT TO POINT OUT HERE
14 WHICH WAS NEAT IN APRIL IS WE SENT THREE PROGRAMS
15 FOR WHAT WE CALL BUDGET REVIEW. AND THAT'S BEFORE
16 WE SEND THESE THINGS TO THE GRANTS WORKING GROUP FOR
17 ACTUAL SCIENTIFIC ADJUDICATION, WE SEND THEM FOR
18 EXTERNAL BUDGET REVIEW TO MAKE SURE THAT THE BUDGETS
19 ARE APPROPRIATE FOR THE SCOPE OF WORK BEING OFFERED.
20 WE ACTUALLY HAD ONE FAIL. AND I LIKE THAT BECAUSE
21 THAT SAYS THAT SYSTEM IS WORKING. AND IF SOMETHING
22 IS GOING TO GO THROUGH THE PROCESS AND HAVE A BUDGET
23 THAT'S NOT JUSTIFIABLE, WE'RE ABLE TO CATCH IT AND
24 WE'RE ABLE TO KICK IT OUT. IN THIS CASE WE MADE
25 THEM GO BACK AND THINK THROUGH THEIR BUDGET A LITTLE

BARRISTERS' REPORTING SERVICE

1 MORE CLOSELY.

2 WITH ALL THAT SAID, IT SEEMS TO BE WORKING
3 WELL FROM A METRICS STANDPOINT. WE'RE VERY PLEASED.
4 ONLY IN JANUARY DID WE HAVE THE ONE DELAY, AND WE
5 HAVEN'T HAD AN OFF MARK SINCE.

6 NEXT UP I'D LIKE TO TELL YOU ABOUT OUR NEW
7 HOME. SO AS EVERYONE KNOWS FROM THE PREVIOUS BOARD
8 MEETINGS, OUR LEASE AT OUR CURRENT FACILITY, OUR
9 KING STREET FACILITY, IS UP. IT WAS A VERY GOOD
10 LEASE. IT WAS TEN YEARS AND IT WAS FREE. SO THAT
11 WAS HARD TO FIND. AND SO WE HAD TO COME UP WITH A
12 NEW PLACE TO LIVE, AND IT WAS A PROCESS LED BY
13 SENATOR TORRES. AND HE DID A GREAT JOB REALLY
14 LOOKING AT EVERYTHING THAT WAS AVAILABLE. WE HAD TO
15 WEIGH A LOT OF DIFFERENT OPTIONS, NO. 1 BEING
16 DISRUPTION TO THE TEAM, BUT ALSO ACCESS TO PUBLIC
17 TRANSPORTATION AND OBVIOUSLY FINANCIAL
18 CONSIDERATIONS.

19 BECAUSE OF THE FINANCIAL PARTS OF THAT
20 CONSIDERATION, WE WILL BE LEAVING SAN FRANCISCO. SO
21 OUR NEW HOME IS 1999 HARRISON STREET IN OAKLAND,
22 JUST DOWN THE STREET FROM HERE. SO WE'RE A LITTLE
23 EXCITED ABOUT IT, BUT CHANGE IS VERY DIFFICULT, AND
24 IT'S GOING TO BE HARD, AND WE ARE JUST GOING TO HAVE
25 TO WORK THROUGH IT AS A TEAM.

BARRISTERS' REPORTING SERVICE

1 SPEAKING OF TEAM, ONE OF THE THINGS WE'VE
2 DONE SINCE THE LAST BOARD MEETING I'M VERY PLEASED
3 OF IS WE'VE HAD A SIGNIFICANT ADDITION TO OUR TEAM.
4 WE'VE HIRED A VICE PRESIDENT OF THERAPEUTICS.
5 THAT'S RAMONA DOYLE. WE PUT OUT A PRESS RELEASE
6 ABOUT IT IN ADDITION WITH THE OTHER MEMBERS OF THE
7 LEADERSHIP TEAM THAT WERE PROMOTED, MARIA MILAN AND
8 MARIA BONNEVILLE. DR. DOYLE IS A NEW ENTRY TO US.
9 COMES TO US FROM GENENTECH WHERE SHE DID DRUG
10 DEVELOPMENT WORK INTERNATIONALLY AND PARTICULARLY
11 THE PULMONARY DIVISION. SHE'S A RHODES SCHOLAR.
12 SHE HAD HER MEDICAL DEGREE FROM EMORY UNIVERSITY.
13 SHE DID HER RESIDENCY AND FELLOWSHIP AT UCSF IN
14 PULMONOLOGY. SHE'S A CLINICIAN. SHE STILL SEES
15 PATIENTS ON THE SIDE. SHE'S A PROFESSOR OF MEDICINE
16 AT STANFORD WHERE SHE LED THE PULMONARY TRANSPLANT
17 UNIT. AND WE ARE VERY, VERY PLEASED TO BE ABLE HAVE
18 SOMEBODY WITH THAT ACADEMIC, CLINICAL, AND DRUG
19 DEVELOPMENT BACKGROUND. AND SO WE'RE REALLY PLEASED
20 THAT RAMONA HAS JOINED OUR TEAM.

21 (APPLAUSE.)

22 DR. MILLS: NOW ON THE STRATEGIC PLANNING
23 PROCESS, THIS IS SOMETHING WE WERE GOING TO BRING UP
24 AT THIS BOARD MEETING, BUT FOR IN-PERSON ATTENDANCE
25 REASONS, WE THOUGHT IT WOULD BE BEST TO SHIFT OFF TO

BARRISTERS' REPORTING SERVICE

1 THE SEPTEMBER MEETING, WHICH IS GOOD BECAUSE IT'S
2 ALLOWED ME A LOT MORE TIME TO INTERACT WITH VARIOUS
3 STAKEHOLDERS, WHICH WE'VE BEEN DOING, WHICH HAVE
4 BEEN NOT ONLY A LOT OF FUN, BUT ALSO VERY
5 INSIGHTFUL. AND SO AS WE GO AROUND, WE REALLY ARE
6 LISTENING. I THINK WE'RE COMING UP WITH A BETTER
7 PLAN.

8 I TALKED ABOUT LAST TIME SORT OF THE
9 DEMYSTIFICATION OF THE STRATEGIC PLANNING STUFF.
10 REALLY THERE'S ONLY THREE THINGS YOU DO IN STRATEGIC
11 PLANNING AT THE END OF THE DAY. FIRST IS YOU HAVE
12 TO HONESTLY EVALUATE WHERE YOU ARE. SECONDLY, YOU
13 HAVE TO EVALUATE WHERE IT IS YOU WANT TO GO. AND
14 THEN THE THIRD THING IS FIGURING OUT HOW IT IS
15 YOU'RE GOING TO GET THERE. AND THAT'S THE STRATEGY
16 PART OF THE STRATEGIC PLAN.

17 WHAT WE'RE DOING AT CIRM AND SORT OF THE
18 PROMISE I'LL MAKE THAT WHAT WE'RE GOING TO GET WHEN
19 WE COME BACK IS WE'RE NOT LOOKING TO BE GOOD THROUGH
20 THIS PROCESS. WE'RE NOT SEEING IF WE CAN EKE OUT
21 THE REMAINDER OF OUR EXISTENCE. WE'RE LOOKING TO BE
22 OUTSTANDING, TO BE TRULY REMARKABLE IN WHAT WE DO.
23 SO WE'RE BEING VERY CREATIVE IN PUTTING PRETTY MUCH
24 EVERYTHING ON THE TABLE THAT COULD POSSIBLY BE
25 CONSIDERED IN ORDER FOR US TO ACCOMPLISH OUR

BARRISTERS' REPORTING SERVICE

1 MISSION.

2 ONE OF THE THINGS I'M VERY HAPPY ABOUT IS
3 MISSION CONFIRMATION IS ONE OF THE FIRST THINGS THAT
4 YOU DO IN THE STRATEGIC PLANNING PROCESS. THAT'S
5 THE WHERE YOU ARE. IT'S PART OF THE WHERE YOU ARE
6 PROCESS. AND WHAT I LIKE IS WE WERE ABLE TO CONFIRM
7 AT LEAST THAT WE HAD OUR MISSION RIGHT. EVERY
8 SUBSET OF RESPONDENTS FROM THE SURVEYS THAT WE SENT
9 OUT, PEOPLE WE ASKED CONFIRMED, AND THE BOARD DID
10 UNANIMOUSLY CONFIRM, THAT WE HAVE AT LEAST AGREEMENT
11 AROUND OUR MISSION. AND SO THAT'S A GOOD PLACE FOR
12 US TO START.

13 EVERYTHING WE'RE GOING TO DO IS TOWARDS
14 DRIVING THAT MISSION AND DOING AS BEST WE CAN ON
15 THAT MISSION. AND BASICALLY, JUST TO PREVIEW, IF
16 YOU THINK ABOUT GETTING STEM CELL TREATMENTS TO
17 PATIENTS AS TRYING TO PUSH A BOULDER OVER A HILL,
18 WE'VE BEEN SO FAR IN THE PUSH BUSINESS. WE'RE GOING
19 TO CONTINUE TO DO THAT. A LOT OF WHAT WE SEE WITH
20 CIRM 2.0 IS VERY OPERATIONAL STUFF ASSOCIATED WITH
21 HOW WE PUSH AND PUSH HARDER ON THIS BOULDER TO GET
22 IT OVER THIS HILL.

23 ONE OF THE THINGS WE HAVEN'T DONE YET AND
24 WHICH WE KNOW THERE ISN'T SUFFICIENT DEMAND RATE FOR
25 NOW IS INDUSTRY PULL. SO WE'RE NOT HAVING ENOUGH

BARRISTERS' REPORTING SERVICE

1 INDUSTRY GETTING ENGAGED IN HELPING US FROM THE
2 OTHER SIDE OF THAT EQUATION TO PULL US OVER.

3 THE THIRD THING THAT JUST JUMPED OFF THE
4 PAGE WITH REGARDS TO FEEDBACK THAT WE'VE GOTTEN FROM
5 ALL THESE DIFFERENT STAKEHOLDERS, FROM ALL THE
6 VARIOUS METHODS IS THAT THE NO. 1, BIGGEST
7 IMPEDIMENT THAT PEOPLE PERCEIVE, THEY'RE PROBABLY
8 RIGHT, TO BRINGING STEM CELL TREATMENTS TO PATIENTS
9 IS THE REGULATORY ENVIRONMENT THAT WE'RE IN RIGHT
10 NOW. SO YOU CAN KIND OF THINK ABOUT THAT AS THE
11 SIZE OF THE HILL. AND HAVING LIVED IT IN INDUSTRY
12 AND DEVELOPING STEM CELL DRUGS, THE HILL IS
13 DISPROPORTIONATELY LARGE, PARTICULARLY WHEN YOU
14 COMPARE IT AGAINST SOME OF THE THINGS THAT PATIENT
15 GROUPS ARE FACING. WE NEED TO ALSO FIGURE OUT HOW
16 WE WORK WITH THE FOOD AND DRUG ADMINISTRATION TO
17 COME UP WITH NOVEL, INTERESTING PARADIGMS SO WE CAN
18 ACTUALLY LOWER THAT HILL. SO THE STRATEGY IS A SORT
19 OF PUSH-PULL AND TO MAKE THE HILL SMALLER IF WE CAN
20 DO THAT.

21 THINGS TO COME. WHAT'S UP? SO IN
22 SEPTEMBER YOU'LL HAVE THE DRAFT STRATEGIC PLAN.
23 WE'LL ALSO HAVE A CONCEPT PLAN FOR THE ACCELERATING
24 CENTER. THIS WAS THE OTHER PIECE ORIGINALLY
25 CONTEMPLATED BY THE ALPHA CLINICS PROPOSAL. THROUGH

BARRISTERS' REPORTING SERVICE

1 THE REMAINDER OF THE YEAR WE ARE INITIATING WHAT WE
2 CALL CIRM 2.0 CORE, WHICH IS NOW THAT WE'VE --
3 HOPEFULLY AFTER TODAY, WE'LL HAVE ALL OF THE
4 DEVELOPMENT AREAS FOR WHAT WE CALL 2.0. WE NEED TO
5 DO IT INTERNALLY TOO AND HAVE OUR INTERNAL
6 OPERATIONS, ADMINISTRATION, I.T., AND THE LIKE, UP
7 TO 2.0 STANDARDS.

8 WE'RE OBVIOUSLY GOING TO BE RELOCATING.
9 THAT'S GOING TO BE ROUGH, AND WE HAVE TO FIND A WAY
10 TO DO IT WITHOUT DISRUPTION. AND THEN WE HAVE TO
11 OPERATIONALIZE THESE NEW PLANS, THE DISCOVERY PLAN,
12 THE TRANSLATION, CREATIVITY, AND BRIDGES PROGRAM,
13 AND NOT SKIP A BEAT ON THE CLINICAL SIDE. SO WE
14 HAVE A PRETTY BUSY REST OF 2015, BUT I THINK WE HAVE
15 A GREAT TEAM AND WE'RE UP FOR IT.

16 WITH THAT, I WILL STOP TALKING. IF
17 ANYBODY HAS ANY QUESTIONS, I'LL BE HAPPY TO ANSWER.

18 MR. TORRES: FIRST OF ALL, I WANT TO THANK
19 DR. MILLS AND THE STAFF WHO WORKED SO HARD FOR A
20 YEAR TO TRY AND FIND US A NEW OFFICE BUILDING.
21 ALSO, MY GRATITUDE TO MAYOR LEE OF SAN FRANCISCO,
22 WHO REALLY TRIED TO FIND US A PROPERTY FOR OVER A
23 YEAR AND EVEN PROVIDED ALTERNATIVES THAT WERE JUST
24 SO EXPENSIVE. AND WE WERE FORTUNATE TO FIND THIS
25 LOCATION AND TO HAVE A TEAM THAT WORKED ON IT, WITH

BARRISTERS' REPORTING SERVICE

1 THE LEADERSHIP OF DR. MILLS, TO MAKE SURE THAT THE
2 TRANSITION WILL BE EASY FOR STAFF. AND IT WILL BE A
3 BURDEN ON SOME STAFF FOR COMMUTING, NO QUESTION
4 ABOUT IT, BUT I THINK WE CAME TO THE RIGHT DECISION.
5 AND WE HAVE A VERY FRIENDLY, ACCEPTING MAYOR HERE IN
6 OAKLAND WHO HAS BEEN VERY HELPFUL SO FAR IN RESPECT
7 TO THESE ACCOMMODATIONS. AND I THINK IT'S IMPORTANT
8 TO SAY THANK YOU TO THOSE PEOPLE THAT WORKED ON THIS
9 PROJECT. JAMES HARRISON BECAME A REAL ESTATE LAWYER
10 IN THE PROCESS. AND CHILA SILVA-MARTIN, AMANDA, AND
11 MARIE AND OTHERS WHO WORKED SO HARD ON MAKING THIS
12 TRANSITION.

13 IT'S ALSO IMPORTANT TO KNOW THAT BECAUSE
14 OF LT. GOVERNOR GAVIN NEWSOM'S SOLUTION TEN YEARS
15 AGO TO GIVE US FREE RENT FOR TEN YEARS AND FREE
16 PARKING FOR TEN YEARS SAVED THE STATE OF CALIFORNIA
17 \$12 MILLION. SO THAT'S NOT -- THAT'S A FIGURE THAT
18 NEEDS TO BE REPEATED. WE SAVED THE STATE \$12
19 MILLION BECAUSE OF THE EFFORTS OF MAYOR NEWSOM, THE
20 DOLBYS, AND OTHERS WHO CONTRIBUTED TO OUR RESIDENCY
21 AT 200 KING SAVED THE TAXPAYERS AND THE IMPACT THAT
22 IT HAD ON THE BUDGET IN CALIFORNIA AND CLEARLY
23 ALLOWED US TO HAVE MORE MONIES AVAILABLE FOR
24 RESEARCH. SO I THINK IT'S QUITE LAUDABLE FOR LT.
25 GOVERNOR NEWSOM, AND ALSO TO MAYOR LEE, THANK YOU.

BARRISTERS' REPORTING SERVICE

1 AND NOW WE MOVE ON TO A NEW ERA. AND, AGAIN, I'M
2 JUST SO GRATEFUL FOR THE LEADERSHIP THAT WE'VE HAD
3 FROM DR. MILLS. THANK YOU.

4 CHAIRMAN THOMAS: THANK YOU, SENATOR
5 TORRES. I'D JUST LIKE TO ADD CONGRATULATIONS AS
6 WELL. THIS WAS A VERY LENGTHY AND SOMEWHAT ARDUOUS
7 PROCESS THAT HAS YIELDED WHAT I THINK WILL BE A
8 GREAT NEW HOME FOR CIRM WHICH WE'RE LOOKING FORWARD
9 TO.

10 I PERSONALLY HAVE ENJOYED BEING AT THE 210
11 KING STREET ADDRESS FOR A VARIETY OF REASONS, NOT
12 THE LEAST OF WHICH IS I GOT A CHANCE TO LOOK DOWN ON
13 THE MANY GIANTS FANS MILLING IN AND OUT. I HAD TO
14 GET THAT ON THE RECORD. ANYWAY, THANK YOU, SENATOR
15 TORRES, FOR YOUR COMMENTS.

16 SO, DR. MILLS, DOES THAT CONCLUDE YOUR
17 REPORT?

18 DR. GASSON: I JUST WANTED TO THANK DR.
19 MILLS AND GIL SAMBRANO AND THE STAFF WHO CAME TO
20 VISIT OUR CAMPUS AND THE OTHER CAMPUSES TO TALK
21 ABOUT THE EXCITING NEW PROGRAMS IN BASIC RESEARCH,
22 DISCOVERY, TRANSLATION, AND CREATIVITY. IT WAS A
23 FANTASTIC MEETING. IT REALLY GOT ALL THE SCIENTISTS
24 ENGAGED. I KNOW IT'S A HASSLE FOR YOU GUYS TO
25 TRAVEL AROUND, BUT IT WAS REALLY VERY EXCITING AND A

BARRISTERS' REPORTING SERVICE

1 GREAT LAUNCH TO THIS PROGRAM. SO THANK YOU VERY
2 MUCH.

3 DR. MILLS: IT'S OUR PLEASURE.

4 DR. LEVIN: I'LL SECOND THAT MOTION.

5 CERTAINLY THANK YOU FOR ALSO COMING TO OUR CAMPUS
6 AND NOT MAKING US GO UP TO UCLA OR CITY OF HOPE AS
7 WAS ORIGINALLY DISCUSSED. WE HAD A VERY GOOD
8 SHOWING, AND I THINK EVERYBODY REALLY APPRECIATED
9 THE AMOUNT OF COMMUNICATION AND THE ABILITY TO HAVE
10 FEEDBACK AND INTERACT AND REALLY UNDERSTAND CIRM 2.0
11 ACROSS THE WHOLE INSTITUTION.

12 DR. MILLS: I'LL MAKE A COMMENT ABOUT THAT
13 TOO IS FOR THOSE OF YOU WHO WERE IN THOSE MEETINGS,
14 I THINK YOU COULD PROBABLY TELL THAT WASN'T A
15 BOX-CHECKING EXERCISE. THAT WAS A REAL HONEST
16 SERIES OF DISCUSSIONS THAT WE HAD. AND I'LL TELL
17 YOU THE PROGRAMS THAT WE'RE GOING TO PUT UP TODAY
18 WITH REGARDS TO DISCOVERY AND TRANSLATION ARE BETTER
19 BECAUSE OF IT. WE REALLY WERE GETTING BETTER AND
20 LEARNING FROM YOU GUYS. WE VERY MUCH APPRECIATE THE
21 TIME AND THE FEEDBACK.

22 CHAIRMAN THOMAS: ANY OTHER QUESTIONS FOR
23 DR. MILLS? THANK YOU VERY MUCH.

24 MARIA.

25 MS. BONNEVILLE: I JUST WANT TO CONFIRM

BARRISTERS' REPORTING SERVICE

1 THAT BOARD MEMBERS HAVE JOINED US ON THE PHONE.
2 LAUREN MILLER. LLOYD MINER. WE'LL CHECK. WE'RE
3 OBVIOUSLY HAVING SOME HEARING ISSUES, SO WE'LL GET
4 BACK.

5 CHAIRMAN THOMAS: THANK YOU. NEXT ITEM IS
6 THE CONSENT CALENDAR, WHICH, AS YOU CAN SEE,
7 INCLUDES ITEMS 6 THROUGH 9.

8 MR. HARRISON: WE NEED TO ADDRESS THE
9 TECHNICAL ISSUE BECAUSE WE NEED THOSE MEMBERS IN
10 ORDER TO OBTAIN A QUORUM.

11 CHAIRMAN THOMAS: THANK YOU.

12 (PAUSE IN PROCEEDINGS.)

13 CHAIRMAN THOMAS: SO WHILE WE'RE TRYING TO
14 SORT OUT OUR TECHNICAL DIFFICULTIES, I THINK WE'RE
15 GOING TO TAKE SOMETHING OUT OF ORDER HERE TO
16 ACCOMMODATE A NUMBER OF FOLKS WHO MADE A LONG TRIP
17 UP TO OAKLAND TO GIVE A CHANCE FOR THEM TO TALK TO
18 US IN PUBLIC COMMENT. SO WE'RE GOING TO TAKE THAT
19 SEGMENT OUT OF ORDER AND PROCEED AT THIS POINT AND
20 ASK IF THERE ARE MEMBERS OF THE PUBLIC WHO WOULD
21 LIKE TO ADDRESS THIS BOARD. PLEASE, IF YOU WOULD,
22 EVERYBODY TELL US YOUR NAME AND REMEMBER THAT YOU
23 HAVE UP TO THREE MINUTES TO GIVE YOUR COMMENT.

24 MS. GOULD: OKAY. I'LL TALK FAST. MY
25 NAME IS SHERRIE GOULD. I AM A NURSE PRACTITIONER

BARRISTERS' REPORTING SERVICE

1 ACTUALLY AT SCRIPPS CLINIC IN LA JOLLA, CALIFORNIA.
2 AND I AM A SERIOUS PATIENT ADVOCATE FOR PARKINSON'S
3 DISEASE.

4 FOUR YEARS AGO DR. JEANNE LORING AND DR.
5 MELISSA HOUSER GOT TOGETHER, AND THEY BASICALLY HAD
6 A CONVERSATION THAT WENT LIKE THIS. DR. HOUSER
7 SAID, "I HAVE THE PATIENTS." DR. LORING SAID, "I
8 HAVE THE SCIENCE." AND WE DECIDED TO START A
9 RESEARCH PROJECT. THE PROBLEM WAS MONEY. WE DIDN'T
10 HAVE ANY MONEY. SO SUMMIT4STEM CELL WAS BORN FOUR
11 YEARS AGO FOR THE SOLE PURPOSE OF MAKING THIS HAPPEN
12 AND PROVIDING THE LONG-TERM THERAPY FOR PATIENTS
13 WITH PARKINSON'S.

14 FOUR YEARS HAVE GONE BY. WE HAVE WITH
15 BLOOD, SWEAT, AND TEARS, CLIMBING MOUNTAINS, BIKE
16 RIDES, PARTIES, FUND RAISERS OF EVERY POSSIBLE KIND,
17 HUNDREDS OF PATIENTS WITH PARKINSON'S JOINING
18 TOGETHER TO HELP US RAISE THIS KIND OF MONEY. WE'VE
19 RAISED ALMOST \$2 MILLION AND GOTTEN THE RESEARCH TO
20 WHERE IT IS TODAY. AT THIS POINT WE DESPERATELY
21 NEED CIRM'S FUNDING. WE HAVE -- THIS IS NOT A
22 CONCEPT ANYMORE. WE ARE IN A TRANSLATIONAL PHASE OF
23 OUR RESEARCH. WE'VE COME SO FAR. WE'VE TESTED OUR
24 CELLS, WHICH ARE INDUCED PLURIPOTENT STEM CELLS, NOT
25 EMBRYONIC, WHICH BRINGS ME TO SAY SOMETHING TO THE

BARRISTERS' REPORTING SERVICE

1 BOARD AND EVERYONE IN THIS ROOM, THAT I KNOW THAT
2 IPSC CELLS HAVE NOT BEEN APPROVED BY CIRM FOR USE IN
3 PEOPLE. I UNDERSTAND THAT. BUT HAD WE NOT APPROVED
4 FOR ANTIBIOTICS, WE WOULD HAVE ALL BEEN DYING OF
5 INFECTIONS. IF WE HAD NOT TRIED THE ANTIBIOTIC IN
6 PEOPLE, IT WOULDN'T BE THERE AVAILABLE FOR US NOW.
7 IF WE HADN'T TRIED THE POLIO VACCINE AS A PREVENTIVE
8 TYPE OF DISEASE PREVENTION, THE SAME THING WOULD
9 HAVE HAPPENED. WE HAVE TO BREAK THE MOLD. WE HAVE
10 TO BE BRAVE ENOUGH TO TRY A NEW TYPE OF STEM CELL
11 THERAPY.

12 WE HAVE COME SO VERY FAR. I JUST WANT TO
13 READ TO EVERYONE REAL QUICKLY, AND I'M GOING TO JUST
14 READ IT FROM MY PHONE, THIS IS FROM ONE OF OUR
15 PATIENT PARTICIPANTS WHO WE CHOSE FOUR YEARS AGO.
16 SHE WAS SCHEDULED TO GET ON THE PLANE FROM SAN DIEGO
17 TO TRAVEL WITH US TODAY. "SHERRIE, MY BODY WON'T
18 MOVE THIS MORNING. SO I AM NOT GOING TO MAKE THE
19 TRIP. I AM SO VERY SORRY. PLEASE CALL ME AFTER YOU
20 HEAR ANY DECISIONS THE CIRM BOARD HAS MADE."

21 SECONDLY, GETTING OFF THE AIRPLANE JUST
22 TODAY, ANOTHER ONE OF OUR PATIENT ADVOCATES -- OUR
23 PATIENT PARTICIPANTS ATTEMPTED TO GET OFF THAT
24 SOUTHWEST PLANE AND HE GOT STUCK. HE GOT FROZEN.
25 HE COULD NOT MOVE. HE WAS LITERALLY LIKE THE NAILS

BARRISTERS' REPORTING SERVICE

1 WERE IN HIS SHOES. AND WE GOT HIM A WHEELCHAIR SO
2 WE COULD GET TO THE TAXI. THESE ARE REAL LIFE
3 STORIES. TIME IS GOING BY.

4 CIRM SAYS YOU HAVE MONEY AND YOU HAVE
5 TIME. WE DON'T HAVE EITHER. WE DON'T HAVE MONEY
6 AND WE DON'T HAVE TIME. TIME IS RUNNING OUT. OKAY.
7 THANK YOU VERY MUCH. AND I JUST REAL QUICKLY WANT
8 EVERYONE IN THIS ROOM WHO REPRESENTS PARKINSON'S
9 DISEASE TO PLEASE STAND UP. THANK YOU VERY MUCH.

10 CHAIRMAN THOMAS: THANK YOU. ARE THERE
11 ADDITIONAL SPEAKERS? THANK YOU. WOULD LIKE TO
12 THANK EVERYBODY WHO MADE THIS TRIP. I KNOW IT'S A
13 HARDSHIP, AND WE APPRECIATE YOU COMING AND
14 APPRECIATE YOUR COMMENTS. THANK YOU.

15 MARIA.

16 MS. BONNEVILLE: CAN WE TAKE A FIVE-MINUTE
17 BREAK, AND THEN WE'LL BE BACK AND READY TO GO.

18 CHAIRMAN THOMAS: YOU'D LIKE TO HAVE A
19 FIVE-MINUTE BREAK? WE'RE STILL TRYING TO SORT OUT
20 OUR TECHNICAL DIFFICULTIES. SO FIVE-MINUTE BREAK,
21 AND THEN WE'LL RESUME. THANK YOU.

22 (A RECESS WAS TAKEN.)

23 CHAIRMAN THOMAS: CAN EVERYBODY TAKE THEIR
24 SEATS PLEASE? WE SEEM TO HAVE SORTED OUT OUR
25 VARIOUS TECHNICAL DIFFICULTIES AND ARE READY TO

BARRISTERS' REPORTING SERVICE

1 CONTINUE.

2 WELCOME TO EVERYBODY ON THE PHONE. THANK
3 YOU FOR YOUR PATIENCE AND CONNECTING HERE AS WE WORK
4 OUT ISSUES ON OUR END. WE'RE NOW GOING TO PROCEED
5 WITH THE CONSENT AGENDA WHICH IS IN YOUR MATERIALS
6 THERE.

7 MS. BONNEVILLE: FOR THE RECORD, I'M GOING
8 TO CALL ROLL FOR THE THREE PEOPLE ON THE PHONE.

9 CHAIRMAN THOMAS: THANK YOU.

10 MS. BONNEVILLE: DONNA WESTON.

11 DR. WESTON: HERE.

12 MS. BONNEVILLE: KRISTINA VUORI.

13 DR. VUORI: HERE.

14 MS. BONNEVILLE: JOE PANETTA.

15 MR. PANETTA: HERE.

16 MS. BONNEVILLE: KATHY LAPORTE. THANK
17 YOU.

18 CHAIRMAN THOMAS: WELCOME, EVERYBODY.

19 THE CONSENT CALENDAR, ITEMS 6 TO 9, DID
20 ANYBODY SEE ANYTHING ON THE AGENDA UNDER CONSENT
21 THEY WOULD LIKE TO HAVE PULLED FOR SPECIFIC
22 DISCUSSION?

23 MR. TORRES: MOVE CONSENT CALENDAR.

24 CHAIRMAN THOMAS: IT'S BEEN MOVED BY
25 SENATOR TORRES.

BARRISTERS' REPORTING SERVICE

1 DR. PRIETO: SECOND.

2 CHAIRMAN THOMAS: SECONDED BY DR. PRIETO.
3 ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED? MARIA,
4 DO I NEED TO POLL? YES, FOR EVERYTHING, WE NEED TO
5 HAVE INDIVIDUAL POLLING.

6 MS. BONNEVILLE: JOE PANETTA.

7 MR. PANETTA: YES.

8 MS. BONNEVILLE: KRISTINA VUORI.

9 DR. VUORI: YES.

10 MS. BONNEVILLE: DONNA WESTON.

11 DR. WESTON: YES.

12 CHAIRMAN THOMAS: THAT MOTION PASSES.

13 THANK YOU.

14 WE'RE ON TO ACTION ITEM NO. 10, WHICH IS
15 CONSIDERATION OF AMENDMENTS TO THE CONCEPT PLAN FOR
16 CLINICAL STAGE PROJECTS AND ALLOCATION OF ADDITIONAL
17 FUNDING FOR CLINICAL STAGE PROJECTS FOR FISCAL
18 '15-'16. DR. JORGENSON.

19 DR. JORGENSON: GOOD MORNING, MEMBERS OF
20 THE BOARD. IN DECEMBER OF LAST YEAR, WE LAUNCHED
21 THE CIRM 2.0 CLINICAL PROGRAM. AND SINCE THAT TIME,
22 WE HAVE MET SIX APPLICATION DEADLINES AND CONDUCTED
23 FOUR REVIEWS. AS PROMISED, WE'VE CONTINUED TO LOOK
24 FOR WAYS TO IMPROVE THE PROGRAM. AND AS SUCH, WE'VE
25 IDENTIFIED FIVE UPDATES TO THE CLINICAL PROGRAM

BARRISTERS' REPORTING SERVICE

1 ANNOUNCEMENTS THAT WE WOULD LIKE TO MAKE THAT
2 REQUIRE MODIFICATION OF THE CONCEPT PLAN APPROVED BY
3 THIS BOARD.

4 THE FIRST TWO UPDATES THAT WE WOULD LIKE
5 TO MAKE AFFECT PROGRAM ANNOUNCEMENT 15-03, WHICH IS
6 FOR SUPPLEMENTAL ACCELERATING ACTIVITIES TO EXISTING
7 CIRM CLINICAL PROGRAM AWARDS. WE CURRENTLY REQUIRE
8 40 PERCENT CO-FUNDING FOR APPLICANTS TO THIS PROGRAM
9 ANNOUNCEMENT. WHEN WE WERE PROCESSING APPLICATIONS
10 UNDER THIS PROGRAM ANNOUNCEMENT, WE FOUND THAT THIS
11 CREATED A HIGHER BURDEN ON THE APPLICANTS IN TERMS
12 OF CO-FUNDING THAN WHAT WAS REQUIRED UNDER THE
13 PARENT AWARD. AND FOR EASE OF ADMINISTRATION OF THE
14 AWARDS AND TO NOT PLACE AN UNNECESSARY BURDEN ON THE
15 APPLICANTS, WE ARE PROPOSING TO AMEND THE PROGRAM
16 ANNOUNCEMENT SUCH THAT THE REQUIRED MATCH IS
17 EQUIVALENT TO THAT OF THE MATCH THAT WAS REQUIRED
18 UNDER THE PARENT AWARD.

19 THE SECOND ITEM ALSO RELATES TO PROGRAM
20 ANNOUNCEMENT 15-03, AND THAT IS RELATED TO THE
21 OBJECTIVE OF THE PROJECT SUBMITTED UNDER THIS
22 PROGRAM ANNOUNCEMENT. WE WOULD LIKE TO REQUIRE THAT
23 THESE PROJECTS BE FOCUSED ON A SINGLE PROJECT
24 OBJECTIVE. THE APPLICANT CAN STILL PROPOSE MULTIPLE
25 ACTIVITIES, BUT WE WOULD LIKE THEM TO ALL BE FOCUSED

BARRISTERS' REPORTING SERVICE

1 ON A SINGLE PROJECT. AND THAT IS FOR TWO REASONS.
2 ONE, IT ALLOWS THE REVIEW TO BE FOCUSED ON THE
3 OBJECTIVE OF THE APPLICATION. AND IT ALSO FORCES
4 THE APPLICANT TO BE FOCUSED ON A SINGLE OBJECTIVE,
5 AND WE THINK THAT IS IMPORTANT IF THEY ARE TO
6 PROPOSE AN ACTIVITY THAT COULD ACCELERATE OR IMPROVE
7 THE LIKELIHOOD OF SUCCESS OF THE PARENT AWARD.

8 THE THIRD UPDATE WE WOULD LIKE TO MAKE
9 RELATES TO PROGRAM ANNOUNCEMENT 15-01, WHICH IS THE
10 LATE STAGE PROJECTS, AND PROGRAM ANNOUNCEMENT 15-02,
11 WHICH IS THE CLINICAL STAGE PROJECTS. UNDER THESE
12 TWO PROGRAM ANNOUNCEMENTS, WE CURRENTLY REQUIRE THAT
13 THE INVESTIGATOR BE SEEKING AN INVESTIGATIONAL NEW
14 DRUG APPLICATION OR AN IND OR THAT THEY HAVE AN IND
15 TO CONDUCT A CLINICAL TRIAL.

16 WHEN WE PUBLISHED THIS PROGRAM
17 ANNOUNCEMENT, WE CONSIDERED AN INVESTIGATIONAL
18 DEVICE EXEMPTION TO BE EQUIVALENT TO THAT; HOWEVER,
19 IN ORDER TO PROVIDE CLARITY TO THE APPLICANT, WE
20 WOULD LIKE TO SPECIFICALLY STATE THAT IN THE PROGRAM
21 ANNOUNCEMENT. AND THAT IS ALSO IN LINE WITH
22 PROVIDING A CONTINUOUS DEVELOPMENT PATHWAY TO OUR
23 APPLICANTS WHICH WILL BE DISCUSSED LATER WHEN THE
24 DISCOVERY AND TRANSLATION CONCEPT PLANS ARE
25 PRESENTED.

BARRISTERS' REPORTING SERVICE

1 THE FOURTH ITEM ALSO RELATES TO PROGRAM
2 ANNOUNCEMENT 15-01 AND 15-02. AND THIS IS THAT WE
3 WOULD LIKE TO INCREASE THE PERCENT EFFORT
4 REQUIREMENT FOR PROGRAM MANAGERS FROM THE CURRENT 50
5 PERCENT TO 75 PERCENT. WE BELIEVE THAT 75 PERCENT
6 EFFORT IS MORE COMMENSURATE WITH THE AMOUNT OF WORK
7 THAT IS REQUIRED FOR PROGRAM MANAGERS FOR THIS TYPE
8 OF PROJECT.

9 THE LAST ITEM RELATES TO ALL THREE PROGRAM
10 ANNOUNCEMENTS. AND WE ARE PROPOSING TO ELIMINATE
11 INDIRECT COST ALLOWANCE FOR FOR-PROFIT
12 ORGANIZATIONS. UNLIKE ACADEMIC AND NONPROFIT
13 ORGANIZATIONS THAT PAY FOR OVERHEAD THROUGH INDIRECT
14 COSTS, FOR-PROFIT ORGANIZATIONS PAY FOR THEIR
15 OVERHEAD OUT OF CORPORATE COSTS. IN OUR CONTINUED
16 EFFORT TO DIRECT AS MUCH OF THE REMAINING FUNDING AS
17 POSSIBLE TOWARDS DIRECT RESEARCH ACTIVITIES THAT
18 WOULD FURTHER OUR MISSION, WE ARE PROPOSING TO
19 ELIMINATE THE INDIRECT COST ALLOWANCE FOR FOR-PROFIT
20 ORGANIZATIONS. AND WE DO NOT BELIEVE THAT THIS WILL
21 HINDER ANY COMPANIES FROM APPLYING TO THESE PROGRAM
22 ANNOUNCEMENTS.

23 IN ADDITION TO THESE UPDATES, WE ALSO WANT
24 TO REQUEST THE BUDGET ALLOCATION FOR THE FISCAL YEAR
25 2015-2016. IN THE PREVIOUS YEAR \$50 MILLION WAS

BARRISTERS' REPORTING SERVICE

1 ALLOCATED FOR THE PERIOD FROM JANUARY TO JUNE OF
2 2015. TWENTY-FIVE MILLION OF THAT WAS COMMITTED TO
3 NEW AWARDS, AND THAT REPRESENTS THREE REVIEWS THAT
4 WERE CONDUCTED AND APPROVED FROM THE ICOC. THAT
5 REPRESENTS ONE-QUARTER OF THE REVIEWS THAT WE EXPECT
6 TO CONDUCT DURING FISCAL YEAR 2015-2016. AND AS
7 SUCH, WE ARE REQUESTING A \$100 MILLION ALLOCATION
8 FOR THE FOLLOWING FISCAL YEAR. I'M HAPPY TO TAKE
9 ANY QUESTIONS.

10 MR. SHEEHY: YES. SO I'D LIKE TO MOVE
11 ADOPTION OF THESE PROPOSALS AND NOTE THAT THIS WAS
12 ALL HEARD IN THE SCIENCE SUBCOMMITTEE, AND THE
13 COMMITTEE UNANIMOUSLY APPROVED MOVING THIS FORWARD.

14 CHAIRMAN THOMAS: THANK YOU, MR. SHEEHY.
15 IS THERE A SECOND?

16 DR. PRICE: SECOND.

17 CHAIRMAN THOMAS: SECONDED BY DR. PRICE.
18 ANY QUESTIONS OR COMMENTS FROM MEMBERS OF THE BOARD?
19 ANY COMMENT FROM MEMBERS OF THE PUBLIC? HEARING
20 NONE, IS THIS A VOICE VOTE AND POLLING? IN THE ROOM
21 ALL THOSE IN FAVOR PLEASE SAY AYE. OPPOSED? MARIA,
22 PLEASE CALL THE ROLL FOR THOSE ON THE PHONE.

23 MS. BONNEVILLE: DONNA WESTON.

24 DR. WESTON: AYE.

25 MS. BONNEVILLE: KRISTINA VUORI. JOE

BARRISTERS' REPORTING SERVICE

1 PANETTA.

2 MR. PANETTA: AYE.

3 MS. BONNEVILLE: LAUREN MILLER.

4 MS. MILLER: AYE.

5 MS. BONNEVILLE: MICHAEL FRIEDMAN.

6 DR. FRIEDMAN: YES.

7 CHAIRMAN THOMAS: MR. HARRISON, I PRESUME
8 THAT MOTION PASSES.

9 MR. HARRISON: IT PASSES.

10 CHAIRMAN THOMAS: THANK YOU. WELCOME TO
11 THOSE WHO JUST JOINED ADDITIONALLY ON THE PHONE.
12 GREAT TO HAVE YOU HERE.

13 ON TO ITEM NO. 11, WHICH IS CONSIDERATION
14 OF APPLICATIONS SUBMITTED IN RESPONSE TO PA 15-02,
15 WHICH IS PARTNERSHIP OPPORTUNITY FOR CLINICAL TRIAL
16 STAGE PROJECTS, AND PA 15-03, WHICH IS PARTNERING
17 OPPORTUNITIES FOR SUPPLEMENTAL ACCELERATING
18 ACTIVITIES. DR. JORGENSON.

19 DR. JORGENSON: I AM PRESENTING TO YOU THE
20 RESULTS OF THE JUNE 30TH GRANTS WORKING GROUP
21 REVIEW. WE REVIEWED THREE APPLICATIONS AT THAT
22 REVIEW, TWO UNDER PROGRAM ANNOUNCEMENT 15-02 AND ONE
23 UNDER PROGRAM ANNOUNCEMENT 15-03. THIS IS A
24 REMINDER OF THE PROGRAM ANNOUNCEMENTS AVAILABLE
25 UNDER THE CLINICAL PROGRAM, WHICH ARE 15-01, LATE

BARRISTERS' REPORTING SERVICE

1 STAGE CLINICAL PROJECTS; 15-02, THE CLINICAL TRIAL
2 STAGE PROJECTS; AND 15-03, SUPPLEMENTAL ACCELERATING
3 ACTIVITIES.

4 THE REVIEWERS PROVIDED A SCORE UNDER THE
5 NEW 2.0 SCORING SYSTEM. A SCORE OF ONE WILL
6 INDICATE THAT THE GRANTS WORKING GROUP FELT THAT THE
7 APPLICATIONS HAD EXCEPTIONAL MERIT AND WARRANT
8 FUNDING. A SCORE OF TWO INDICATES THAT THE GRANTS
9 WORKING GROUP THINKS THE APPLICATION NEEDS
10 IMPROVEMENT AND DOES NOT WARRANT FUNDING AT THIS
11 TIME, BUT THAT IT CAN BE RESUBMITTED TO ADDRESS
12 AREAS FOR IMPROVEMENT. A SCORE OF THREE INDICATES
13 THAT THE GRANTS WORKING GROUP FELT THE APPLICATION
14 WAS SUFFICIENTLY FLAWED TO NOT WARRANT FUNDING AT
15 THIS TIME, AND ALSO THAT THE APPLICATION CANNOT BE
16 RESUBMITTED FOR FURTHER REVIEW.

17 THE APPLICATIONS ARE SCORED BY ALL THE
18 SCIENTIFIC MEMBERS OF THE GRANTS WORKING GROUP THAT
19 DO NOT HAVE A CONFLICT WITH AN INDIVIDUAL
20 APPLICATION.

21 THE FIRST APPLICATION I'D LIKE TO PRESENT
22 IS CST-08289. THIS IS AN APPLICATION RECEIVED UNDER
23 PROGRAM ANNOUNCEMENT 15-02. THE APPLICANT IS
24 PROPOSING TO CONDUCT A PHASE I CLINICAL TRIAL TO
25 TEST THE SAFETY AND FEASIBILITY OF GENETICALLY

BARRISTERS' REPORTING SERVICE

1 MODIFIED HEMATOPOIETIC STEM CELLS TO GENERATE
2 HIV-RESISTANT IMMUNE CELLS AND IMPROVE THE IMMUNE
3 FUNCTION OF PATIENTS WITH AIDS-RELATED LYMPHOMA.

4 THE PROPOSED MAJOR ACTIVITIES INCLUDE
5 PRODUCTION OF THE MATERIAL NECESSARY FOR THE
6 CLINICAL TRIAL, WHICH IS BOTH THE VECTOR AND THE
7 HIV-RESISTANT HEMATOPOIETIC STEM CELLS, THE CONDUCT
8 OF THE CLINICAL TRIAL, AND THE EVALUATION AND
9 MONITORING OF THE FUNCTION OF THE TRANSPLANTED CELLS
10 AND THEIR EFFECT ON HIV VIRAL LOAD.

11 THE APPLICANT HAS REQUESTED \$8.5 MILLION
12 TO CONDUCT THESE ACTIVITIES. THE APPLICATION WAS
13 DETERMINED BY CIRM TEAM TO BE IN SCOPE AND IT PASSED
14 THE BUDGET REVIEW, INDICATING THAT THE PROPOSED
15 BUDGET WAS APPROPRIATE FOR THE PROPOSED ACTIVITIES.

16 THE GRANTS WORKING GROUP GAVE THIS
17 APPLICATION A SCORE OF ONE, INDICATING THAT IT HAS
18 EXCEPTIONAL MERIT AND WARRANTS FUNDING. TEN MEMBERS
19 OF THE WORKING GROUP VOTED ON THIS APPLICATION, ALL
20 OF WHOM GAVE IT A SCORE OF ONE. THE CIRM TEAM
21 LOOKED AT THE COMMENTS OF THE GRANTS WORKING
22 GROUP, AND WE CONCUR WITH THE GRANTS WORKING GROUP
23 RECOMMENDATION THAT THIS APPLICATION HAS EXCEPTIONAL
24 MERIT AND WARRANTS FUNDING IN THE AMOUNT REQUESTED
25 BY THE APPLICANT OF \$8.5 MILLION.

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY, WOULD YOU LIKE TO MOVE TO
2 PROGRAMMATIC REVIEW?

3 MR. SHEEHY: THANK YOU, DR. JORGENSON.
4 AND I THINK SINCE WE'RE NOW DOING THE APPLICATION
5 REVIEW SEPARATELY, SO I THINK THE CONSTRUCTS OF THAT
6 PROCESS, I WILL TAKE A MOTION FROM AN ELIGIBLE
7 MEMBER NOT CONFLICTED.

8 MS. WINOKUR: MOVE TO APPROVE.

9 MR. TORRES: SECOND.

10 MR. SHEEHY: SO MS. WINOKUR MOVES TO
11 APPROVE WITH A SECOND BY SENATOR TORRES. IS THERE
12 ANY DISCUSSION BY MEMBERS? ANY PUBLIC COMMENT?
13 THEN I THINK WE CAN GO AHEAD AND CALL THE ROLL ON
14 THIS, PLEASE, MS. BONNEVILLE.

15 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

16 DR. DULIEGE: YES.

17 MS. BONNEVILLE: DAVID HIGGINS.

18 DR. HIGGINS: YES.

19 MS. BONNEVILLE: STEPHEN JUELSGAARD.

20 KATHY LAPORTE.

21 MS. LAPORTE: YES.

22 MS. BONNEVILLE: LAUREN MILLER.

23 MS. MILLER: YES.

24 MS. BONNEVILLE: ADRIANA PADILLA.

25 DR. PADILLA: YES.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: JOE PANETTA.
2 MR. PANETTA: YES.
3 MS. BONNEVILLE: FRANCISCO PRIETO.
4 DR. PRIETO: AYE.
5 MS. BONNEVILLE: ROBERT QUINT. AL
6 ROWLETT.
7 DR. ROWLETT: YES.
8 MS. BONNEVILLE: JEFF SHEEHY.
9 MR. SHEEHY: YES.
10 MS. BONNEVILLE: OS STEWARD.
11 DR. STEWARD: YES.
12 MS. BONNEVILLE: JONATHAN THOMAS.
13 CHAIRMAN THOMAS: YES.
14 MS. BONNEVILLE: ART TORRES.
15 MR. TORRES: AYE.
16 MS. BONNEVILLE: DIANE WINOKUR.
17 MS. WINOKUR: YES.
18 MR. HARRISON: MOTION PASSES WITH 13
19 VOTES.
20 MR. SHEEHY: DR. JORGENSON, CAN WE MOVE TO
21 THE NEXT APPLICATION?
22 DR. JORGENSON: THE SECOND APPLICATION I'D
23 LIKE TO PRESENT IS CTS1-8231. THIS WAS ALSO
24 RECEIVED UNDER PROGRAM ANNOUNCEMENT 15-02. AND THIS
25 IS A PHASE I-II TRIAL WHERE THE APPLICANT IS

BARRISTERS' REPORTING SERVICE

1 PROPOSING THE CONDUCT OF A CLINICAL TRIAL TO TEST
2 THE SAFETY AND EFFICACY OF GENETICALLY MODIFIED
3 HEMATOPOETIC STEM CELLS TO REPLACE THE PATIENT'S
4 CELLS WITH GENETICALLY CORRECTED CELLS IN ORDER TO
5 IMPROVE IMMUNE FUNCTIONS IN PATIENTS WITH CHRONIC
6 GRANULOMATOUS DISEASE.

7 THE PROPOSED MAJOR ACTIVITIES INCLUDE THE
8 PRODUCTION OF THE MATERIAL NECESSARY TO CONDUCT THE
9 CLINICAL TRIAL; THAT IS, THE PATIENT-SPECIFIC
10 GENE-CORRECTED HEMATOPOIETIC STEM CELLS, TRANSPLANT
11 OF THE PATIENTS WHO HAVE SEVERE XCGD WHO LACK
12 MATCHED DONORS, AND TO PERFORM TWO-YEAR FOLLOW-UP TO
13 ASSESS CLINICAL TRIAL ENDPOINTS IN PATIENTS
14 RECEIVING TRANSPLANTS.

15 THE APPLICANT REQUESTED \$7.4 MILLION TO
16 CONDUCT THESE ACTIVITIES AND IS PROVIDING A \$4.6
17 MILLION MATCH OR CO-FUND AMOUNT.

18 THIS APPLICATION WAS DETERMINED BY THE
19 CIRM TEAM TO BE IN SCOPE AND IT PASSED THE BUDGET
20 REVIEW, INDICATING THAT THE PROPOSED BUDGET WAS
21 APPROPRIATE FOR THE CONDUCT OF THE PROPOSED
22 ACTIVITIES.

23 THIS APPLICATION RECEIVED A GRANTS WORKING
24 GROUP SCORE OF ONE, INDICATING THAT IT HAS
25 EXCEPTIONAL MERIT AND WARRANTS FUNDING. TEN GRANTS

BARRISTERS' REPORTING SERVICE

1 WORKING GROUP MEMBERS VOTED ON THIS APPLICATION,
2 FIVE OF WHOM GAVE IT A SCORE OF ONE, ONE OF WHOM
3 GAVE IT A SCORE OF TWO, AND FOUR WHO GAVE IT A SCORE
4 OF THREE. THE CIRM TEAM CONSIDERED THE COMMENTS OF
5 THE GRANTS WORKING GROUP, AND WE CONCUR WITH THE
6 GRANTS WORKING GROUP RECOMMENDATION THAT THIS
7 APPLICATION HAS EXCEPTIONAL MERIT AND WARRANTS
8 FUNDING IN THE AMOUNT REQUESTED BY THE APPLICANT OF
9 \$7.4 MILLION.

10 MR. SHEEHY: THANK YOU, DR. JORGENSON.
11 COULD I PERHAPS PASS THE CHAIR TO DR. STEWARD
12 BECAUSE I'D LIKE TO MAKE A MOTION RELEVANT TO THIS,
13 AND I THINK THE CHAIR SHOULD NOT BE MAKING MOTIONS.

14 DR. STEWARD: SURE.

15 MR. SHEEHY: SO I'D LIKE TO MOVE ADOPTION
16 OF THE CIRM TEAM RECOMMENDATION AND TO FUND THIS
17 APPLICATION. TO ADDRESS THE CONCERN THAT FOUR OF
18 THE REVIEWERS HAVE, THE CONCERN WAS ABOUT ACCRUAL
19 BECAUSE THIS IS A RARE DISEASE. I BELIEVE THAT THE
20 CIRM TEAM, AND I WOULD LIKE TO MAKE THIS PART OF MY
21 MOTION, THE CIRM TEAM SET STRICT MILESTONES
22 REGARDING ACCRUAL. SO THAT IF IT TURNS THAT IT'S
23 TRUE THAT RECRUITING FOR THIS TRIAL IS NOT GOING TO
24 BE POSSIBLE, WE TAKE ACTION ON THAT AS SOON AS
25 POSSIBLE, BUT THAT I THINK WE SHOULD GIVE THIS TEAM

BARRISTERS' REPORTING SERVICE

1 A CHANCE. THIS IS A RARE DISEASE, AN ORPHAN
2 DISEASE, AND I THINK CIRM IS UNIQUELY POSITIONED IN
3 ORDER TO MAKE AN IMPACT IN SUCH A DISEASE. AND I
4 THINK WE SHOULD TAKE A CHANCE MYSELF.

5 THE SCIENCE IS GOOD. THE SCIENCE IS SOLID
6 AND THE PATIENTS HAVE THE NEED, AND THAT'S WHY WE
7 EXIST. SO THAT IS MY MOTION.

8 DR. STEWARD: IF I COULD MAYBE BRIEFLY
9 RESTATE THE MOTION, IT IS TO APPROVE WITH
10 CONTINGENCIES FOR MILESTONE ACHIEVEMENT. IS THAT A
11 FAIR SUMMARY?

12 MR. SHEEHY: WELL, TO REALLY FOCUS ON
13 ACCRUAL MILESTONES BECAUSE THAT WAS A SERIOUS
14 CONCERN OF THE REVIEWERS, WHICH IS WHY WE HAD THE
15 SCORES -- MAJOR REASON WHY THERE WERE SCORES OF
16 THREE WAS THAT SOME OF THE REVIEWERS DID NOT BELIEVE
17 THAT THEY COULD ACHIEVE ACCRUAL.

18 DR. STEWARD: OKAY.

19 DR. MILLS: JUST TO MAKE JUST A COMMENT
20 ABOUT THIS AND ABOUT THE WAY THE CIRM 2.0 CLINICAL
21 WORKS. NOW ALL OF OUR PAYMENTS ARE NOW MILESTONE
22 BASED, SO IT WILL HAPPEN BECAUSE IT HAPPENS ANYWAY.
23 WE'VE ALREADY DONE THE FIRST PASS AT THE MILESTONES
24 FOR THIS TRIAL, AND THEY ARE ACCRUAL BASED. SO WHAT
25 THAT MEANS IS IF THEY'RE NOT HITTING THEIR ACCRUAL

BARRISTERS' REPORTING SERVICE

1 NUMBERS, WE'RE NOT PAYING THEM ANY MONEY. WE ONLY
2 PAY THEM OUT WHEN THEY HIT IT. SO THE MOTION IS
3 FINE, BUT IT WILL HAPPEN ANYWAY.

4 MR. SHEEHY: THANK YOU, DR. MILLS.

5 DR. STEWARD: SO IS THERE SECOND?

6 DR. PRIETO: I'LL SECOND.

7 DR. STEWARD: OTHER DISCUSSION?

8 CHAIRMAN THOMAS: I'LL JUST NOTE THAT
9 THERE WAS CONSIDERABLE ENTHUSIASM FOR THE SCIENCE
10 HERE AND THE EXPERIENCE OF THE TEAM, CORRECT, MR.
11 SHEEHY? AND THIS IS A GROUP THAT HAS A GREAT DEAL
12 OF EXPERIENCE IN THE TECHNOLOGY THAT UNDERLIES THIS
13 PARTICULAR WORK IN THIS INDICATION. SO I THINK THAT
14 I WOULD CONCUR WITH MR. SHEEHY, THAT THIS IS
15 SOMETHING THAT WE SHOULD BE FUNDING.

16 DR. STEWARD: OTHER DISCUSSION?

17 MR. ROWLETT: AS A PATIENT ADVOCATE, I GOT
18 TO REVIEW THIS PROPOSAL. AND, DR. MILLS, YOUR
19 COMMENTS ARE REASSURING. THE PROPOSAL THAT THE TEAM
20 IS, AGAIN, AS J.T. SAID, AN EXEMPLARY TEAM, THE
21 CONCERNS RELATED TO PATIENT ENROLLMENT ACCRUAL, THAT
22 WAS THE CONVERSATION, THE DISCUSSION WAS VIGOROUS,
23 AND LOT TO DO WITH THAT. AND SO LOOKING FORWARD TO
24 HEARING FROM YOU THAT THEY'RE MEETING THEIR
25 MILESTONES.

BARRISTERS' REPORTING SERVICE

1 DR. STEWARD: OTHER DISCUSSION BY BOARD
2 MEMBERS? IF NOT, PUBLIC DISCUSSION? IF NO PUBLIC
3 DISCUSSION, WE CAN MOVE IT TO MARIA.

4 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

5 DR. DULIEGE: YES.

6 MS. BONNEVILLE: DAVID HIGGINS.

7 DR. HIGGINS: YES.

8 MS. BONNEVILLE: STEPHAN JUELSGAARD.

9 KATHY LAPORTE.

10 MS. LAPORTE: YES.

11 MS. BONNEVILLE: LAUREN MILLER.

12 MS. MILLER: YES.

13 MS. BONNEVILLE: ADRIANA PADILLA.

14 DR. PADILLA: YES.

15 MS. BONNEVILLE: JOE PANETTA.

16 MR. PANETTA: YES.

17 MS. BONNEVILLE: FRANCISCO PRIETO.

18 DR. PRIETO: AYE.

19 MS. BONNEVILLE: ROBERT QUINT. AL

20 ROWLETT.

21 DR. ROWLETT: YES.

22 MS. BONNEVILLE: JEFF SHEEHY.

23 MR. SHEEHY: YES.

24 MS. BONNEVILLE: OS STEWARD.

25 DR. STEWARD: YES.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: JONATHAN THOMAS.

2 CHAIRMAN THOMAS: YES.

3 MS. BONNEVILLE: ART TORRES.

4 MR. TORRES: AYE.

5 MS. BONNEVILLE: DIANE WINOKUR.

6 MS. WINOKUR: YES.

7 MR. HARRISON: MOTION PASSES WITH 13

8 VOTES.

9 CHAIRMAN THOMAS: THANK YOU. DR.

10 JORGENSON, DO YOU HAVE ANYTHING ELSE FOR US, OR DOES
11 THAT CONCLUDE YOUR PRESENTATION?

12 DR. JORGENSON: ONE MORE. FINAL ONE I
13 WANT TO PRESENT IS SAA1-8273, WHICH WAS AN
14 APPLICATION RECEIVED TO PROGRAM ANNOUNCEMENT 15-03
15 FOR SUPPLEMENTAL ACCELERATING ACTIVITIES TO AN
16 EXISTING CIRM CLINICAL STAGE AWARD.

17 THE PARENT AWARD IS AN ONGOING PHASE I
18 CLINICAL TRIAL TESTING A MONOCLONAL ANTIBODY IN
19 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. THE
20 PROPOSED SUPPLEMENT TO THIS IS AN EXTENSION STUDY
21 THAT WOULD ADMINISTER REPEAT DOSES OF THE CANDIDATE
22 THERAPEUTIC TO PATIENTS WHO ARE ALREADY ENROLLED IN
23 THE ONGOING PHASE I TRIAL.

24 THE PROPOSED ACTIVITIES INCLUDE PRODUCTION
25 OF ADDITIONAL ANTIBODY TO COMPLETE THE EXTENSION

BARRISTERS' REPORTING SERVICE

1 STUDY AND THE CONDUCT OF THE PROPOSED EXTENSION
2 STUDY. THE APPLICANT REQUESTED \$2.9 MILLION FOR THE
3 CONDUCT OF THESE ACTIVITIES.

4 THE APPLICATION WAS DETERMINED TO BE IN
5 SCOPE WITH THE PROGRAM ANNOUNCEMENT AND PASSED THE
6 BUDGET REVIEW, INDICATING THAT THE ACTIVITIES ARE IN
7 LINE WITH THE AMOUNT OF MONEY REQUESTED TO CONDUCT
8 THEM.

9 THE GRANTS WORKING GROUP GAVE THIS
10 APPLICATION A SCORE OF TWO, INDICATING THAT IT NEEDS
11 IMPROVEMENT AND DOES NOT WARRANT FUNDING AT THIS
12 TIME, BUT IT CAN BE RESUBMITTED TO ADDRESS AREAS FOR
13 IMPROVEMENT.

14 ELEVEN WORKING GROUP MEMBERS VOTED ON THIS
15 PARTICULAR APPLICATION, TWO OF WHOM GAVE IT A SCORE
16 OF ONE, SIX OF THEM GAVE IT A SCORE OF TWO, AND
17 THREE GAVE IT A SCORE OF THREE. CIRM CONSIDERED THE
18 COMMENTS OF THE GRANTS WORKING GROUP, AND WE CONCUR
19 WITH THE RECOMMENDATION TO NOT FUND THIS
20 APPLICATION. MR. SHEEHY.

21 MR. SHEEHY: SO DO WE HAVE A MOTION ON
22 THIS APPLICATION?

23 MR. TORRES: MOVE TO ACCEPT THE CIRM TEAM
24 RECOMMENDATION.

25 DR. STEWARD: SECOND.

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: SECONDED BY DR. STEWARD.
2 JUST WANT TO NOTE FOR THE RECORD OR TO
3 EMPHASIZE THAT THEY'RE MORE THAN WELCOME TO
4 RESUBMIT. I THINK THAT'S A GREAT FEATURE OF CIRM
5 2.0. WE'RE NOT SENDING THEM TO THE DOOR. THEY CAN
6 BE BACK IN ANOTHER COUPLE OF MONTHS IF THEY ADDRESS
7 THE CONCERNS OF THE REVIEWERS, WHICH I BELIEVE HAVE
8 BEEN PRESENTED TO THEM CLEARLY. AND SO IS THERE ANY
9 BOARD DISCUSSION? ANY PUBLIC COMMENT? MS.
10 BONNEVILLE, WILL YOU CALL THE ROLL PLEASE?

11 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

12 DR. DULIEGE: AYE.

13 MS. BONNEVILLE: DAVID HIGGINS.

14 DR. HIGGINS: YES.

15 MS. BONNEVILLE: STEPHAN JUELGAARD.

16 KATHY LAPORTE.

17 MS. LAPORTE: YES.

18 MS. BONNEVILLE: LAUREN MILLER.

19 MS. MILLER: YES.

20 MS. BONNEVILLE: ADRIANA PADILLA.

21 DR. PADILLA: YES.

22 MS. BONNEVILLE: JOE PANETTA.

23 MR. PANETTA: YES.

24 MS. BONNEVILLE: FRANCISCO PRIETO.

25 DR. PRIETO: AYE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: ROBERT QUINT. AL
2 ROWLETT.

3 DR. ROWLETT: YES.

4 MS. BONNEVILLE: JEFF SHEEHY.

5 MR. SHEEHY: YES.

6 MS. BONNEVILLE: OS STEWARD.

7 DR. STEWARD: YES.

8 MS. BONNEVILLE: JONATHAN THOMAS.

9 CHAIRMAN THOMAS: YES.

10 MS. BONNEVILLE: ART TORRES.

11 MR. TORRES: AYE.

12 MS. BONNEVILLE: DIANE WINOKUR.

13 MS. WINOKUR: YES.

14 MR. HARRISON: MOTION PASSES WITH 13
15 VOTES.

16 CHAIRMAN THOMAS: THANK YOU, DR.
17 JORGENSON. THANK YOU, MEMBERS OF THE BOARD.

18 WE'RE NOW GOING TO MOVE ON TO ITEM 12,
19 CONSIDERATION OF CONCEPT PLAN FOR THE DISCOVERY
20 STAGE PROGRAM ANNOUNCEMENTS. BEFORE I TURN IT OVER
21 TO DR. MILLS, I JUST WANT TO POINT OUT THAT I THINK
22 THE BOARD AND MEMBERS OF THE PUBLIC WILL BE
23 EXTREMELY IMPRESSED WITH THE WORK THAT HAS BEEN PUT
24 INTO THIS COMING AGENDA TOPIC. IT HAS TAKEN MONTHS
25 AND MONTHS OF CONSIDERABLE EFFORT BY A NUMBER OF

BARRISTERS' REPORTING SERVICE

1 MEMBERS OF THE TEAM, AND I BELIEVE YOU WILL FIND
2 THIS TO BE AN EXCEPTIONAL WORK PRODUCT.

3 IT IS A BIT LENGTHY. THE PRECALL FOR THE
4 SCIENCE SUBCOMMITTEE TO CONSIDER THIS TOOK AN HOUR
5 AND A HALF. THE SCIENCE SUBCOMMITTEE TOOK ABOUT
6 THAT AMOUNT OF TIME, AND HOPEFULLY WE HAVE BEEN ABLE
7 TO RAISE AND ADDRESS MANY OF THE QUESTIONS THAT
8 MEMBERS OF THE BOARD MAY HAVE ON THIS. BUT I THINK
9 THIS WILL ROUND OUT THE CIRM 2.0 MENU ALONG OUR
10 RESEARCH SPECTRUM, AND I HOPE THAT YOU WILL FIND
11 THIS TO BE AS EXCEPTIONAL AS WE ALL DID ON THE
12 SCIENCE SUBCOMMITTEE. WITHOUT FURTHER ADO, DR.
13 MILLS.

14 DR. MILLS: THANK YOU GUYS VERY MUCH FOR
15 THE OPPORTUNITY TO PRESENT THIS TO YOU TODAY. I
16 WANT TO ECHO J.T.'S COMMENTS. THE TEAM AT CIRM LED
17 BY DR. OLSON, KELLY SHEPARD, MICHAEL YAFFE, AND A
18 WHOLE BUNCH OF OTHER PEOPLE DID A TREMENDOUS AMOUNT
19 OF WORK IN COMING UP WITH AN INNOVATIVE PROCESS FOR
20 THE DISCOVERY AND TRANSLATIONAL STAGE PROGRAMS.

21 I'M GOING TO DO AN OVERVIEW TODAY FOR HOW
22 THE WHOLE THING WORKS TOGETHER, AND THEN DR. SHEPARD
23 WILL ACTUALLY PRESENT THE SPECIFIC CONCEPT PLANS.

24 SO, AGAIN, THE SPECTRUM OF THE DIFFERENT
25 THINGS WE FUND: INFRASTRUCTURE, DISCOVERY,

BARRISTERS' REPORTING SERVICE

1 TRANSLATIONAL, CLINICAL, AND EDUCATION. THE PARTS
2 WE'RE TALKING ABOUT FOR THE PURPOSES OF THIS
3 PRESENTATION ARE THE THREE THAT ARE IN THE MIDDLE,
4 DISCOVERY, TRANSLATION, WE DID CLINICAL, WHICH WE
5 LAUNCHED IN 2001, AND A LOT OF WHAT WE'RE DOING HERE
6 IS LINKING THE DISCOVERY, THE TRANSLATIONAL ASPECTS
7 UP TO THAT. A RECURRING THEME YOU'RE GOING TO HEAR
8 TODAY IS NO LONGER LOOKING AT THESE PROGRAMS AS
9 SEPARATE, DISCRETE LITTLE PROGRAMS, BUT INSTEAD
10 TRYING TO CONNECT THEM ALL TOGETHER SO WE CAN CREATE
11 BASICALLY A MACHINE, A PROCESS, THAT WILL
12 EXPEDITIOUSLY DISCOVER THINGS, BUT TRANSLATE THEM
13 AND THEN MOVE THEM INTO THE CLINIC AND HAVE THAT
14 CONTINUUM WORK INSTEAD OF ONE SPECIFIC AREA.

15 SO OUR OBJECTIVE HERE WAS TO PROMOTE THE
16 DISCOVERY OF PROMISING NEW STEM CELL TECHNOLOGIES
17 AND, AS WAS CORRECTLY POINTED OUT, THAT'S ANY KIND
18 OF STEM CELL TECHNOLOGY, AND DRIVE THEIR RAPID
19 TRANSLATION TOWARDS IMPROVING PATIENT CARE. SO FOR
20 THIS STAGE WE CARE ABOUT DISCOVERING THINGS, BUT WE
21 DON'T CARE ABOUT THEM JUST FOR THE SAKE OF
22 DISCOVERING THEM. WE ACTUALLY WANT TO MOVE THEM
23 DOWN THE TRACK AND ULTIMATELY IMPACT PATIENT CARE.

24 WHEN WE WENT THROUGH THIS, WE NOTICED
25 THERE WERE FOUR ISSUES THAT WE NEEDED TO TARGET OF

BARRISTERS' REPORTING SERVICE

1 WE WERE GOING TO MAKE THE DISCOVERY AND
2 TRANSLATIONAL SECTIONS OF THIS BRIDGE WORK
3 EFFECTIVELY. THE FIRST WAS WE NEEDED A CONTINUOUS,
4 PREDICTABLE PATHWAY FOR THESE THINGS TO RUN ON. THE
5 SECOND ONE CENTERS AROUND WHAT WE'LL CALL
6 PROGRESSION EVENT. IT'S ONE THING TO DO INTERESTING
7 RESEARCH, BUT WE WANT THAT RESEARCH TO MOVE DOWN THE
8 LINE TOWARDS PATIENTS.

9 RESPONSIVENESS, WHERE WILL IDEAS COME FROM
10 AND CAN WE BE OPEN AND MORE FLEXIBLE ABOUT THAT,
11 AND, LASTLY, MULTIPLE DEVELOPMENT PATHWAYS.

12 SO WHEN YOU THINK ABOUT THE WAY SORT OF
13 LOGICALLY, YOU CAN IMAGINE THIS WOULD BE LAID OUT.
14 THIS WOULD BE KIND OF WHAT WOULD COME TO MIND WHERE
15 GRANT A WOULD PROGRESS TO GRANT B AND GRANT B WOULD
16 PROGRESS TO GRANT C, AND THOSE THINGS WOULD LINK UP
17 AND OVERLAP. THIS WAS THE FIRST THING WE NOTICED
18 THAT WE NEEDED TO FIX BECAUSE THIS IS ACTUALLY MORE
19 WHAT OUR CURRENT SYSTEM LOOKS LIKE. I SHOWED YOU
20 THIS LAST TIME WHEN WE ACTUALLY HAD IT ON A
21 POWERPOINT. IT'S NOT EVEN LIKE THIS. THESE
22 DIFFERENT SPANS OF TRACK POP UP AND GO AWAY. THAT
23 WAS THE RFA MODEL THAT WE WERE USING. WE'D ISSUE AN
24 RFA; IT WOULD GO AWAY.

25 THE PROBLEM WAS THESE THINGS WEREN'T

BARRISTERS' REPORTING SERVICE

1 LINKED TOGETHER IN ANY SORT OF COORDINATED FASHION.
2 SO IT WAS VERY DIFFICULT FOR OUR INVESTIGATORS TO
3 START SOMEWHERE AND BE ABLE TO MOVE DOWN THE LINE
4 WITH ANY SORT OF PREDICTABILITY.

5 SO THIS IS THE FIRST THING WE'RE FIXING
6 WITH IT ON CIRM 2.0, THE DISCOVERY AND TRANSLATION,
7 IS MAKING SURE WE HAVE CONTINUOUS TRACK. SO IF YOU
8 DISCOVER SOMETHING, LET'S SAY GRANT A, A PRODUCT OF
9 GRANT A, IF IT'S SUCCESSFUL, IS THE PREREQUISITE OF
10 GRANT B. AND THE PRODUCT OF GRANT B IS A
11 PREREQUISITE OF GRANT C, AND THOSE THINGS WORK IN
12 HARMONY.

13 THE SECOND THING IS WE'VE GOTTEN AWAY FROM
14 THIS WHACK A MOLE STUFF. AND THE PROBLEM WITH THAT
15 PROCESS WAS NOBODY KNEW -- INVESTIGATORS DIDN'T KNOW
16 WHEN AN RFA WOULD OPEN UP AND WHEN AN RFA WOULD OPEN
17 UP AGAIN IF EVER. SO WHAT WOULD HAPPEN IS ANY TIME
18 AN RFA OPENED THAT WAS REMOTELY ASSOCIATED WITH
19 THEIR AREA, THEY WOULD ALL JUMP IN AND APPLY FOR IT,
20 NOT WHEN THEY WERE READY, NOT THE ONE THAT MATCHED
21 BEST, BUT ANY TIME IT HAPPENED BECAUSE THEY DIDN'T
22 KNOW WHEN IT WOULD OPEN BACK UP AGAIN.

23 SO WHAT WE WANT TO DO HERE IS WE WANT TO
24 LAY OUT A SCHEDULE AND SAY, LOOK, THESE ARE GOING TO
25 HAPPEN PREDICTABLY FOR DISCOVERY AND TRANSLATION.

BARRISTERS' REPORTING SERVICE

1 WE'RE GOING TO HAVE TWO SETS OF REVIEWS A YEAR. YOU
2 KNOW WHEN, YOU KNOW THAT THEY WILL BE OPEN, AND YOU
3 CAN APPLY WHEN YOU'RE READY, NOT WHEN YOU HAVE TO
4 BECAUSE YOU DON'T KNOW IF THAT PROGRAM IS GOING TO
5 EVER BE OPEN AGAIN.

6 THE SECOND THING WE NOTICED WE NEEDED TO
7 DO CENTERED AROUND WHAT WE CALL PRESCRIBED PROGRESS.
8 WHAT WE FOUND OUT IN LOOKING BACK WAS WHEN WE ISSUED
9 AN RFA AND WE DIDN'T PUT INTENT IN THAT RFA FOR
10 THERE TO BE PROGRESSION, PROGRESSION SPONTANEOUSLY
11 HAPPENED ONLY 5 PERCENT OF THE TIME. SPECIFICALLY,
12 IF WE WOULD PUT OUT A CALL FOR A BASIC RESEARCH
13 PROJECT, ONLY 5 PERCENT OF THE TIME DID SOMETHING
14 ABOUT THAT PROJECT ACTUALLY GO ON TO SOMETHING DOWN
15 THE STREAM.

16 WHEN WE ISSUED AN RFA WHERE THE INTENT OF
17 THE RFA WAS TO GO INTO -- THE INTENT OF GRANT A WAS
18 PRESPECIFIED TO LEAD TO GRANT B, THAT 5-PERCENT
19 NUMBER JUMPED TO 35 PERCENT. AND SO THAT WAS A REAL
20 WAKE-UP CALL FOR US THAT SAID WE NEED TO MAKE SURE
21 THE APPLICANTS FOR CIRM AND FOR CIRM'S PROGRAMS
22 UNDERSTAND AHEAD OF TIME AND NEED TO BE THINKING
23 ABOUT AHEAD OF TIME IF THIS WORKS, IF GRANT A WORKS
24 THE WAY YOU THINK IT DOES, WHAT ARE YOU GOING TO DO
25 TO GET TO GRANT B, WHICH LEADS TO A SECOND ISSUE,

BARRISTERS' REPORTING SERVICE

1 AND ONE OF THE MORE, I THINK, INNOVATIVE ASPECTS
2 THAT THE TEAM CAME UP WITH HERE. AND THAT'S AROUND
3 INCENTIVISATION.

4 WE USED TO HAVE A PROCESS WHERE -- SO
5 LET'S JUST SAY IF YOU WERE A DISCOVERY STAGE
6 RESEARCHER, YOU AT THE END OF THAT MAY NOT WANT TO
7 GO INTO TRANSLATIONAL RESEARCH. IT MIGHT NOT BE
8 WHAT YOU DO. AND SO WHAT WE WOULD FIND OUT IS WE
9 WOULD SORT OF REINVENT MORE AND MORE THINGS TO STUDY
10 ON A PROGRAM IN DISCOVERY INSTEAD OF ACTUALLY HAVING
11 THAT PROGRAM PROGRESS FURTHER DOWN THE TRACK. WHAT
12 WE'RE NOW SAYING IS IF YOU ARE GOOD AT DISCOVERY AND
13 YOU CAN TAKE A CONCEPT AND YOU CAN GET, IF YOU DON'T
14 WANT TO DO IT, SOMEBODY ELSE TO TAKE IT INTO
15 TRANSLATION, THEN WE WANT TO GIVE YOU ANOTHER
16 BASICALLY SEED GRANT TO COME UP WITH THE NEXT GREAT
17 DISCOVERY IDEA. THIS CENTERS AROUND THIS CONCEPT OF
18 NOT ASKING FISH TO TAKE FLYING LESSONS. LET FISH
19 SWIM AND LET BIRDS FLY. THIS CONCEPT OF PRESCRIBED
20 PROGRESSION IS, I THINK, A PRETTY BIG DEAL HERE
21 UNDER CIRM 2.0.

22 THE THIRD CENTERED AROUND RESPONSIVENESS.
23 WE JUST DIDN'T HAVE A GREAT WAY OF HAVING GREAT NEW
24 IDEAS COME INTO OUR SYSTEM. WE WOULD ASK SOMEWHAT
25 SPECIFIC QUESTIONS WHICH WE HOPED WERE THE

BARRISTERS' REPORTING SERVICE

1 CUTTING-EDGE CONCEPTS THAT NEEDED TO BE EVALUATED.
2 WHAT WE CHANGED HERE WITH CIRM 2.0 AND DISCOVERY AND
3 TRANSLATION IS WE'VE NOW OPENED THAT UP, AND WE
4 SAID, YOU KNOW WHAT, YOU PROBABLY HAVE THE BEST
5 IDEAS AND THE MOST CUTTING-EDGE. AND INSTEAD OF US
6 PRESCRIBING THAT TO YOU, WE'RE GOING TO BE MORE OPEN
7 IN TERMS OF WHICH IDEAS ARE PRESENTED TO US.

8 THE OTHER THING WE'VE DONE HERE IS WE'VE
9 ALSO CREATED A MECHANISM TO WHERE WE HAVE A SPECIFIC
10 NEED, LET'S SAY WE HAVE A CLINICAL PROGRAM WHERE
11 THERE'S A SPECIFIC EARLIER STAGE, LET'S SAY SOMEBODY
12 NEEDS A POTENCY ASSAY DONE, AND THE INVESTIGATORS
13 THAT ARE DOING THE CLINICAL STAGE WORK JUST DON'T
14 HAVE THE CAPABILITIES TO DO THAT. WE CAN ACTUALLY
15 NOW UNDER THIS PROGRAM ASK WHAT WE CALL A VERY
16 HIGHLY SPECIFIC QUESTION AND GIVE AN AWARD TO SOLVE
17 A DOWNSTREAM PROBLEM.

18 THE LAST ASPECT ABOUT THIS IS WHILE IN
19 DISCOVERY HISTORICALLY WE WOULD ALLOW PROGRAMS THAT
20 WOULD GO AFTER AND THAT WOULD INVESTIGATE
21 DIAGNOSTICS OR DEVICES OR TOOLS. WE DIDN'T ACTUALLY
22 HAVE ANY PATHWAY OR TRAIN TRACK THAT WOULD GO TO ALL
23 THOSE DIFFERENT DESTINATIONS. AND SO WITH THIS NEW
24 PROCESS THAT WE HAVE, WE'VE NOT ONLY MADE CONTINUOUS
25 TRACK, BUT WE'VE MADE TRACK THAT ACTUALLY GOES TO

BARRISTERS' REPORTING SERVICE

1 ALL THE DIFFERENT KINDS OF TECHNOLOGIES THAT WE WANT
2 OUT OF THIS.

3 AND SO THIS IS SORT OF A STEPPING BACK AND
4 SEEING NOW NOT JUST THE DISCOVERY AND TRANSLATION,
5 BUT ACTUALLY HOW ALL THREE PIECES, DISCOVERY,
6 TRANSLATION, AND CLINICAL, UNDER THIS SYSTEM ARE
7 LINKED TOGETHER IN THAT WE ACTUALLY NOW HAVE A
8 FUNCTIONAL BRIDGE FROM ONE SIDE TO THE OTHER WHERE A
9 LOGICALLY LEADS TO THE B AND C AND SO ON AND SO
10 FORTH.

11 SO IF WE'RE SUCCESSFUL HERE TODAY
12 CONVINCING YOU THIS IS GOOD, WHAT WE WOULD END UP
13 WITH FOR DISCOVERY, TRANSLATION, AND CLINICAL WOULD
14 BE TEN STANDING PROGRAMS THAT ALL LINKED TOGETHER,
15 WHICH WE WOULD ANTICIPATE ISSUING SOMEWHERE BETWEEN
16 70 TO 75 NEW AWARDS EVERY YEAR FOR ABOUT 190 MILLION
17 IN AWARD MONEY. AND YOU CAN SEE THAT INCLUDES 50
18 AWARDS IN THE DISCOVERY PHASE, 12 AWARDS IN
19 TRANSLATION, AND ABOUT 12 AWARDS IN CLINICAL.
20 AGAIN, THESE ARE ALL APPROXIMATE, BUT TO GIVE YOU
21 SORT OF AN IDEA OF THE SCOPE OF WHAT IT IS WE'RE
22 TRYING TO CREATE.

23 SO UNLESS THERE ARE QUESTIONS FOR ME, WHAT
24 WE HAVE UP NEXT IS DR. KELLY SHEPARD TO TALK ABOUT
25 THE SPECIFIC CONCEPT PLANS FOR BOTH DISCOVERY AND

BARRISTERS' REPORTING SERVICE

1 TRANSLATION. I'M HAPPY TO TAKE ANY QUESTIONS IF
2 ANYONE HAS ANY.

3 CHAIRMAN THOMAS: MR. SHEEHY.

4 MR. SHEEHY: I'D JUST LIKE TO MAKE A QUICK
5 COMMENT. AGAIN, THIS WAS HEARD IN THE SCIENCE
6 SUBCOMMITTEE, AND GENERALLY IT WAS WELL RECEIVED
7 THOUGH I THINK THERE MAY BE ONE OR TWO DETAILS THAT
8 MEMBERS MAY HAVE HAD CONCERNS ABOUT, BUT IT WAS
9 SUPPORTED ALMOST UNANIMOUSLY.

10 CHAIRMAN THOMAS: I'D LIKE TO ADD THAT MR.
11 SHEEHY DID AN EXPERT JOB IN NAVIGATING THROUGH ALL
12 THE ELEMENTS OF THESE CONCEPT PLANS AND THE VARIOUS
13 DISCUSSIONS AND APPROVALS THAT FOLLOWED. SO THANK
14 YOU FOR THAT LEADERSHIP, MR. SHEEHY.

15 DR. FINE: I CONTINUE TO HAVE DIFFICULTY
16 UNDERSTANDING WHERE THE BOUNDARIES OF THE WORD
17 "TRANSLATION" LIE. THE WORD MEANS SO MANY THINGS TO
18 SO MANY DIFFERENT PEOPLE, AND I JUST HOPE THAT IN
19 THE UPCOMING DISCUSSIONS LET'S CALL IT DEFINITIONS
20 BECOME CLEARER TO UNDERSTAND BECAUSE MANY PEOPLE ARE
21 DOING WHAT ARE CALLED DISCOVERY RESEARCH SPILLING
22 OVER INTO TRANSLATION IN PART OF WHAT THEY DO, AND
23 THAT BOUNDARY TO ME IS FUZZY.

24 CHAIRMAN THOMAS: THANK YOU. DR. MILLS,
25 DO YOU WANT TO COMMENT ON THAT?

BARRISTERS' REPORTING SERVICE

1 DR. MILLS: SO VERY SPECIFICALLY, WE CALL
2 THEM OUT IN THE CONCEPT PLANS. AND IT'S MORE
3 SPECIFICALLY EVEN IN THE PROGRAM ANNOUNCEMENTS THAT
4 WILL GO OUT. AND THAT'S BECAUSE THOSE BOUNDARIES
5 FOR US ARE VERY IMPORTANT IN TERMS OF INCLUSION AND
6 EXCLUSION CRITERIA TO TELL WHETHER OR NOT AN
7 APPLICATION IS IN SCOPE. DR. SHEPARD IS PROBABLY
8 GOING TO GO OVER AND TOUCH ON THOSE SPECIFIC ITEMS.

9 DR. LEVIN: CAN I JUST ASK HOW THE BUDGET
10 ESTIMATES FOR THE DIFFERENT CATEGORIES THERE WORK?
11 I REALIZE THAT THEY'RE ESTIMATES, BUT HOW DID YOU
12 ARRIVE AT THEM?

13 DR. MILLS: THE OVERALL NUMBERS FOR THE
14 DIFFERENT PROGRAMS? SO THERE'S A TOTAL OF SEVEN NEW
15 SUBPROGRAMS, THREE IN DISCOVERY AND FOUR IN
16 TRANSLATION. THE TRANSLATION, THAT'S PURELY JUST AN
17 ESTIMATE FOR US. BASED ON HISTORICAL EXPERIENCE, WE
18 THINK THERE'S A NEED FOR QUALITY TRANSLATIONAL
19 PROGRAMS THAT WOULD BE ABOUT \$40 MILLION A YEAR, BUT
20 WE DON'T KNOW THAT FOR SURE YET RIGHT NOW. SO
21 THAT'S THE FIRST NUMBER WE WOULD ASK.

22 ONE OF THE CONCEPTS HERE IS IF WE HAD
23 THESE PROGRAMS, IF WE HAD THEM STANDING AND
24 OPERATING OVER TIME, THEN THE BOARD CAN MAKE
25 ADJUSTMENTS TO THESE THINGS AS WE LEARN. AND SO

BARRISTERS' REPORTING SERVICE

1 THAT'S A STARTING PLACE THERE.

2 THE DISCOVERY, YOU WILL SEE, IS A LITTLE
3 BIT MORE INTRICATE IN THAT WE BELIEVE THE DEMAND FOR
4 AWARDS WILL EXCEED OUR SUPPLY AND PROBABLY
5 SIGNIFICANTLY. AND SO WE BASICALLY SET TARGETS AT
6 THE NUMBER OF DIFFERENT TYPES OF AWARDS WE WANTED,
7 AND WE KNOW HOW MUCH THOSE AWARDS COST FULLY
8 BURDENED. AND SO THAT'S HOW THAT CAME ABOUT.

9 CHAIRMAN THOMAS: ANY QUESTIONS OF DR.
10 MILLS?

11 DR. PRICE: I NOTICE THAT THE INCEPTION
12 AWARDS ARE A MAXIMUM OF A HUNDRED FIFTY THOUSAND A
13 YEAR. I'M JUST CURIOUS IF ANYBODY KNOWS OFF THE TOP
14 OF YOUR HEAD WHAT THE AVERAGE AWARD WAS FOR BASIC
15 BIOLOGY IN THE CIRM 1.0.

16 DR. MILLS: THE CLOSEST AWARD WE HAD TO AN
17 INCEPTION AWARD WE DID TWICE WHICH WERE THE SEED.

18 DR. SHEPARD: THE CLOSEST IN THE OVERALL
19 LEVEL OF SUPPORT WERE THE SEED GRANTS, WHICH WERE
20 THE FIRST RESEARCH -- INDIVIDUAL SPONSORED RESEARCH
21 AWARDS THAT WERE OFFERED BY CIRM. IF YOU'RE
22 THINKING ABOUT THE BASIC BIOLOGY PROGRAM, OF WHICH
23 THERE WERE FIVE ITERATIONS, THE DIRECT PROJECT COST
24 SUPPORT FOR THAT WAS APPROXIMATELY \$300,000 DIRECT
25 PER YEAR FOR THREE YEARS.

BARRISTERS' REPORTING SERVICE

1 DR. PRICE: AND THE SEED?

2 DR. SHEPARD: THE SEED GRANT, I BELIEVE IT
3 WAS UP -- I'M NOT SURE OF THE EXACT FIGURE IT'S BEEN
4 SO LONG, AND IT WAS BEFORE MY TIME TOO, BUT I THINK
5 IT WAS CLOSER TO 200 TO 250,000.

6 MR. SHEEHY: I THINK IT'S IMPORTANT TO
7 NOTE THAT THERE'S TWO DIFFERENT TYPES OF BASIC
8 SCIENCE AWARDS OR DISCOVERY AWARDS. AT LEAST WHAT
9 IT LOOKS LIKE TO ME, THE NAMES, I CAN'T GET THESE
10 NAMES RIGHT, THE INCEPTION, THE SMALLER ONE, THOSE
11 LOOK TO ME LIKE SOMETHING THAT THE GATES FOUNDATION
12 HAS DONE. AND MY UNDERSTANDING OF THESE, VERY
13 LITTLE PRELIMINARY DATA, JUST A GREAT IDEA, YOU GET
14 SOME MONEY, SEE IF IT WORKS. IT REALLY STIMULATES
15 TRUE DISCOVERIES. AND THEN THE OTHERS ARE MUCH
16 HIGHER. I THINK THE SECOND CATEGORY, WHAT IS THE --

17 DR. SHEPARD: QUEST AWARDS. I WILL GO
18 INTO THE DETAILS.

19 MR. SHEEHY: HOW MUCH PER PROJECT?

20 DR. MILLS: 1.4 MILLION.

21 MR. SHEEHY: THOSE ARE ACTUALLY MUCH
22 BIGGER. THAT KIND OF GIVES YOU -- I DIDN'T MEAN TO
23 INTERRUPT YOU, DR. SHEPARD. THERE WAS THIS
24 QUESTION. WE KIND OF HAD A DIFFERENT TYPE OF
25 FUNDING THAT FUNDED IN THE MIDDLE A BROADER RANGE OF

BARRISTERS' REPORTING SERVICE

1 PROJECTS, AND I THINK WE DID LOSE SOME OF THE GREAT
2 IDEAS BECAUSE IT CAME IN WITH -- WE WEREN'T REALLY
3 SPONSORING THE KIND OF INNOVATION, GETTING THE NEW
4 INVESTIGATORS INVOLVED BECAUSE WE HAD SUCH A STRICT
5 REQUIREMENT FOR PRELIMINARY DATA. AND ALL THESE
6 CATEGORIES OF ANALYSIS, DATA, PUBLICATIONS, TRACK
7 RECORD REALLY, I THINK, TEND TO MAKE IT WHERE IT'S
8 NOT AVAILABLE TO NEW INVESTIGATORS AND WE MISSED
9 SOME OF THE NEW IDEAS. I THINK BREAKING THIS UP
10 INTO THESE TWO DIFFERENT CATEGORIES, TO ME I WAS
11 IMPRESSED BY THE TEAM'S DECISION TO DO THAT.

12 CHAIRMAN THOMAS: I THINK THE DETAIL THAT
13 DR. SHEPARD WILL PROVIDE IN HER PRESENTATION WILL
14 ADDRESS A NUMBER OF THESE ISSUES. ARE THERE ANY
15 QUESTIONS OF DR. MILLS BY MEMBERS ON THE PHONE?
16 OKAY. HEARING NONE, LET'S PROCEED NOW, DR. SHEPARD,
17 TO YOUR PRESENTATION.

18 DR. SHEPARD: THANK YOU. GOOD AFTERNOON,
19 MR. CHAIRMAN, MEMBERS OF THE BOARD, AND MEMBERS OF
20 THE PUBLIC. I APPRECIATE THE OPPORTUNITY TO COME
21 BEFORE YOU TODAY AND TELL YOU ABOUT THE CONCEPTS
22 WE'VE DEVELOPED FOR THE CIRM 2.0 DISCOVERY AND
23 TRANSLATION PROGRAMS. AND I ALSO THANK DR. MILLS
24 FOR GIVING A WONDERFUL INTRODUCTION TO THIS PROGRAM
25 TO GIVE YOU A LITTLE BIT OF THE CONTEXT IN WHICH WE

BARRISTERS' REPORTING SERVICE

1 DEVELOPED THESE NEW CONCEPTS.

2 THESE ARE ACTUALLY TWO DIFFERENT AGENDA
3 ITEMS, AND I'M GOING TO BE GOING OVER THE DETAILS OF
4 BOTH OF THESE. I'M NOT SURE IF YOU WANT ME TO PAUSE
5 AFTER DISCOVERY FOR DISCUSSION BEFORE WE MOVE INTO
6 THE NEXT ONE.

7 CHAIRMAN THOMAS: YES. WE'LL BE VOTING IN
8 ORDER.

9 DR. SHEPARD: SO I'M GOING TO BEGIN WITH A
10 FAIRLY HIGH LEVEL OVERVIEW OF THE CIRM 2.0 DISCOVERY
11 STAGE CONCEPT PLAN. THERE ARE MANY MORE DETAILS
12 ASSOCIATED WITH THIS IN THE DOCUMENTS THAT WERE
13 PROVIDED AS PART OF THE AGENDA. IN ADDITION TO
14 DESCRIBING THE CONCEPTS THEMSELVES, I'M ALSO GOING
15 TO SUMMARIZE AN OPTIMIZED REVIEW PROCESS THAT WE'VE
16 DEVELOPED THAT WE THINK WILL HELP US MOST
17 EFFECTIVELY IMPLEMENT THIS CONCEPT PLAN, AND THAT
18 WILL ALSO BE PART OF MY PRESENTATION.

19 LET ME BEGIN JUST BY PUTTING THIS UP ON
20 THE SLIDE IN FRONT OF YOU. DR. MILLS HAS ALREADY
21 DESCRIBED HOW DISCOVERY AND TRANSLATION PROGRAMS
22 WITH THE IMPROVEMENTS THAT HE'S DESCRIBED WILL FIT
23 INTO THE OVERALL FRAMEWORK OF CIRM 2.0, WHICH IS TO
24 HELP US BUILD THIS ACCELERATING MACHINE THAT WILL
25 PROVIDE FUNDING OPPORTUNITIES TO HELP DEVELOP NEW

BARRISTERS' REPORTING SERVICE

1 STEM CELL TECHNOLOGIES FROM THEIR INCEPTION AS NEW
2 IDEAS ALL THE WAY THROUGH THEIR EVENTUAL REALIZATION
3 AS TOOLS, DIAGNOSTICS, DEVICES, OR DRUGS THAT CAN
4 HELP PATIENTS WITH UNMET MEDICAL NEEDS.

5 SO IN ORDER TO FOCUS ON THE DISCOVERY PART
6 OF THIS PROGRAM, I'D LIKE TO INTRODUCE YOU TO THE
7 DISCOVERY CONCEPTS, WHICH ACTUALLY COMPRISES THREE
8 NEW PROGRAMS, EACH WITH A SLIGHTLY DIFFERENT
9 OBJECTIVE, BUT ALL SUPPORTING DISCOVERY STAGE
10 RESEARCH IN WAYS THAT WORK TOGETHER TO ACHIEVE ALL
11 OF THOSE REQUIREMENTS THAT DR. MILLS LAID OUT FOR
12 YOU TO IMPROVE THIS PROGRAM.

13 SO I'M JUST GOING TO HIGHLIGHT A FEW
14 FEATURES OF EACH OF THESE AWARDS SO YOU CAN SEE THEM
15 TOGETHER, BUT THEN I'M GOING TO GO INTO A LITTLE BIT
16 MORE DETAIL ABOUT EACH ONE INDIVIDUALLY ON THE
17 SUBSEQUENT SLIDES.

18 FIRST OF ALL, ON THE LEFT HAND OF MY SLIDE
19 WE HAVE THE INCEPTION AWARDS. THIS IS THE SMALLER
20 SEED-LIKE GRANT THAT WE'RE TALKING ABOUT, ALTHOUGH I
21 DO WANT TO EMPHASIZE THIS IS NOT THE SAME AS THE
22 SEED GRANT THAT WAS OFFERED EARLIER IN CIRM'S
23 HISTORY. THIS WAS DEVELOPED AFTER TALKING TO THE
24 FIELD AND ASSESSING THE STATE AND TRYING TO
25 UNDERSTAND WHAT WE NEED NOW AND THE LEVEL OF SUPPORT

BARRISTERS' REPORTING SERVICE

1 THAT WOULD BE APPROPRIATE FOR THAT. AND WE DID HAVE
2 DISCUSSIONS WITH OTHER PROGRAMS THAT SUPPORTED SORT
3 OF COMPARABLE ACTIVITIES TO GET A GOOD IDEA OF WHAT
4 WOULD BE APPROPRIATE.

5 SO, AGAIN, THE INCEPTION AWARDS ARE
6 SMALLER SEED-TYPE FUNDING TO SUPPORT REALLY
7 EXPLORATION OF NOVEL IDEAS PERHAPS THAT COULD BE
8 TRANSFORMATIONAL. IDEALLY THESE COULD GENERATE
9 EARLY DATA THAT WOULD PROVIDE RATIONALE FOR A LARGER
10 FOLLOW-ON AWARD, SUCH AS THE QUEST AWARD, WHICH
11 BRINGS ME TO THE SECOND TYPE OF AWARD OF OUR NEW
12 DISCOVERY STAGE CONCEPT.

13 THE PURPOSE OF THE QUEST AWARDS ARE TO
14 SUPPORT EARLY RESEARCH ON NEW STEM CELL IDEAS OR
15 CONCEPTS. WE THINK OF THIS AS THE REAL WORKHORSE OF
16 THE DISCOVERY PROGRAM. THIS IS THE PROGRAM WHERE AN
17 IDEA IS GOING TO BE DISCOVERED AND DEVELOPED FURTHER
18 INTO A CONCEPT THAT COULD BE PLACED ON THAT TRACK
19 THAT MOVES INTO TRANSLATION.

20 SO THE OUTCOME OF A SUCCESSFUL QUEST AWARD
21 WOULD BE A CANDIDATE STEM CELL TECHNOLOGY THAT IS
22 READY TO MOVE INTO TRANSLATION AND WILL LINK TO THE
23 TRANSLATIONAL AWARD PROGRAM, THE CONCEPT OF WHICH WE
24 WILL BE GOING OVER NEXT. AND RANDY ALSO HINTED THAT
25 THERE IS A NEW ELEMENT THAT WE DEVELOPED

BARRISTERS' REPORTING SERVICE

1 SPECIFICALLY FOR THE QUEST AWARDS THAT WE THINK WILL
2 PROVIDE AN INCENTIVE FOR ONE OF THE MOST DIFFICULT
3 TASKS, WHICH IS GOING UP THAT TRACK INTO
4 TRANSLATION. I SAY UP BECAUSE IT'S DEPICTED AS A
5 FLAT TRACK ON THE SLIDE, BUT REALLY IT IS AN UPHILL
6 CLIMB TO GET INTO PATIENTS. AND WE'RE DOING
7 EVERYTHING WE CAN TO HELP PUSH THAT UP THAT HILL
8 FASTER.

9 AND THE THIRD ELEMENT OF THE DISCOVERY
10 PROGRAM IS THE CHALLENGE AWARDS. THIS IS TO PUT OUT
11 TIMELY CALLS TO ADDRESS HIGHLY SPECIFIC TOPICS, SUCH
12 AS AN EMERGING CONCEPT IN THE FIELD OR PERHAPS AN
13 UNEXPECTED PROBLEM THAT ARISES IN ONE OF OUR
14 EXISTING DEVELOPMENT PROGRAMS WOULD ALLOW US AN
15 OPPORTUNITY TO BRING THE TALENTS AND RESOURCES OF
16 THE DISCOVERY RESEARCH COMMUNITY IN CALIFORNIA TO
17 ATTEMPT TO HELP US OVERCOME SOME OF THOSE TYPES OF
18 PROBLEMS.

19 SO NOW I'M JUST GOING TO GO INTO A LITTLE
20 BIT MORE DETAIL THAT I PROMISED FOR EACH OF THE
21 PROGRAMS, STARTING WITH THE SMALLEST AWARD, THE
22 INCEPTION AWARD. AGAIN, THE PURPOSE OF THIS IS TO
23 PROVIDE SEED FUNDING FOR EXPLORING A POTENTIALLY
24 TRANSFORMATIONAL, BUT EARLY STAGE NEW IDEA INVOLVING
25 STEM CELLS. THE INVESTMENT IN THIS TYPE OF PROJECT

BARRISTERS' REPORTING SERVICE

1 WOULD BE UP TO \$150,000 IN DIRECT COSTS, WHICH FULLY
2 BURDENED WOULD BE APPROXIMATELY \$250,000. I WANT TO
3 GO ON THE RECORD AND CORRECT WHAT I HAD SAID EARLIER
4 ABOUT THE FIRST SEED PROGRAM. THE DIRECT COST FOR
5 THAT WAS \$600,000, AND THAT WAS A TWO-YEAR PROGRAM.

6 SO THE DURATION OF THESE AWARDS WILL NOT
7 BE PRESCRIBED BY CIRM. RATHER, WE EXPECT THE
8 APPLICANT TO PROPOSE AND JUSTIFY THIS BASED ON THE
9 TYPE OF PROBLEM THEY WOULD LIKE TO EXPLORE. AND AS
10 FAR AS PROGRESSION, THAT IS MOVING THINGS DOWN THE
11 TRACK, WE ACKNOWLEDGE THIS IS EARLY STAGE RESEARCH,
12 POTENTIALLY HIGH SCIENTIFIC RISK, POTENTIALLY HIGH
13 REWARD, BUT WE WILL EXPECT THE APPLICANTS TO PROVIDE
14 A VISION OF THE SUCCESSFUL OUTCOME AND SUBSEQUENT
15 PROGRESSION STEPS. IN OTHER WORDS, WE'RE GOING TO
16 ASK THEM IN THE APPLICATION TO STATE IF I'M
17 SUCCESSFUL AND MY IDEA COMES TO FRUITION, WHAT ARE
18 THE NEXT STEPS I WOULD TAKE? HOW COULD I BRING THAT
19 ONTO THE TRACK WHERE IT COULD POTENTIALLY MOVE INTO
20 TRANSLATION? WE WANT THEM TO BE THINKING AHEAD HOW
21 THEY CAN MOVE THAT FROM THE BENCH TO THE BEDSIDE.

22 AND BEFORE I GO ON TO MY NEXT SLIDE, I
23 WANT TO MENTION THAT WE DO EXPECT TO RECEIVE A LARGE
24 NUMBER OF APPLICATIONS FOR THIS TYPE OF A PROGRAM
25 BASED ON OUR HISTORY. AND I BRING THAT TO YOUR

BARRISTERS' REPORTING SERVICE

1 ATTENTION BECAUSE I NEED TO COME BACK TO THAT IN A
2 FEW MINUTES WHEN I TELL YOU ABOUT SOME OF THE
3 PROPOSED PROCESS IMPROVEMENTS THAT WE DEVELOPED TO
4 HELP US EFFECTIVELY MANAGE THESE NUMBERS OF
5 APPLICATIONS.

6 NOW MOVING ON TO THE SECOND TYPE OF
7 DISCOVERY AWARD, THE QUEST AWARDS, THE ONE I
8 DESCRIBED AS THE WORKHORSE OF THE PROGRAM. SO THE
9 GOAL OF THIS IS TO DISCOVER A NOVEL CANDIDATE
10 THERAPEUTIC, DEVICE, DIAGNOSTIC, OR TOOL AND PREPARE
11 IT FOR TRANSLATIONAL RESEARCH. THIS GRANT HAS A
12 DELIVERABLE, AND THE DELIVERABLE IS A CANDIDATE OF
13 ANY OF THESE VARIOUS TYPES, STEM-CELL BASED
14 TECHNOLOGY THAT IS READY TO MOVE INTO TRANSLATION.
15 AND THIS IS A LITTLE BIT DIFFERENT WHETHER IT'S A
16 TOOL OR A THERAPEUTIC, BUT I MENTION THIS BECAUSE
17 YOU HAD ASKED EARLIER ABOUT HOW WE DEFINE DISCOVERY
18 AND TRANSLATION.

19 SO THE INVESTMENT FOR THIS TYPE OF AWARD
20 WOULD BE UP TO \$1.4 MILLION IN DIRECT COST PER
21 PROJECT IF THE PROJECT IS SEEKING TO DEVELOP A
22 CANDIDATE THAT IS A THERAPEUTIC, WHICH IS ESTIMATED
23 TO BE \$2.25 MILLION FOR A FULLY BURDENED AWARD. THE
24 INVESTMENT WOULD BE UP TO \$700,000 IF THE CANDIDATE
25 IS TO BE A DIAGNOSTIC DEVICE OR A TOOL, WHICH IS

BARRISTERS' REPORTING SERVICE

1 \$1.1 MILLION FULLY BURDENED. AND ALL OF THESE
2 NUMBERS NEED TO BE JUSTIFIED BY THE APPLICANT AS
3 WELL FOR SOMETHING THAT MAKES SENSE WITH THEIR
4 PROJECT.

5 THE DURATION OF THE QUEST AWARDS WILL BE
6 UP TO TWO YEARS. AND HERE WE ACTUALLY EXPECT, AS
7 RANDY DISCUSSED IN HIS PRESENTATION, WE EXPECT
8 PROGRESSION. IDEALLY IF EVERYTHING WORKS OUT, THE
9 SCIENCE WORKS OUT, THIS WILL DELIVER A CANDIDATE
10 THAT IS READY FOR TRANSLATION. SO WE EXPECT THE
11 APPLICANT TO PROVIDE A VISION OF A SUCCESSFUL
12 OUTCOME AND WHAT THEY WOULD DO TO PROGRESS THAT INTO
13 TRANSLATION IF THEY DO ACHIEVE THAT SUCCESSFUL
14 OUTCOME. BUT WE WANT TO INCENTIVIZE THEM DO THIS
15 BECAUSE THIS IS NO EASY FEAT. WE'RE OFFERING A NEW
16 ELEMENT IN THE CIRM 2.0 VERSION OF THIS PROGRAM
17 WHICH IS THE INCENTIVE AWARD. AND I'M GOING TO
18 DESCRIBE THAT ON MY NEXT SLIDE.

19 FIRST I WANT TO MENTION THAT THIS IS ALSO
20 A TYPE OF RESEARCH THAT WE EXPECT WILL HAVE A HIGH
21 APPLICATION VOLUME. AND SO THE PROCESS IMPROVEMENT
22 THAT I WILL BE DESCRIBING WILL ALSO APPLY TO THIS
23 PROGRAM.

24 CHAIRMAN THOMAS: QUICK QUESTION. WHAT IS
25 PREVIOUSLY KNOWN IN AN EARLIER LIFE AS TOOLS AND

BARRISTERS' REPORTING SERVICE

1 TECHNOLOGIES, DOES THAT COME UNDER HERE? I NOTICE
2 YOU REFERENCE TOOLS HERE, BUT YOU ALSO REFERENCE
3 BOTTLENECKS UNDER THE CHALLENGE AWARDS. WHICH
4 CATEGORY DOES THAT COME UNDER?

5 DR. SHEPARD: WELL, TOOLS COULD COME INTO
6 EITHER OF THOSE AWARDS DEPENDING ON THE STAGE. IF
7 IT'S A TOOL THAT YOU WANT TO TRANSLATE AND
8 COMMERCIALIZE FOR BROAD USE AND IT WAS AT THE STAGE
9 WHERE YOU'RE READY FOR THOSE ACTIVITIES -- SORRY.
10 IF IT'S AT A STAGE WHERE IT'S CLOSE TO THAT, IT
11 COULD COME INTO QUEST TO GET IT TO THE POINT WHERE
12 IT COULD GO INTO TRANSLATION; OR IF IT'S SOMETHING
13 THAT'S MORE IN THE EARLY STAGES AND AS A CONCEPT
14 IT'S SOMETHING YOU WANT TO FLESH OUT A LITTLE BIT
15 FURTHER TO TEST ITS POTENTIAL, IT COULD COME IN AS
16 AN INCEPTION AWARD. IF IT'S A TOOL THAT SOMEBODY
17 HAS DEVELOPED TO ADDRESS A VERY SPECIFIC BOTTLENECK
18 THAT THIS IS THE SUBJECT OF A CALL FOR A CHALLENGE
19 AWARD, THEN IT COULD EVEN COME IN UNDER THAT PROGRAM
20 DEPENDING WHAT THE CALL IS FOR THE TIME.

21 SO, YES, WE ARE CAPTURING WHAT WE FORMERLY
22 CALLED TOOLS AND TECHNOLOGIES, BUT RATHER THAN
23 HAVING THESE OCCASIONAL RFA'S THAT CAME OUT
24 UNPREDICTABLY, IT'S ALWAYS GOING TO BE OPEN UNDER
25 THE NEW DISCOVERY PROGRAM.

BARRISTERS' REPORTING SERVICE

1 OKAY. GETTING BACK TO THE INCENTIVE PIECE
2 OF THE QUEST AWARDS, SO THE PURPOSE OF THIS
3 INCENTIVE IS TO INCREASE THE EFFICIENCY AT WHICH
4 PROMISING DISCOVERY RESEARCH PROGRESSES INTO THE
5 TRANSLATIONAL STAGE AND TO REINVEST IN THE DISCOVERY
6 STAGE RESEARCHERS THAT SUCCESSFULLY ADVANCE
7 RESEARCH. RANDY ALLUDED TO THIS WHEN WE TALKED
8 ABOUT WHEN THERE'S AN INTENT TO PROGRESS, WE WOULD
9 SEE ABOUT 30 PERCENT, BUT WE THINK WE CAN DO BETTER
10 THAN THAT. WE KNOW IT'S AN UPHILL BATTLE, AND WE
11 WANT TO INCENTIVIZE THE INVESTIGATORS ON OUR QUEST
12 AWARDS TO DO EVERYTHING IN THEIR POWER TO GET THAT
13 INTO TRANSLATION EVEN IF IT MEANS HANDING OVER THAT
14 PROJECT TO SOMEBODY WHO HAS THE RIGHT TYPE OF
15 TRAINING AND EXPERIENCE TO DO THAT. SO THAT'S THE
16 LOGIC BEHIND THIS.

17 THE INVESTMENT FOR THIS PIECE OF THE
18 INCENTIVE AWARD, AS RANDY ALLUDED TO EARLIER ALSO,
19 IS VERY MUCH LIKE THE SEED-LIKE INCEPTION GRANT.
20 THE INVESTMENT FOR THAT WOULD 150,000 IN DIRECT COST
21 PER PROJECT, ESTIMATED \$250,000 FULLY BURDENED,
22 WITHOUT SPECIFIED DURATION. IT DEPENDS ON WHAT
23 MAKES SENSE FOR WHAT THEY PROPOSE TO DO WITH THIS
24 INCENTIVE AWARD. IT HAS TO BE ALIGNED WITH CIRM'S
25 MISSION. JUST AS WITH THE INCEPTION AWARDS, THE

BARRISTERS' REPORTING SERVICE

1 APPLICANT IS EXPECTED TO PROVIDE A VISION OF THE
2 SUCCESSFUL OUTCOME AND WHAT THEY WOULD DO IF THEY
3 WERE SUCCESSFUL IN ACHIEVING THAT OUTCOME. SO THEY
4 CAN'T TAKE THIS PROGRESSION INCENTIVE AND DO
5 WHATEVER THEY WANT. THEY'RE STILL GOING TO BE DOING
6 SOMETHING THAT IS ALIGNED WITH CIRM'S MISSION. AND
7 THIS IS WHAT WE'RE REFERRING TO WHEN WE SAY WE ARE
8 REINVESTING IN THE DISCOVERY STAGE RESEARCHERS THAT
9 HAVE BEEN SUCCESSFUL IN GETTING THEIR DELIVERABLE
10 INTO TRANSLATION.

11 SO WE EXPECT THE VOLUME OF THIS TO BE
12 SOMEWHAT LOW BECAUSE IT'S ONLY GOING TO BE OPEN TO
13 QUEST AWARDEES WHO HAVE NOT ONLY SUCCEEDED IN
14 ACHIEVING THE DELIVERABLE OF THEIR QUEST AWARD, BUT
15 THEY WILL HAVE TO PROVIDE EVIDENCE THAT THEY HAVE
16 SUCCESSFULLY MOVED THAT PROJECT INTO TRANSLATION
17 WITH THE FUNDING BEHIND IT TO KEEP IT GOING. AND AT
18 THE TIME THEY THINK THEY HAVE DONE THAT, THEY WILL
19 SUBMIT THIS DOCUMENTATION TO CIRM SO THAT WE CAN
20 VERIFY THAT THIS HAS OCCURRED AND SO THAT WE CAN
21 MAKE SURE THAT THE PROGRESSION AWARD OR THE
22 INCENTIVE THAT THEY RECEIVED IS ALIGNED WITH CIRM'S
23 MISSION AND IN SCOPE WITH THE OBJECTIVES OF THE
24 PROGRESSION AWARD.

25 DR. PRICE: I'D LIKE TO FOLLOW UP ON

BARRISTERS' REPORTING SERVICE

1 DR. FINE'S QUESTION ABOUT WHAT'S YOUR OPERATIONAL
2 DEFINITION OF TRANSLATIONAL? YOU KEEP SAYING MOVE
3 INTO TRANSLATIONAL RESEARCH. IF YOU TALK TO ME
4 ABOUT MOVING INTO CLINICAL RESEARCH, I UNDERSTAND
5 WHAT A CLINICAL TRIAL IS. BUT IT SEEMS TO ME THIS
6 TRANSLATIONAL THING IS QUITE SQUISHY, AND I JUST
7 WANT TO HAVE AN OPERATIONAL DEFINITION SO THAT WE
8 KNOW THE DIFFERENCE BETWEEN WHAT'S BEING DONE IN THE
9 QUEST AWARD AND HOW MUCH IS GOING TO BE DONE IN THE
10 TRANSLATION OF THAT QUEST AWARD TO SOMETHING ELSE.

11 DR. SHEPARD: THE TRANSLATION AWARDS,
12 WHICH WE'LL TALK ABOUT NEXT, ARE REALLY SUPPORTING
13 THE ACTIVITIES THAT ARE STARTING TO MOVE INTO THE
14 REGULATED ENVIRONMENT. THE DISCOVERY AWARDS, WHAT
15 WE EXPECT THEM TO HAVE BY THE END OF THE AWARD IS
16 BASICALLY IF THEY'RE LOOKING AT DEVELOPING A
17 THERAPY, THEY'RE GOING TO HAVE A SINGLE LEAD
18 CANDIDATE FOR WHICH THEY HAVE REPRODUCIBLE EVIDENCE
19 OF DISEASE-MODIFYING ACTIVITY IN A RELEVANT MODEL.
20 SO THE BASIS OF WHAT THEY NEED TO START THINKING
21 ABOUT IS TALKING TO THE FDA BECAUSE THE NEXT STAGE,
22 THE TRANSLATION, IS GOING TO BE DONE UNDER THE
23 REGULATED ENVIRONMENT WHERE THEY DO HAVE TO MEET ALL
24 THOSE SPECIFICATIONS. AND THE TOOLS AND DEVICES
25 AND -- THE DEVICES AND THE DIAGNOSTICS HAVE A

BARRISTERS' REPORTING SERVICE

1 REGULATORY PATHWAY THAT CAN DIFFER DEPENDING ON THE
2 TYPE OF TOOL, DIAGNOSTIC, OR DEVICE IT IS.

3 SO WE'VE MAPPED THAT OUT IN THE ALLOWED
4 ACTIVITIES FOR EACH OF THE INDIVIDUAL PROGRAMS IN
5 BOTH THE QUEST AWARD CONCEPT AND THE TRANSLATIONAL
6 AWARD CONCEPTS.

7 ANOTHER QUESTION?

8 DR. FINE: I THINK THAT LAST COMMENT IS
9 HELPFUL. AND IF THAT BECOMES THE UNDERSTANDABLE
10 DEFINITION, THE WORDS "MOVING INTO THE REGULATED
11 ENVIRONMENT" SHOULD BE PART OF THE DESCRIPTOR OF
12 THIS PARTICULAR AWARD TO MAKE IT CLEAR THAT THIS IS
13 REALLY WHAT'S BEING TALKED ABOUT.

14 DR. SHEPARD: WE'LL TAKE NOTE OF THAT.
15 THANK YOU FOR THAT SUGGESTION.

16 ARE THERE ANY OTHER QUESTIONS BEFORE I
17 MOVE ON?

18 THE THIRD TYPE OF DISCOVERY AWARD IS THE
19 CHALLENGE AWARD. REMEMBER THE PURPOSE OF THIS IS TO
20 ADDRESS HIGHLY SPECIFIC QUESTIONS ON EMERGING
21 CONCEPTS, BOTTLENECKS, OR DOWNSTREAM NEEDS AS
22 REQUESTED BY CIRM OR THE BOARD. THIS IS MORE OF A
23 REAL-TIME OPPORTUNITY TO BE FLEXIBLE AND ADDRESS
24 POTENTIALLY PROBLEMS THAT COME UP THAT WEREN'T
25 ANTICIPATED OR, AS RANDY MENTIONED, NEW CONCEPTS

BARRISTERS' REPORTING SERVICE

1 THAT ARE EMERGING THAT WOULD BENEFIT FROM THE
2 RESOURCES OF THE CALIFORNIA STEM CELL DISCOVERY
3 RESEARCH COMMUNITY IN HELPING TO SOLVE OR
4 INVESTIGATE.

5 THE INVESTMENT FOR THE CHALLENGE AWARDS
6 WOULD BE SPECIFICALLY TAILORED TO THE QUESTION THAT
7 WAS ASKED. SO THIS WOULD NOT LIKELY BE MORE THAN UP
8 TO \$2 MILLION ALL TOLD FOR ALL THE CHALLENGE
9 ANNOUNCEMENTS THAT WE WOULD PUT OUT. SIMILARLY, THE
10 DURATION WOULD BE TAILORED FOR THE SPECIFIC QUESTION
11 OR TOPIC OF THE CHALLENGE AWARD.

12 AS FAR AS PROGRESSION, THAT ALSO DEPENDS
13 ON THE TOPIC BECAUSE IN MANY CASES WE WILL USE THE
14 CHALLENGE AWARDS TO ADDRESS SPECIFIC BOTTLENECKS.
15 SO WHILE SOLVING A PROBLEM MIGHT NOT IN AND OF
16 ITSELF PROGRESS, IT SHOULD BE ENABLING FOR OTHER
17 THINGS TO PROGRESS IF THEY'RE A SPECIFIC PROJECT IN
18 OUR PIPELINE OR MORE BROADLY ENABLING FOR THE FIELD.

19 BECAUSE THESE TOPICS WILL BE SO SPECIFIC,
20 WE ANTICIPATE A LOW APPLICATION VOLUME; HOWEVER, IN
21 THE PROCESS IMPROVEMENT THAT I DESCRIBED, IF FOR
22 SOME REASON WE RECEIVE MORE THAN WE FELT THAT WE
23 COULD REALISTICALLY REVIEW OR FEASIBLY REVIEW IN A
24 GRANTS WORKING GROUP MEETING, WE WOULD IMPLEMENT
25 THIS IMPROVED PROCESS THAT I'M GOING TO DESCRIBE ON

BARRISTERS' REPORTING SERVICE

1 MY NEXT COUPLE OF SLIDES.

2 SO AS PROMISED, I'M GOING TO NOW BRIEFLY
3 DESCRIBE THE OPTIMIZED REVIEW PROCESS THAT WE'VE
4 DEVELOPED TO HELP US EFFECTIVELY MANAGE HIGH VOLUME
5 PROGRAMS. AND THIS IS DESCRIBED IN MUCH MORE DETAIL
6 IN THE APPENDIX THAT ACCOMPANIED THE CONCEPTS, BUT
7 I'LL GIVE YOU AN OVERVIEW ON MY NEXT SLIDE.

8 SO BASICALLY FOR ROUNDS WHERE WE DO
9 RECEIVE A HIGH APPLICATION VOLUME, WE ARE PROPOSING
10 TO CREATE A TWO-STEP OR TWO-STAGE REVIEW PROCESS OUT
11 OF OUR GRANTS WORKING GROUP REVIEW. SO THE STAGE 1
12 PART OF THIS REVIEW PROCESS, WHICH WE HAVE NICKNAMED
13 POSITIVE SELECTION, WILL BE A PEER REVIEW THAT WILL
14 BE CONDUCTED BY THE GRANTS WORKING GROUP; THAT IS,
15 22 MEMBERS OF THE GRANTS WORKING GROUP COMPRISING 15
16 SCIENTIFIC MEMBERS AND 7 PATIENT ADVOCATE MEMBERS.
17 THE PURPOSE OF PREREVIEW WILL BE TO SELECT A SUBSET
18 OF APPLICATIONS TO ADVANCE TO STAGE 2. CIRM WILL
19 ALSO HAVE AN OPPORTUNITY TO SELECT APPLICATIONS FOR
20 REVIEW AFTER THE GRANTS WORKING GROUP HAS MADE THEIR
21 SELECTIONS.

22 THE SECOND STAGE IS THE STANDARD IN-PERSON
23 GRANTS WORKING GROUP REVIEW MEETING. THIS IS THE
24 MEETING THAT RESULTS IN FUNDING DECISIONS. SO
25 THAT'S IMPORTANT TO NOTE. THE FIRST STAGE ADVANCES

BARRISTERS' REPORTING SERVICE

1 PROPOSALS TO THE SECOND STAGE OF REVIEW, BUT IT IS
2 THE SECOND STAGE WHICH IS THE ROUTINE GRANTS WORKING
3 GROUP MEETING THAT WE'VE HAD FACE TO FACE THAT
4 RESULTS IN FUNDING RECOMMENDATIONS THAT ARE BROUGHT
5 TO THE BOARD FOR YOU TO MAKE THE FINAL DECISIONS
6 ABOUT FUNDING.

7 WHAT WE BELIEVE THIS PROCESS IMPROVEMENT
8 OFFERS IS A SINGLE-STEP APPLICATION PROCESS. SO
9 SOME OF YOU REMEMBER THAT FOR OUR PAST ROUNDS OF
10 HIGH VOLUME APPLICATION WHERE WE RECEIVED HUNDREDS
11 IN RESPONSE TO A CALL, WE WERE USING SOMETHING
12 CALLED THE PREAPP PROCESS WHICH INVOLVES A TWO-STEP
13 APPLICATION PROCESS WHERE APPLICANTS SUBMITTED A
14 SHORT VERSION OF AN APPLICATION, THEY WERE SENT OUT
15 FOR REVIEW BY EXPERTS, SCORED, AND THEN THE TOP
16 RANKED ONES WERE INVITED TO SUBMIT FULL PROPOSALS.
17 IN THIS NEW PROCESS THERE WILL BE ONE APPLICATION
18 STEP. EVERYBODY WILL SUBMIT THEIR FULL APPLICATION,
19 AND THAT PREAPP STEP AND REVIEW I DESCRIBED DOESN'T
20 HAVE TO HAPPEN IN THIS. IT'S GOING TO SHAVE A
21 COUPLE OF MONTHS OFF THE OVERALL TIMELINE FROM
22 APPLICATION SUBMISSION TO FINAL DECISIONS. SO
23 THAT'S A SIGNIFICANT IMPROVEMENT IN OUR MIND.

24 WE ALSO BELIEVE THAT THIS NEW PROCESS IS
25 SCALABLE IN RESPONSE TO APPLICATION VOLUME. SO WE

BARRISTERS' REPORTING SERVICE

1 THINK IT WILL BE EFFECTIVE WHETHER IT'S THE 500
2 APPLICATIONS OR IF WE ONLY RECEIVE 100 APPLICATIONS.
3 AND WE DO BELIEVE THAT IT WILL FACILITATE SELECTION
4 OF PROPOSALS WITH HIGH POTENTIAL FOR IMPACT FOR WHAT
5 IS ANTICIPATED TO BE A VERY BROAD APPLICANT POOL.

6 ARE THERE ANY QUESTIONS BEFORE I MOVE TO
7 THE PROPOSED ACTION?

8 MR. ROWLETT: MY ASSUMPTION IS THAT IN
9 STAGE 1, AND I DO SUPPORT THIS, I JUST WANT TO BE
10 CLEAR, I WANT IT TO BE CLEARLY STATED THAT I ASSUME
11 THAT THE CIRM STAFF REVIEW IN STAGE 1 AND THE GWG
12 REVIEW IN STAGE 1 WILL USE THE SAME REVIEW CRITERIA.

13 DR. SHEPARD: THE CIRM STAFF REVIEW --
14 WE'RE NOT PARTICIPATING AS REVIEWERS THE WAY YOU
15 WILL BE, THE WAY THE GRANTS WORKING GROUP WILL BE.
16 THE PROCESS WILL BE CONDUCTED BY MEMBERS OF THE
17 GRANTS WORKING GROUP. AND AFTER THOSE DECISIONS ARE
18 MADE, CIRM JUST WANTS TO LOOK AT THE -- BECAUSE
19 THERE'S GOING TO BE POSSIBLY MANY HUNDREDS OF
20 APPLICATIONS, WE WANT TO LOOK AT ALL OF THEM THAT
21 WEREN'T SELECTED JUST TO MAKE SURE NOTHING STANDS
22 OUT AS HAVING BEEN OVERLOOKED, SOMETHING WE MIGHT
23 RECOGNIZE FROM OUR OWN EXPERIENCE AS BEING
24 IMPORTANT, AND WE CAN BRING THAT TO THE ATTENTION OF
25 A GRANTS WORKING GROUP MEMBER AND ASK THEM TO HAVE

BARRISTERS' REPORTING SERVICE

1 ANOTHER LOOK AT IT, OR WE COULD ACTUALLY MOVE IT
2 FORWARD TO THE SECOND STAGE IF WE DETERMINE THAT
3 THERE'S A REASON TO DO THAT. WE'RE NOT ACTING AS A
4 MEMBER OF THE GRANTS WORKING GROUP AND PERFORMING AS
5 AN EQUAL IN SELECTING THE SAME NUMBER. IT'S MORE OF
6 AN ASSURANCE THAT THE PROCESS IS WORKING.

7 MR. ROWLETT: THAT WASN'T CLEAR TO ME IN
8 YOUR REPORT. AND, AGAIN, YOU SAID THAT THE CIRM
9 STAFF MIGHT REVIEW AN APPLICATION THAT WAS REVIEWED
10 BY THE GRANTS WORKING GROUP, DECIDE THAT SOMETHING
11 WAS MISSED, AND THEN FORWARD IT TO THE BOARD OR
12 FORWARD IT BACK --

13 DR. SHEPARD: NO. NO. NO. NOT FORWARD
14 IT TO THE BOARD. FORWARD IT TO THE SECOND STAGE OF
15 REVIEW, WHICH IS THE GRANTS WORKING GROUP. SO IT
16 WOULD JUST BE ASSIGNED TO THE GRANTS WORKING GROUP
17 MEMBERS AND DISCUSSED IN THE FACE-TO-FACE MEETING
18 JUST LIKE THE OTHER APPLICATIONS.

19 MR. ROWLETT: I THOUGHT THAT'S WHAT YOU
20 WERE IMPLYING. THANK YOU.

21 DR. PRICE: IN STAGE 1, ARE ALL 22 MEMBERS
22 OF THE GRANTS WORKING GROUP GOING TO REVIEW ALL THE
23 PROPOSALS?

24 DR. SHEPARD: NO. IN THE APPENDIX -- THEY
25 CAN IF THEY WANT.

BARRISTERS' REPORTING SERVICE

1 DR. PRICE: YOU SAID SOMETHING LIKE 500.
2 I WAS WONDERING ABOUT THE MATH HERE.

3 DR. SHEPARD: SO THE PROCESS IS DESCRIBED
4 IN A BIT MORE DETAIL IN THE APPENDIX, AND I DON'T
5 KNOW IF YOU'VE HAD ENOUGH TIME TO REALLY DELVE INTO
6 IT. BASICALLY YOU WILL HAVE ACCESS -- PARTICIPANTS
7 WILL HAVE ACCESS TO ALL THE APPLICATIONS, AND THEY
8 CAN LOOK AT THEM, AS MANY AS THEY WANT, BUT WE WILL
9 GIVE THEM A MINIMUM NUMBER TO LOOK AT TO ENSURE THAT
10 WE HAVE COVERAGE ACROSS THE ENTIRE POOL. AND THEY
11 WILL SELECT THE ONES THAT THEY FEEL MOST EXCITED
12 ABOUT AS HAVING POTENTIAL TO ADVANCE OUR MISSION AND
13 THINK THEY WOULD LIKE TO SEE MORE OF IN THE SECOND
14 STAGE. AND THEN THOSE THAT MAKE IT THROUGH THE --
15 I'M SORRY. SO THEY WILL BE SELECTED AND MOVED TO
16 THE FULL GRANTS WORKING GROUP WHERE THEN THEY WILL
17 BE ASSIGNED TO THE SCIENTIFIC MEMBERS, AND PATIENT
18 ADVOCATE MEMBERS AND SCIENTIFIC MEMBERS WILL CONDUCT
19 THAT MEETING AS PER USUAL AND COME UP WITH
20 RECOMMENDATIONS TO BRING TO THE BOARD.

21 DR. LEVIN: IF I COULD JUST MAKE A COMMENT
22 ON THIS PROCESS. I THINK IT COULD BE VERY EFFECTIVE
23 IF HANDLED PROPERLY AND ALL THE PIECES IN PLACE TO
24 DO THAT, BUT WE NEED TO ENSURE THAT IT IS AND PEOPLE
25 KNOW THAT IT IS. THAT THIS IDEA OF A POSITIVE

BARRISTERS' REPORTING SERVICE

1 RECOMMENDATION, IT'S EFFECTIVELY A TRIAGE, WHICH A
2 NUMBER OF GRANT AGENCIES USE. AND RATHER THAN -- IN
3 MY OFFICE WE HANDLE THE CAMPUS SUBMISSIONS, SO WE DO
4 WHAT'S EFFECTIVELY PREAPP. AND PEOPLE PREFERRED
5 THAT SOMETIMES BECAUSE IT'S MUCH SHORTER AND THEY
6 DON'T HAVE TO GO THROUGH ALL THE WORK. IF WE
7 REQUIRE THAT PEOPLE PUT THE FULL PROPOSAL TOGETHER,
8 WE'LL WORK WITH THEM HAND IN HAND ALONG THE WAY SO
9 THAT WE CAN MADE GOOD GO/NO-GO DECISION EARLY ON.

10 THAT IS PART OF 2.0, RIGHT, THIS
11 COUNSELING AND GIVING PEOPLE FEEDBACK ON THEIR IDEAS
12 ALONG THE WAY SO THAT ONLY GOOD IDEAS GET WRITTEN IN
13 FULL PROPOSAL, BUT I THINK THAT THAT ASPECT OF THE
14 PROCESS IS CRITICAL TO GETTING IT BUY-IN BY ALL OF
15 THE APPLICANTS, KNOWING THAT THEY CAN GET SOME
16 GUIDANCE ALONG THE WAY AS TO WHETHER -- SUBMITTING
17 ALL OF THESE FULL APPLICATIONS. I ENCOURAGE YOU TO
18 COMMUNICATE THAT OFTEN AND AS CLEAR AS YOU CAN.

19 DR. MILLS: ONE OF THE THINGS THAT WE IN
20 GOING AROUND TO THE DIFFERENT INSTITUTIONS AND
21 LISTENING, PARTICULARLY ON THE ACADEMIC SIDE, WAS
22 JUST AN ABSOLUTE FRUSTRATION WITH THE PREAPP THE WAY
23 IT USED TO BE. AS A FORMER REVIEWER, THE PREAPP
24 PROCESS WAS CLEARLY BROKEN. AND SO THIS WAS OUR
25 ATTEMPT TO TRY FIX IT. BUT I THINK THAT'S A VERY

BARRISTERS' REPORTING SERVICE

1 IMPORTANT POINT, AND OUR REVIEW TEAM IS ACTUALLY
2 PRETTY GOOD AT THAT IN REACHING OUT OR BEING
3 AVAILABLE TO PEOPLE THAT REACH OUT TO US THAT WANT
4 HELP IN FIGURING OUT WHAT'S IN SCOPE AND WHAT MAKES
5 THE MOST COMPETITIVE APPLICATION. VERY GOOD POINT.

6 DR. GASSON: THANK YOU, DR. SHEPARD, FOR
7 AN EXCELLENT PRESENTATION. I HAD JUST TWO QUICK
8 QUESTIONS ABOUT THIS VERY EXCITING PROGRAM FROM THE
9 WRITTEN MATERIALS. IN THE INCEPTION GRANTS, THE
10 WRITTEN MATERIAL SAID THAT THE FIRST PAYMENT WOULD
11 BE 75 PERCENT OF ALLOWABLE FUNDS AND THE FINAL 25
12 PERCENT WOULD BE DISTRIBUTED UPON AWARD CLOSEOUT. I
13 TOTALLY GET IT ABOUT IT ACHIEVING A MILESTONE TO
14 SHOW THAT YOU'RE EXPENDING THE FUNDS WISELY, BUT I
15 JUST THINK ADMINISTRATIVELY IT WOULD BE VERY
16 DIFFICULT TO AWARD THE SECOND 25 PERCENT AFTER THE
17 CLOSEOUT AND WONDER IF YOU COULD RECONSIDER LOOKING
18 AT THE MILESTONES EARLIER IN THE PROCESS.

19 DR. SHEPARD: WELL, ACTUALLY IT'S STANDARD
20 PRACTICE AT CIRM TO WITHHOLD THE LAST PAYMENT UNTIL
21 AFTER CLOSEOUT. IT HELPS MOTIVATE ALL MATERIALS TO
22 COME IN AND ALL THE REQUIREMENTS LAID OUT IN PROP 71
23 AND OUR POLICY, SUCH AS ENSURING THAT ANY
24 PUBLICATIONS OR INVENTIONS THAT HAVE BEEN REALIZED
25 ARE PROPERLY DISCLOSED TO CIRM. THAT PART'S

BARRISTERS' REPORTING SERVICE

1 STANDARD PRACTICE AND WOULDN'T ADD BURDEN. BUT
2 BECAUSE THIS IS SUCH A SHORT PROGRAM, IT'S AN AMOUNT
3 OF MONEY AND WE'RE NOT SPECIFYING A LINK, BUT WE ARE
4 THINKING IT'S VERY UNLIKELY THAT THIS WOULD BE MORE
5 THAN TWO YEARS GIVEN THE AMOUNT OF FUNDING OF
6 \$150,000. AND NORMALLY WE REQUIRE A PROGRESS REPORT
7 FOR SOME OF OUR LONGER PROGRAMS AT ONE YEAR, AND
8 SOMETIMES IT JUST EVEN TAKES THEM A LITTLE BIT
9 LONGER TO GET THINGS LAUNCHED THAN THEY THOUGHT. SO
10 BECAUSE THIS IS SUCH A SMALL AWARD AND IT'S HIGH
11 RISK RESEARCH, WE FELT THAT IT WOULD PUT LESS
12 BUREAUCRACY AND LET THEM DO WHAT THEY DO BEST, WHICH
13 IS USE THAT MONEY AND EXPLORE IT, BUT THEY WILL BE
14 REPORTING IN TO GET THAT FINAL PAYMENT. AND WE JUST
15 WANT TO MAKE SURE THAT IT'S IN COMPLIANCE AND IS
16 MOVING FORWARD.

17 DR. GASSON: THANK YOU FOR THAT
18 CLARIFICATION.

19 MY SECOND QUESTION IS ON THE QUEST AWARDS.
20 AND THOSE AWARDS ARE FOR TWO YEARS FOR THE PROJECT
21 DELIVERABLE. WE ALL KNOW THAT SCIENCE DOESN'T
22 ALWAYS PROCEED IN A LINEAR WAY. I JUST WONDERED IF
23 THERE WOULD BE ANY POSSIBLE FLEXIBILITY, NOT WITH
24 MORE FUNDING, BUT TO POTENTIALLY REQUEST AN
25 EXTENSION OF TIME.

BARRISTERS' REPORTING SERVICE

1 DR. SHEPARD: SO WE'VE TRADITIONALLY
2 ALLOWED NO-COST EXTENSIONS IF THEY ARE JUSTIFIED BY
3 THE APPLICANT, AND WE WOULD CONSIDER THAT HERE AS
4 WELL. BUT IT'S IMPORTANT TO KEEP IN MIND THAT WE
5 ARE TRYING TO ACCELERATE, AND SO THESE ARE FAIRLY
6 LEAN AWARDS, AND WE HAVE SOME -- IN ORDER TO GET TO
7 THAT STAGE IN TWO YEARS, WE'RE GOING TO NEED TO
8 PRESENT A CASE TO THE REVIEWERS THAT THEY HAVE
9 ENOUGH BASIS TO GO ON THAT THEY CAN ACTUALLY ACHIEVE
10 THAT WITHIN TWO YEARS. SO, YES, WE WILL CONSIDER
11 THAT IF THERE'S A NEED AND IT'S WELL JUSTIFIED, BUT
12 WE'RE REALLY HOPEFUL THAT THESE TYPES OF AWARDS WILL
13 REALLY HELP ACCELERATE PROGRESS INTO TRANSLATION.

14 DR. GASSON: THANK YOU VERY MUCH. IT'S A
15 VERY EXCITING PROGRAM.

16 DR. PRICE: MAY I FOLLOW UP THE FIRST PART
17 OF YOUR QUESTION? I HATE TO GET DOWN IN THE WEEDS
18 ON THIS, BUT I THINK THE WAY THAT IS WORDED, AND
19 I'VE CHECKED WITH MY FOLKS AT THE UNIVERSITY, MAY
20 CREATE A PROBLEM FOR GETTING THESE AWARDS THROUGH
21 UNIVERSITY OF CALIFORNIA'S GRANTS ADMINISTRATION
22 PROGRAM. AND THAT'S THE LANGUAGE WHICH SAYS
23 ACCEPTABLE PROGRESS. WHAT IS THAT PHRASE YOU USE?
24 THE 25 PERCENT WILL ONLY BE AWARDED AFTER THE REVIEW
25 OF THE FINAL REPORT.

BARRISTERS' REPORTING SERVICE

1 DR. SHEPARD: IT'S MAINLY TO ENSURE
2 COMPLIANCE.

3 DR. PRICE: I UNDERSTAND WHAT YOU ARE
4 SAYING, BUT IT DOESN'T SAY THAT. THE PROBLEM IS
5 THAT THAT WORDING IS READ AS SOMETHING WHICH COULD
6 LEAD A FUNDING AGENCY, THIS IS GENERAL POLICY, IT'S
7 NOT ABOUT CIRM, LEAD A FUNDING AGENCY TO REFUSE TO
8 FUND THE LAST AMOUNT IF THEY DON'T LIKE THE RESULTS
9 OF A PARTICULAR GRANT. THAT'S HOW THEY DEFINE
10 PROGRESS. SO THIS IS GOING TO BE A RED FLAG. I'VE
11 CHECKED WITH OUR FOLKS IN THE GRANTS ADMINISTRATION.

12 DR. MILLS: I THINK THAT'S A GOOD POINT.
13 AND THAT'S EASILY ADDRESSABLE BECAUSE THIS IS THE
14 CONCEPT. IT'S NOT THE PROGRAM ANNOUNCEMENT. SO THE
15 ACTUAL --

16 DR. PRICE: THAT'S WHY I'M RAISING THAT.
17 JUST WHAT YOU JUST SAID TO ME IN ANSWER WHEN I ASKED
18 WHAT YOU MEAN BY PROGRESS, THAT WILL PASS MUSTER.

19 DR. MILLS: WE WILL FIX IT.

20 DR. SHEPARD: SO I'LL JUST READ THE EXACT
21 LANGUAGE SO WE CAN NAIL DOWN THE PART THAT WE NEED
22 TO FIX. SO WE SAY THE FINAL 25 PERCENT WILL BE
23 DISBURSED UPON AWARD CLOSEOUT, INCLUDING RECEIPT AND
24 CIRM APPROVAL OF THE PROGRESS REPORT AND FINANCIAL
25 REPORTS. WHAT THAT REALLY MEANS IS WE WANT THEM TO

BARRISTERS' REPORTING SERVICE

1 JUST SUBMIT EVERYTHING THAT THEY'RE SUPPOSED TO TO
2 CLOSE OUT THE AWARD. IF THEY HIT A SCIENTIFIC
3 BOTTLENECK OR A TECHNICAL HURDLE AND THEY REALLY
4 TRIED AND THEY JUST WEREN'T ABLE TO GET THROUGH IT,
5 THAT'S NOT A LACK OF PROGRESS.

6 DR. PRICE: I UNDERSTAND. IF YOU DON'T
7 LIKE THE HYPOTHESIS.

8 DR. LEVIN: ONE LAST TECHNICAL QUESTION,
9 PROBABLY. IN THE INCEPTION AWARDS AND I THINK THE
10 OTHER ONES, IT SAYS THAT YOU'RE NOT ALLOWED TO APPLY
11 FOR THE GRANT IF YOU ALREADY HAVE AN INCEPTION AWARD
12 OR HAVE ONE UNDER CONSIDERATION.

13 DR. SHEPARD: WHAT THAT MEANS IS YOU CAN
14 SUBMIT ONE APPLICATION PER CYCLE. IF YOU SUBMIT
15 THROUGH THE FIRST CYCLE AND RECEIVE AN INCEPTION
16 AWARD, WE'RE NOT GOING TO STOP YOU FROM APPLYING FOR
17 A QUEST AWARD OR ANOTHER INCEPTION AWARD WHEN THE
18 TIME COMES AROUND.

19 DR. LEVIN: I THOUGHT I READ WITH THE
20 INCEPTION THAT IF YOU HAVE AN INCEPTION AWARD,
21 YOU'RE NOT ELIGIBLE TO HAVE ANOTHER GOOD IDEA FOR
22 THAT TIME, WHICH I KNOW THAT OUR FACULTY WILL AT
23 LEAST THINK THAT THEY HAVE GOOD IDEAS.

24 DR. SHEPARD: SO THE LANGUAGE WE NEED TO
25 CLARIFY IS MUST NOT CURRENTLY HAVE ANOTHER

BARRISTERS' REPORTING SERVICE

1 APPLICATION PENDING A REVIEW OR APPROVAL UNDER THIS
2 FUNDING OPPORTUNITY. SO WE NEED TO CLARIFY THAT
3 IT'S WITHIN THE CYCLE.

4 DR. LEVIN: APPROVAL UNDER THE FUNDING
5 OPPORTUNITY. SO YOU'RE SAYING IF SOMEBODY HAS AN
6 INCEPTION AWARD, THEY CAN TWO MONTHS LATER PUT IN
7 ANOTHER?

8 DR. SHEPARD: YES. YES. ANY FURTHER
9 QUESTIONS?

10 NOW I'M GOING TO MOVE ON TO THE PROPOSED
11 ACTION. THE PROPOSED ACTION, THE REQUEST THAT WE
12 NEED A BOARD DECISION IN ORDER TO IMPLEMENT THIS
13 CONCEPT PLAN. SO I HAVE TWO SLIDES TO DESCRIBE THIS
14 BECAUSE, FIRST OF ALL, IN ORDER TO HELP US MOST
15 EFFECTIVELY IMPLEMENT THIS PROCESS, WE WOULD LIKE TO
16 REQUEST DELEGATION OF BOARD AUTHORITY TO THE
17 PRESIDENT OR DESIGNEES TO ACCOMPLISH THE FOLLOWING.
18 THIS RELATES TO THE PROCESS IMPROVEMENTS AND NEW
19 ELEMENTS THAT I DESCRIBED FOR YOU.

20 SO THE FIRST ONE HAS TO DO WITH THE
21 TWO-STAGE REVIEW PROCESS THAT I DESCRIBED,
22 SPECIFICALLY THAT FIRST STEP, WHICH I CALLED
23 POSITIVE SELECTION. WE REQUEST DELEGATION OF BOARD
24 AUTHORITY TO THE PRESIDENT OR HIS DESIGNEE TO ENABLE
25 EXAMINATION AND SELECTION OF OTHER APPLICATIONS THAT

BARRISTERS' REPORTING SERVICE

1 MERIT SECOND STAGE REVIEW BEYOND THOSE SELECTED BY
2 THE GRANTS WORKING GROUP, IF ANY, AND TO DETERMINE
3 NOT TO FUND THE REMAINING.

4 THE SECOND REQUEST FOR DELEGATION IS TO
5 DETERMINE THAT IF A PROGRESSION EVENT HAS BEEN
6 ACHIEVED UNDER A QUEST AWARD, IN OTHER WORDS, THE
7 QUEST AWARDEE HAS COMPLETED THEIR GRANT, ACHIEVED
8 THEIR DELIVERABLE, AND SUCCESSFULLY MOVED IT INTO
9 TRANSLATION AND FOUND A WAY TO FUND THAT TO MOVE
10 FORWARD. WE ARE ASKING FOR THE AUTHORITY TO
11 DETERMINE THAT THAT CRITERIA HAS BEEN MET AND TO
12 ENSURE THAT THE PROGRESSION OR THE INCENTIVE PIECE
13 THAT WOULD COME INTO PLAY IF THAT BAR IS MET AND
14 THAT CONFORMING AWARD AT THAT TIME.

15 AND THEN THE THIRD DELEGATION WE'RE
16 REQUESTING IS THE ABILITY TO ISSUE TIMELY CHALLENGE
17 QUESTION ANNOUNCEMENTS THAT DEFINE A SPECIFIC
18 QUESTION IN CORRESPONDING AWARD TERMS SO THAT A REAL
19 BOTTLENECK COMES UP IN ONE OF OUR DEVELOPMENT
20 PROGRAMS. AN EXAMPLE THAT I'VE HEARD RANDY GIVE IS
21 SOMEBODY NEEDS A POTENCY ASSAY AND THEY NEED THE
22 HELP OF SOME BASIC RESEARCH INVESTIGATORS TO DEVELOP
23 THAT, PUT OUT A SPECIFIC CALL IN THE NEXT CYCLE AND
24 DESIGN A REQUEST FOR APPLICATIONS AROUND THAT
25 BASICALLY. OKAY.

BARRISTERS' REPORTING SERVICE

1 SO THOSE ARE FOR THE PROCESS IMPROVEMENTS.
2 AND THE SECOND PART IS THE FUNDING REQUEST. SO THE
3 TOTAL ALLOCATION THAT WE WOULD REQUEST TO SUPPORT A
4 YEAR'S WORTH OF THIS PROGRAM IS \$53 MILLION WITH THE
5 FOLLOWING ALLOTMENTS. SO APPROXIMATELY 6.5 MILLION
6 FOR SUPPORTING INCEPTION AWARDS. THIS WOULD SUPPORT
7 ABOUT 26 AWARDS. FOR THE QUEST AND PROGRESSION
8 AWARDS AN ALLOCATION OF 42.5 MILLION TO SUPPORT
9 ABOUT 20 AWARDS. IT'S IMPORTANT TO POINT OUT THIS
10 FIGURE OF 42.5 INCLUDES THE PROGRESSION AWARDS. SO
11 35 MILLION OF THAT IS GOING TO SUPPORT THE PARENT
12 AWARD, THE QUEST PART OF IT, AND THE REMAINING 7.5
13 MILLION IS SORT OF A RESERVE THAT WOULD BE TO FUND
14 THOSE PROGRESSION AWARDS. THAT'S ASSUMING THAT A
15 HUNDRED PERCENT OF 30 AWARDS IS SUCCESSFUL. WE
16 REALLY DON'T THINK THAT'S POSSIBLE, BUT WE WOULD BE
17 DELIGHTED IF THAT WERE THE CASE. MOST LIKELY IT
18 WILL BE SOMETHING LOWER THAN THAT, HOPEFULLY HIGHER
19 THAN 35 TO 40 PERCENT.

20 AND FINALLY, FOR THE CHALLENGE AWARDS,
21 THESE ARE THE SPECIFIC TIMELY CALLS, WE ARE
22 REQUESTING AN INVESTMENT OF APPROXIMATELY \$4
23 MILLION, WHICH WOULD SUPPORT UP TO FOUR AWARDS.

24 CHAIRMAN THOMAS: DR. SHEPARD, THESE WOULD
25 BE OVER WHAT TIME FRAME?

BARRISTERS' REPORTING SERVICE

1 DR. SHEPARD: THIS IS AN ANNUALIZED CYCLE
2 OF AWARDS.

3 CHAIRMAN THOMAS: SO EVERYBODY UNDERSTANDS
4 THAT. IT'S AN ANNUAL NUMBER. OKAY.

5 DR. SHEPARD: AND IT'S FOR THIS FIRST YEAR
6 OF THE PROGRAM, YES.

7 CHAIRMAN THOMAS: THANK YOU. DO WE HEAR A
8 MOTION TO ADOPT THIS PROGRAM?

9 MR. SHEEHY: SO MOVED.

10 CHAIRMAN THOMAS: MOVED BY MR. SHEEHY.

11 MR. TORRES: SECOND.

12 CHAIRMAN THOMAS: SECONDED BY SENATOR
13 TORRES. COMMENTS, QUESTIONS FROM MEMBERS OF THE
14 BOARD?

15 DR. FINE: I PROBABLY MISUNDERSTOOD THIS,
16 BUT I THOUGHT I HEARD YOU SAY THAT IN ORDER TO
17 COMPETE FOR THE QUEST PROGRESSION AWARD, ONE MUST
18 SHOW THAT THERE IS ALREADY FUNDING FOR THE
19 TRANSLATIONAL COMPONENT OF THAT PARTICULAR
20 APPLICATION. SINCE TRANSLATION IN THIS RAILROAD
21 TRACK COMES AFTER THE QUEST PROCESS, DOES THAT MAKE
22 SENSE, OR DID I MISUNDERSTAND THAT?

23 DR. SHEPARD: WELL, WHAT WE WANT THEM TO
24 SHOW IS EVIDENCE THAT THEY HAVE A MEANS AND THE
25 MONEY TO GET IT INTO TRANSLATION, AND IT DOESN'T

BARRISTERS' REPORTING SERVICE

1 HAVE TO COME FROM OUR TRANSLATION AWARD PROGRAM. SO
2 WE'RE GOING TO BE TALKING ABOUT THE TRANSLATION
3 PROGRAM NEXT, WHICH WILL HAVE BIENNIAL OPPORTUNITIES
4 TO COMPETE. THAT IS ONE WAY OF MOVING A SUCCESSFUL
5 QUEST AWARD FORWARD, BUT THERE ARE OTHER WAYS.
6 SOMEBODY MIGHT FIND A COLLABORATOR IN A COMPANY WHO
7 IS WILLING TO TAKE THAT ON. SOMEBODY MIGHT APPLY
8 FOR AND RECEIVE A GRANT FROM ANOTHER FUNDING AGENCY.
9 WE DON'T CARE WHERE THE MONEY COMES FROM. IF THEY
10 CAN PROVE THAT THEY HAVE A GOOD TEAM IN PLACE TO DO
11 IT, AN APPROPRIATE TEAM, AND A MEANS TO MOVE THAT
12 FORWARD, NOT JUST SAY IT'S IN TRANSLATION, BUT
13 ACTUALLY PROVIDE EVIDENCE THAT IT IS GOING TO MOVE
14 FORWARD, THAT IS WHAT MERITS THE INCENTIVE.

15 DR. FINE: I STILL DON'T GET IT, I'M
16 AFRAID. IF THE QUEST FUNDING IS TO CREATE A
17 SITUATION WHICH WILL MAKE IT TRANSLATABLE, HOW WOULD
18 IT BE POSSIBLE TO GET THAT ALREADY TRANSLATABLE
19 FUNDING FROM ANY AGENCY IF THAT WORK HASN'T BEEN
20 DONE AND COMPLETED?

21 DR. SHEPARD: I'M SORRY. I LEFT OUT A
22 DETAIL. THEY HAVE A YEAR FROM THE END OF THE QUEST
23 AWARD TO BE ABLE TO DEMONSTRATE THAT.

24 DR. FINE: SO IT MEANS THAT THERE HAS TO
25 BE SUFFICIENT PROGRESS SHOWN DURING THE QUEST

BARRISTERS' REPORTING SERVICE

1 PROCESS TO PERSUADE SOME FUNDING AGENCY THAT THEY'RE
2 READY FOR TRANSLATION AND TO GET SUCH FUNDING. I
3 DON'T KNOW IF ANYBODY HAS THIS PROBLEM. I JUST
4 DON'T UNDERSTAND THAT.

5 DR. SHEPARD: IT'S WITHIN A YEAR OF THE
6 AWARD CLOSING OUT, WHICH IF THE PROGRESS BY THE END
7 OF TWO YEARS ISN'T QUITE THERE, THERE IS THE
8 POSSIBILITY OF A JUSTIFIED NO-COST EXTENSION.
9 HOWEVER, WHILE THIS CONCEPT IS LAYING THIS OUT,
10 WE'RE ALSO WORKING ON OTHER CIRM 2.0 ELEMENTS SUCH
11 AS WE ARE WORKING ON A POTENTIAL WAY TO HELP
12 MATCHMAKE INVESTIGATORS TO HELP THEM FIND PARTNERS
13 TO TAKE THIS INTO TRANSLATION. SO THIS IS JUST ONE
14 PIECE OF THE BIG MACHINE WE'RE TRYING TO BUILD, AND
15 WE THINK THIS IS AN IMPORTANT MOTIVATOR. AND WE'RE
16 JUST TRYING TO GET PEOPLE TO DO EVERYTHING THEY CAN
17 AND THINK AHEAD WHERE WE WANT THEM TO. WE'RE ASKING
18 THEM WHEN THEY APPLY TO LAY OUT WHAT THEY PLAN TO DO
19 IF THEY ARE SUCCESSFUL AND BE THINKING ABOUT IT ALL
20 ALONG THE WAY, AND THEY WILL HAVE AN INTERACTION
21 WITH CIRM ALONG THE WAY AND SCIENCE OFFICE TO HELP
22 ADVISE THEM.

23 MS. WINOKUR: I WAS WONDERING IF THE
24 MOTION INCLUDES INCLUDING THE CHANGES OR
25 CLARIFICATIONS, ET CETERA, THAT WERE SUGGESTED

BARRISTERS' REPORTING SERVICE

1 DURING THIS MEETING.

2 DR. SHEPARD: YES.

3 MS. WINOKUR: IT'S NOT IN THE MOTION.

4 MR. HARRISON: THE CONCEPT PROPOSAL ITSELF
5 WAS REVISED TO REFLECT THE CHANGES THAT WERE MADE OR
6 THE RECOMMENDATIONS THAT WERE MADE AT THE SCIENCE
7 SUBCOMMITTEE. SO, FOR EXAMPLE, THE EXCLUSION OF THE
8 ENRICHMENT FUNDING HAS BEEN ADDRESSED IN THE CONCEPT
9 PROPOSAL.

10 MS. WINOKUR: BUT THERE WERE FURTHER
11 CLARIFICATIONS DURING OUR DISCUSSION.

12 DR. SHEPARD: THE CLARIFICATION, AND
13 SOMEBODY WHO HAS AN INCEPTION AWARD IS ELIGIBLE TO
14 APPLY IN ANOTHER CYCLE, THAT RESTRICTION IS LIMITED
15 TO THE CYCLE. AND THE ONE ABOUT THE CLOSEOUT AND
16 WHAT PROGRESS MEANS.

17 MR. HARRISON: THOSE ARE CLARIFICATIONS
18 THAT WILL MADE IN THE PROGRAM ANNOUNCEMENT ITSELF.

19 MS. WINOKUR: THANK YOU.

20 DR. STEWARD: SO THANK YOU VERY MUCH. IT
21 WAS REALLY A GREAT SUMMARY OF EVERYTHING. I THINK
22 THAT THERE'S A LOT OF MEAT HERE, AS WE SAID IN THE
23 SCIENCE SUBCOMMITTEE MEETING. JEFF ALLUDED TO THIS.
24 I WAS THE ONE WHO ABSTAINED FROM THE VOTING. AND
25 PART OF THE REASON WAS THAT THERE'S STILL SOME

BARRISTERS' REPORTING SERVICE

1 ISSUES I HAVE JUST IN TERMS OF UNDERSTANDING HOW THE
2 INCENTIVE AWARD WORKS. I THINK THERE HAVE BEEN
3 QUESTIONS ABOUT THAT. RANDY, PART OF THIS IS
4 DELEGATED AUTHORITY TO MAKE THOSE DECISIONS. COULD
5 YOU JUST SORT OF WALK US THROUGH HOW YOU ENVISION
6 THIS ACTUALLY HAPPENING, AT THE STAGE WHEN IT WOULD
7 HAPPEN, AND KIND OF THE CRITERIA YOU WOULD USE AND
8 THE WHOLE THING?

9 DR. MILLS: THE PROGRESSION?

10 DR. STEWARD: YEAH. THE INCENTIVE PART.
11 I THINK EVERYTHING IS CLEAR ABOUT THE QUEST AWARD
12 ITSELF, BUT IT'S THAT, OKAY, THEY'VE COME TO THE
13 END, THEY'RE GOING TO HAVE A YEAR TO DO SOMETHING,
14 WHAT THAT SOMETHING IS, AND THEN THEY'RE GOING TO
15 GET AN EXTRA \$150,000. IF YOU COULD KIND OF WALK
16 THROUGH THAT WHOLE THING.

17 DR. MILLS: SO THE CONCEPT IS THEY'VE DONE
18 THE RESEARCH PROJECT AND THEY'VE CLOSED OUT THEIR
19 RESEARCH PROGRAM WITH US. AND HOPEFULLY THEY ARE
20 BEFORE THAT TIME OR DURING THAT TIME, THEY'RE TAKING
21 THE DATA THAT THEY GENERATED UNDER THAT DISCOVERY
22 STAGE AWARD AND THEY ARE EITHER SEEKING ADDITIONAL
23 FOLLOW-ON FUNDING FROM US THROUGH A TRANSLATIONAL
24 PROGRAM FOR WHICH THERE WOULD BE MULTIPLE
25 OPPORTUNITIES IN CYCLE FOR THEM TO BE ABLE TO GET,

BARRISTERS' REPORTING SERVICE

1 ASSUMING ALL STAGES ARE APPROVED, AND THEN THEY
2 WOULD JUST SIMPLY SUBMIT THAT DOCUMENTATION THAT
3 THEY WERE SUCCESSFUL WINNING THAT EITHER FROM US,
4 LIKE WE SAID, NIH, OR INDUSTRY THAT THERE WAS A FIRM
5 COMMITMENT FUNDING DECISION FOR ITS CONTINUED
6 TRANSLATION OR ITS CONTINUED DEVELOPING INTO
7 TRANSLATION HAD BEEN SUCCESSFULLY ACCOMPLISHED AND
8 THAT IT WAS USING THE SAME TECHNOLOGY, THEN WE WOULD
9 EVALUATE THAT. THE TEAM AND MYSELF WOULD EVALUATE
10 WHETHER OR NOT THAT HAD BEEN MET.

11 IF WE HAVE QUESTIONS, OBVIOUSLY WE WOULD
12 TALK WITH THE APPLICANT AND TRY TO GET A
13 CLARIFICATION ON THAT, MAKE A DECISION THAT, IN
14 FACT, THEY HAD MET IT, AND THEN MAKE SURE THAT THEIR
15 INCENTIVE AWARD WAS STILL WITHINSIDE ALL OF THE
16 PARAMETERS OF BASICALLY AN INCEPTION AWARD AND THAT
17 IT FELL WITHIN SCOPE.

18 AND THE IDEA HERE IS THIS COMES OUT OF
19 CONVERSATIONS, AGAIN, WITH THE ACADEMIC
20 INSTITUTIONS. THEY WANT -- THE MOST IMPORTANT THING
21 TO THEM WAS LATITUDE. IT WAS REALLY INTERESTING.
22 WE JUST HAD SOME OF THEM JUST FLAT OUT SAY YOU JUST
23 SHOULD GIVE US MONEY AND LEAVE US ALONE. AND IT WAS
24 A TEMPTING IDEA BECAUSE IT WOULD HAVE BEEN A LOT
25 EASIER THAN THIS. BUT OUT OF THAT GREW THIS IDEA

BARRISTERS' REPORTING SERVICE

1 THAT THIS IS A VERY, VERY IMPORTANT THING, LATITUDE
2 FOR THESE INVESTIGATORS TO BE ABLE TO TRY THINGS ON
3 THEIR OWN, AND SO WE THOUGHT IT WAS SO IMPORTANT AND
4 IT'S SO VALUABLE TO THEM, THAT WE COULD USE IT
5 MEANINGFULLY AS AN INCENTIVE. BUT ONE OF THE THINGS
6 WE KEPT HEARING OVER AND OVER AGAIN, AND I THINK
7 IT'S TRUE, IS IF IT'S GOING TO ACTUALLY WORK AS AN
8 INCENTIVE, IT'S GOT TO BE VERY TIMELY. THAT WAS
9 JUST WHY WE NEEDED IT. I KNOW IT'S UNCOMFORTABLE,
10 THIS DELEGATION, TO BE ABLE TO PULL IT OFF IN A
11 TIMELY FASHION SUCH THAT IT WOULD BE A MEANINGFUL
12 INCENTIVE FOR THEM.

13 DR. STEWARD: IF I COULD JUST FOLLOW UP.
14 REALLY KIND OF GOING BACK TO THE QUESTION THAT CAME
15 UP, WHAT IS DEFINED AS TRANSLATION. SO GETTING
16 FOLLOW-UP FUNDING IS ONE THING, BUT WHAT WOULD
17 DEFINE THAT FOLLOW-UP AS TRANSLATION?

18 DR. MILLS: WE'RE USING THE TRANSLATION
19 SCOPE FOR OUR TRANSLATIONAL AWARD, THAT SCOPE OF
20 ACTIVITIES, TO DEFINE WHETHER OR NOT THEY HAD -- IF
21 THEY WANT A TRANSLATIONAL AWARD, OBVIOUSLY THAT
22 WOULD BE PERFECT. IF NOT, WHATEVER THEY DO HAS TO
23 SHOW THAT IT WOULD BE IN SCOPE FOR ALL AWARDEES.

24 DR. LEVIN: IF I MAY, I THINK THE POINT
25 THAT MIGHT NOT BE CLEAR IN SOME OF THE DISCUSSION

BARRISTERS' REPORTING SERVICE

1 AND THE WRITING IS THAT THE INCENTIVE AWARD IS NOT
2 FOR THE PROJECT THAT IS BEING MOVED FORWARD TO
3 TRANSLATION. IT'S A REWARD FOR PASSING OFF A
4 PROJECT TO TRANSLATION TO BE ABLE TO GO AND WORK ON
5 SOMETHING STILL WITHIN CIRM'S SCOPE, BUT A DIFFERENT
6 PROJECT AT AN EARLIER STAGE.

7 DR. MILLS: THAT'S CORRECT. AND THE IDEA
8 IS IF WHAT YOU DO IS GREAT DISCOVERY RESEARCH AND
9 YOU DON'T WANT TO DO TRANSLATION, BUT YOU DO THE
10 DISCOVERY RESEARCH REALLY, REALLY WELL, WE WANT TO
11 BE INVESTORS ON THAT.

12 MR. SHEEHY: SO I GUESS NOW I'M CONFUSED.
13 BECAUSE I GUESS I HAD NOT UNDERSTOOD THAT THE BATON
14 PASSING HAD TO BE WITHIN CIRM TRANSLATION SCOPE. IT
15 SEEMS TO ME, USING THE TRAIN TRACK ANALOGY, THAT
16 MAYBE THE NEXT STOP ON THE TRACKS DOESN'T
17 NECESSARILY NEED TO BE TRANSLATION. AND CERTAINLY
18 WOULDN'T WE WANT TO REWARD PEOPLE FOR CONTINUING TO
19 SEEK FUNDING TO PROGRESS SCIENCE THAT WE'VE STARTED
20 DOWN THE TRACK EVEN IF IT DOESN'T FALL WITHIN THE
21 SCOPE OF CIRM'S TRANSLATION? SO IF THEY WERE TO
22 HAVE SUCCESSFUL RESULTS, THEY SUBMIT TO NIH, NIH
23 FUNDS THEM, THAT MAY NOT BE A TRANSLATIONAL AWARD,
24 BUT THEY'RE MOVING THAT SCIENCE FORWARD, WHICH IS
25 PRESUMABLY GOING TO GET TO TRANSLATION AT SOME

BARRISTERS' REPORTING SERVICE

1 POINT.

2 I JUST WORRY ABOUT THE RIGIDITY OF THE
3 DEFINITION OF A TRANSLATION EVENT AND WONDER IF
4 IT -- ISN'T OUR GOAL HERE TO KEEP SCIENCE FROM DYING
5 ON THE VINE? PEOPLE DO THE SCIENCE AND THEN NOTHING
6 MOVES FORWARD.

7 DR. MILLS: IT'S THE MOVEMENT PART OF IT.
8 WE COULD GET CIRCULAR STUDYING OF A PARTICULAR TOPIC
9 OVER AND OVER AND OVER AGAIN. WE WANT IT TO GO
10 DOWNSTREAM TOWARDS A PATIENT, NOT BE CHRONICALLY
11 STUDIED, WHICH IS REALLY THE HEART OF THIS. IT'S
12 NOT -- AGAIN, NOT GETTING A PROGRESSION AWARD
13 DOESN'T MEAN YOU DID BAD WORK OR IT WASN'T
14 SUCCESSFUL. THIS WAS DESIGNED TO SPECIFICALLY
15 INCENTIVIZE A KIND OF MOVEMENT TOWARDS THE CLINIC,
16 NOT JUST FURTHER STUDY OF A TOPIC.

17 MR. SHEEHY: OKAY. I'M TORN BETWEEN MY
18 USUAL DESIRE TO, LIKE, HAVE FAIRLY FIRM PARAMETERS,
19 BUT ALSO I WONDER IF THE CRITERIA THAT ARE APPLIED
20 TO BE ELIGIBLE FOR A CIRM TRANSLATION AWARD ARE TOO
21 RESTRICTIVE IN TERMS OF QUALIFYING SOMEONE FOR THE
22 INCENTIVE AWARD IN THIS INSTANCE. SO PEOPLE CAN
23 START TO DO TRANSLATION ACTIVITIES THAT MAY NOT AS A
24 WHOLE HAVE ENABLED THEM TO BE QUALIFIED FOR A CIRM
25 GRANT, BUT CLEARLY PASSING IT ON TO SOMEONE WHO IS

BARRISTERS' REPORTING SERVICE

1 STARTING THE PROCESS OF MOVING THE PROJECT DOWN INTO
2 TRANSLATION. SO I TAKE YOUR POINT. YOU WANT IT TO
3 BE CLEARLY TRANSLATIONAL, BUT I WONDER IF THE FENCE
4 THAT YOU'RE TYING AROUND TRANSLATIONAL MAY BE TOO
5 RESTRICTIVE. I THINK IT'S ALWAYS A CHALLENGE
6 BECAUSE IF IT'S TOO, THE DECISION BECOMES ULTIMATELY
7 ARBITRARY. I THINK THAT MAYBE WE MIGHT WANT TO
8 RETHINK THAT TO KIND OF MORE CLEARLY GIVE THE
9 FLEXIBILITY. PROJECTS JUST DON'T ALL END AT THE
10 SAME STATION, WHICH IS KIND OF THE IMPLICATION HERE,
11 THAT IT WILL END AT TRANSLATION STATION AND IT WILL
12 GET ON THE TRAIN RIGHT IN FRONT OF US AND KEEP
13 MOVING, OR WE'LL RECOUPLE OURSELVES TO A NEW ENGINE
14 THAT WILL CARRY US TO THE NEXT STATION. AND I
15 WONDER IF THERE ARE NOT TRAINS THAT STOP SOMEWHERE
16 SHORT, BUT MAY BE COUPLED TO A TRAIN THAT CARRIES
17 THEM INTO THE TRANSLATION SPACE. TRAIN ANALOGY, I'M
18 SORRY TO ABUSE IT. I'M WONDERING HOW WE'RE GOING TO
19 HAVE THE NECESSARY FLEXIBILITY TO REALLY GET THE
20 MAXIMUM UTILITY OUT OF THE INCENTIVE.

21 DR. MILLS: SO IS THE QUESTION THAT YOU'RE
22 HAVING AROUND THE SCOPE OF THE ENTIRE AWARD VERSUS
23 THE STAGE?

24 MR. SHEEHY: I'M FOCUSED ON THE CRITERIA
25 FOR THE ELIGIBILITY FOR THE INCENTIVE AWARD. AND

BARRISTERS' REPORTING SERVICE

1 THE CRITERIA AS HAS BEEN PRESENTED IS THAT ONCE YOUR
2 AWARD -- YOUR PROGRESSION EVENT WOULD BE ONE INTO A
3 PROJECT THAT WOULD BE ELIGIBLE TO BE REVIEWED AS A
4 CIRM TRANSLATION GRANT. AND I WONDER IF THAT'S TOO
5 RESTRICTIVE. THAT IS MY QUESTION. AND I THINK THAT
6 THE CIRM TRANSLATION GRANTS ALL START AT A CERTAIN
7 STATION, THE CRITERIA VERY WELL DEVELOPED. SO
8 THAT'S WHERE I WONDER IF THAT'S TOO RESTRICTIVE.

9 DR. MILLS: KEEP IN MIND WHAT'S REALLY, I
10 THINK, CRITICAL TO UNDERSTAND IS THE QUEST AWARD HAS
11 A DESTINATION, AND THAT DESTINATION IS THE
12 PREREQUISITE TO THE TRANSLATION AWARD. SO IF THEY
13 WERE SUCCESSFUL IN THEIR QUEST AWARD, THEY WOULD BE
14 THERE. AND IF THEY WEREN'T SUCCESSFUL, THAT WOULD
15 BE THE ONLY REASON THEY WOULD BE SHORT OF MEETING
16 THE TRANSLATION CRITERIA IS IF THEY WEREN'T ACTUALLY
17 SUCCESSFUL WITH THEIR ORIGINAL AWARD BECAUSE THE
18 QUEST AWARD GOES ALL THE WAY TO THE TRANSLATION.

19 CHAIRMAN THOMAS: DR. FINI AND DR. LEVIN.

20 DR. FINI: JEFF SAID SOMETHING THAT HAS
21 HELPED TO CLARIFY WHAT'S BEEN TROUBLING ME A LITTLE
22 BIT TOO ABOUT THIS. IT SEEMS LIKE THERE'S A MISSING
23 PIECE. MAYBE IT'S NOT REALLY MISSING. IT'S JUST
24 UNSAID. IT SEEMS LIKE THERE'S A WHOLE AREA OF
25 DISCOVERY AND FIGURING OUT BEFORE YOU GET TO THE

BARRISTERS' REPORTING SERVICE

1 TRANSLATION THAT IS NOT REALLY BEING FUNDED HERE.
2 AND IN YOUR HEAD YOU MAY BE THINKING, WELL, THEY CAN
3 GO TO NIH AND THEY CAN GO TO FOUNDATIONS, THEY CAN
4 GO TO GET THEIR IDEA TO THE POINT OF TRANSLATION,
5 BUT THAT'S NOT BEING SAID. IS THAT WHAT YOU'RE
6 THINKING? BECAUSE A \$100,000 IS SO LITTLE TO
7 DEVELOP AN IDEA, REALLY, ALMOST NOTHING.

8 DR. MILLS: SO THE IDEA IS THAT THE
9 \$150,000 GRANT IS THE INCEPTION. THE INCEPTION
10 FEEDS INTO THE QUEST AWARD.

11 DR. FINI: I UNDERSTAND THAT, BUT WHAT'S
12 MISSING IS BEFORE YOU GET TO TRANSLATION, THERE'S AN
13 AWFUL LOT OF BASIC SCIENCE THAT HAS TO BE DONE.

14 DR. MILLS: THIS IS NOT TRANSLATION.
15 THESE ARE THE EARLIER STAGE, THE INCEPTION AND THE
16 QUEST AWARDS, AND THEN THE QUEST AWARD FEEDS INTO
17 THE TRANSLATION AWARDS. SO THESE ARE THAT. IT'S
18 FULLY BURDENED. IF YOU HAVE AN INCEPTION AND A
19 QUEST AWARD, IT'S LIKE \$2.75 MILLION. IT'S A CHUNK
20 OF MONEY.

21 DR. FINI: A LOT OF BASIC SCIENCE GETS
22 RENEWED. IT'S NOT THAT IT'S STALLING. IT'S JUST
23 THAT IT HAS TO GET DONE, AND IT TAKES MAYBE LONGER
24 THAN THAT ONE AWARD TAKES.

25 DR. MILLS: YOU CAN REAPPLY FOR AWARDS,

BARRISTERS' REPORTING SERVICE

1 FOR SURE.

2 CHAIRMAN THOMAS: DR. LEVIN, THEN WE'RE
3 GOING TO GO TO MEMBERS ON THE PHONE.

4 DR. LEVIN: I JUST WANT TO QUICKLY RESPOND
5 TO JEFF'S CONCERN. USUALLY, JEFF, I LIKE TO GET A
6 GOOD SENSE ABOUT WHAT OUR REVIEW IS. IT'S A VERY
7 GOOD PLAN. BUT I ACTUALLY LIKE THIS PROGRAM. IT'S
8 UNUSUAL AND UNIQUE IN THAT PEOPLE HAVE BEEN ASKING
9 ABOUT IT. I KIND OF SEE IT AS ALMOST LIKE A LITTLE
10 X BY IT. THE MISSION OF CIRM IS TO GET THERAPIES TO
11 THE CLINIC. AND IF YOU ACHIEVE GREAT STRIDES IN
12 THAT, PASS THINGS TO TRANSLATION, THEN THERE'S A
13 REWARD OF HAVING A LITTLE POT OF MONEY TO DO ANOTHER
14 WORTHY PROJECT THAT YOU WOULD LIKE TO WORK ON AT A
15 MORE EARLY STAGE. IT'S NOT SUPPOSED TO BE A
16 MECHANISM FOR DOING ALL THE THINGS THAT NEED TO GET
17 DONE. IT'S JUST THIS LITTLE TINY STEM CELL FOR A
18 JOB WELL DONE, SATISFYING OUR MISSION. SO WE CAN'T
19 CERTAINLY GIVE AWARDS TO EVERYBODY WHO GETS SCIENCE
20 PROGRESSED ALONG THE WAY, BUT I THINK THIS IS A GOOD
21 IDEA.

22 CHAIRMAN THOMAS: QUESTIONS FROM MEMBERS
23 ON THE PHONE?

24 DR. FRIEDMAN: I TOO WOULD LIKE TO SPEAK
25 IN FAVOR OF THE PROPOSAL AS IT'S BEEN ARTICULATED BY

BARRISTERS' REPORTING SERVICE

1 RANDY AND THE STAFF. I ABSOLUTELY RECOGNIZE THE
2 CHALLENGE OF HOW TO DEFINE THINGS THAT ARE IN AND
3 OUT OF SCOPE. AND I STRUGGLE, AS OTHERS WHO HAVE
4 SPOKEN, WITH EXACTLY HOW THAT'S GOING TO BE DONE.
5 BUT AT THE END, I HAVE A CERTAIN CONFIDENCE IN THE
6 GOODWILL AND THE GOOD THINKING OF THE STAFF AND HOW
7 THEY DESCRIBE THE PROJECTS AND HOW THEY FIT IN.

8 WE'RE TRYING TO PROMOTE THINGS THAT WILL
9 MOVE TO CLINICAL BENEFIT OR AT LEAST CLINICAL
10 UTILITY WITH THE GREATEST SPEED POSSIBLE. AND WE
11 RECOGNIZE ALL THE SCIENTIFIC DEAD ENDS THAT
12 SOMETIMES OCCUR, ALL THE CHALLENGES THAT ARISE, AND
13 THE INCREDIBLE DIFFICULTIES IN DOING THAT, BUT I
14 GIVE THE STAFF CREDIT AND RANDY CREDIT FOR TRYING TO
15 FACILITATE THIS PART OF THE PROCESS. IT MAY NOT
16 WORK OUT AS WELL AS WE ANTICIPATE, AND I KNOW
17 WITHOUT EVEN ASKING THIS WILL BE BROUGHT BACK FOR
18 EVALUATION AT POINTS IN THE FUTURE WHEN WE HAVE DATA
19 TO LOOK AND SEE HOW WELL ARE THESE THINGS SUBSCRIBED
20 TO AND WHAT'S THE FEEDBACK FROM THE INVESTIGATORS
21 WHO ARE APPLYING FOR AND GETTING THESE GRANTS. I
22 JUST WANTED TO SPEAK IN FAVOR OF IT. THANK YOU.

23 CHAIRMAN THOMAS: THANK YOU, MICHAEL. ANY
24 OTHER COMMENTS FROM MEMBERS ON THE PHONE?

25 MS. LAPORTE: I WOULD ADD TO WHAT MICHAEL

BARRISTERS' REPORTING SERVICE

1 JUST SAID. I APPRECIATE STAFF TRYING TO WORK
2 THROUGH ALL THE COMPLICATED ISSUES, AND IT WOULD BE
3 INTERESTING TO SEE HOW IT PLAYS OUT. I THINK THIS
4 IS THE RIGHT DIRECTION.

5 CHAIRMAN THOMAS: THANK YOU. ANY OTHER
6 COMMENTS? COMMENTS FROM MEMBERS OF THE PUBLIC? DR.
7 LORING.

8 DR. LORING: THANK YOU. THIS IS JEANNE
9 LORING. I'M FROM THE SCRIPPS RESEARCH INSTITUTE. I
10 HAVE A VERY SIMPLE QUESTION, WHICH I THINK IT MIGHT
11 BE WELCOME AT THIS STAGE. UNDER THE OLD CIRM, THERE
12 WAS A LIMIT OF THREE GRANTS PER PI. AND THAT
13 COMPLICATES THINGS SINCE SOMETIMES THEY'RE
14 OVERLAPPING, AND THE SIZE OF THE GRANTS MEANS THAT
15 REALLY WE NEED, AS RESEARCHERS, TO GET MORE THAN ONE
16 GRANT. IN FACT, MORE THAN THREE WOULD BE REALLY
17 USEFUL. SO IS THAT POLICY GOING TO CONTINUE INTO
18 CIRM 2.0?

19 DR. SHEPARD: THAT WAS A POLICY THAT
20 APPEARED IN SPECIFIC RFA'S, AND THAT POLICY DOES NOT
21 APPEAR IN THE CLINICAL PROGRAM ANNOUNCEMENTS THAT WE
22 HAVE. I THINK AS LONG AS THERE'S EFFORT AVAILABLE
23 AND THE GRANTS WORKING GROUP BELIEVES THAT THERE'S
24 SUFFICIENT COMMITMENT AND SUFFICIENT COMMITMENT HAS
25 BEEN MADE TOWARDS ACHIEVING THE PROJECT GOALS, WE

BARRISTERS' REPORTING SERVICE

1 WOULDNT WANT TO THROW AWAY THAT OPPORTUNITY.

2 DR. LORING: THAT'S WONDERFUL. THANK YOU.

3 MR. SHEEHY: DR. SHEPARD, COULD I JUST GET
4 CLARITY JUST SO THE PEOPLE ARE CLEAR IN THE PUBLIC
5 WHAT WE MEAN BY EFFORT? SO IN A GRANT TYPICALLY AN
6 INVESTIGATOR OR LEAD INVESTIGATOR, PRIMARY
7 INVESTIGATOR, WILL LIST A PERCENT OF EFFORT ON THE
8 GRANT. AND THEY DO THAT ACROSS A RANGE OF GRANTS
9 THAT THEY MAY BE GETTING, NOT JUST FOR CIRM, AND
10 THEN THAT IS TOTALED UP. ONCE THEY HIT A HUNDRED
11 PERCENT OF EFFORT, THE ASSUMPTION IS THEY'RE NOT
12 ELIGIBLE FOR OTHER GRANTS; IS THAT CORRECT? AND
13 THAT IS OUR POLICY NOT TO COUNT GRANTS, BUT ACTUALLY
14 TO MEASURE PERCENT OF EFFORT.

15 DR. SHEPARD: THE PERCENT OF EFFORT IS HOW
16 MUCH OF THE PI'S TIME THAT IS INVESTED IN MANAGING
17 AND CONDUCTING THE AWARD ACTIVITIES. AND WE'VE SET
18 A MINIMUM PERCENT EFFORT FOR THE TYPE OF THE AWARD.
19 SO, FOR EXAMPLE, THE TRANSLATION AWARDS WHICH WE'LL
20 TALK ABOUT NEXT REQUIRE CONSIDERABLE, WE THINK, MORE
21 INPUT FROM THE PI. SO INVESTIGATORS WHO HAVE OTHER
22 GRANTS HAVE A CERTAIN AMOUNT COMMITTED TO EACH OF
23 THOSE. SO IF SOMEBODY APPLIED FOR AN AWARD THAT
24 DEMANDED A MINIMUM PERCENT AND THEN THEY WERE
25 ALREADY A HUNDRED PERCENT COMMITTED ON OTHER AWARDS,

BARRISTERS' REPORTING SERVICE

1 THAT IS SOMETHING WE'D HAVE TO ASK THEM TO ADJUST SO
2 THAT WE CAN ENSURE THAT THE APPROPRIATE LEVEL OF
3 OVERSIGHT IS APPLIED TO THE AWARDS THAT WE FEEL IS
4 JUSTIFIED.

5 MR. SHEEHY: WE WOULDN'T FUND SOMEONE OVER
6 A HUNDRED PERCENT OF EFFORT.

7 DR. SHEPARD: NO. NO. NO. WE DO A
8 PREFUNDING ADMINISTRATIVE REVIEW OF THE OTHER
9 SUPPORT, AND THAT'S WHERE WE ENSURE THAT THEY ARE
10 ABLE TO COMMIT THE MINIMUM EFFORT THAT WAS DEFINED.

11 MR. SHEEHY: THANK YOU.

12 MR. REED: DON REED, PATIENT ADVOCATE.
13 THIS IS A QUESTION FOR THE PRESIDENT. IF I
14 UNDERSTAND CORRECTLY, YOU WOULD HAVE THE ABILITY TO
15 SAY TO A PROJECT THAT HAD BEEN PASSED OVER, I THINK
16 THIS IS IMPORTANT AND SHOULD BE CONSIDERED FOR
17 FURTHER REVIEW; IS THAT CORRECT?

18 DR. MILLS: YOU'RE SPEAKING IN THE FIRST
19 ROUND OF REVIEW, STAGE 1. YES. SO THE GRANTS
20 WORKING GROUP WOULD SELECT, ALL 22 MEMBERS WOULD
21 SELECT THE PROGRAMS, AND THEN WE WOULD GIVE IT A
22 FINAL REVIEW AND SEE WHETHER OR NOT THERE WAS
23 SOMETHING. THE OTHER THING IS TO MAKE SURE WE HAVE
24 COMPETITIVE REVIEW TO MAKE SURE WE'RE LOOKING AT
25 ENOUGH APPLICATIONS.

BARRISTERS' REPORTING SERVICE

1 MR. REED: THAT MAKES A GREAT DEAL OF
2 SENSE TO ME. NOW I'LL ASK FOR MY OWN PERSONAL
3 CLARIFICATION. THAT COULD NOT BE USED BY YOU IN A
4 NEGATIVE WAY. YOU COULDN'T SAY I DON'T LIKE THAT.
5 I'M NOT GOING TO ADVANCE THEM.

6 DR. MILLS: SO THE GRANTS WORKING GROUP,
7 INCLUDING THE PATIENT ADVOCATE MEMBERS OF THE GRANTS
8 WORKING GROUP, CAN POSITIVELY SELECT THAT. REALLY
9 THE CHANGE WE WANT TO DO IS WE DIDN'T WANT TO HAVE A
10 NEGATIVE, WE DON'T LIKE THIS. WE COULD ONLY
11 POSITIVELY SELECT THINGS FOR REVIEW.

12 MR. REED: I SUPPORT THAT A HUNDRED
13 PERCENT. THANK YOU.

14 MR. BARBER: HI. MY NAME IS JAY BARBER.
15 I TRAINED AT UCSF. I WAS FACULTY THERE FOR MANY,
16 MANY YEARS BEFORE JOINING SIMPATICA MEDICINE. WE'RE
17 A SINGLE SELL CLINICAL MONITORING COMPANY, AND I
18 JUST WANTED TO SPEAK FROM THE PERSPECTIVE OF A
19 CALIFORNIA-BASED BIOTECH COMPANY IN SUPPORT OF SOME
20 OF THE COMMENTS THAT DR. MILLS MADE.

21 THIS DISCOVERY STAGE PROGRAM MECHANISM
22 WOULD BE VERY IMPORTANT TO HELP US ADOPT OUR
23 PLATFORM TO HELP SPEED THE TRANSLATION OF STEM CELL
24 THERAPEUTICS. WE THINK WE CAN HELP A NUMBER OF
25 COMPANIES IN THE CIRM PORTFOLIO SPEED THEIR PRODUCTS

BARRISTERS' REPORTING SERVICE

1 INTO THE CLINIC. SO THANK YOU.

2 DR. CHIU: ARLENE CHIU, CITY OF HOPE. I
3 REALLY WANT TO APPLAUD THE CIRM FOR HAVING
4 CONSTRUCTED SUCH A CLEAR AND LINKED PATHWAY FROM
5 BASIC DISCOVERY TO THE CLINIC. AND, IN FACT, IT
6 SEEMS TO WORK EXTREMELY WELL WITH INCENTIVES ALONG
7 THE WAY.

8 MY ONE CAVEAT WITH THIS PLAN, AS WHAT I
9 UNDERSTAND TODAY, IS THAT IF THIS IS APPROVED AND
10 THIS IS THE WAY FUNDING WILL PROCEED FORWARD, SHINYA
11 YAMANAKA'S WORK, ORIGINAL WORK, AND JOHN GERDON'S
12 WORK WOULD NOT HAVE BEEN FUNDED BECAUSE THEY DIDN'T
13 START OUT USING HUMAN CELLS. AND THERE IS A POINT
14 HERE IN THE PRINTED MATERIAL THAT SAYS YOU HAVE TO
15 USE HUMAN STEM CELLS, AND I DON'T BELIEVE THAT'S
16 MENTIONED.

17 SO IN TRYING TO GET AND SUPPORT
18 TRANSFORMATIONAL RESEARCH, WE WOULD BE CUTTING OUT A
19 LOT OF REALLY GREAT IDEAS TO BE TESTED. SO THAT'S
20 ONE POINT THAT I'M A LITTLE BIT CONCERNED ABOUT.

21 I CAN SEE THE NECESSITY FOR IT GIVEN THE
22 CHARGE OF CIRM, BUT I ALSO WORRY THAT WE ARE THE
23 BEST FUNDING SOURCE OF STEM CELL RESEARCH IN THE
24 COUNTRY TODAY. AND IF PEOPLE DON'T MAKE THESE
25 DISCOVERIES HERE IN CALIFORNIA, THEN OTHER COUNTRIES

BARRISTERS' REPORTING SERVICE

1 WOULD BE DOING IT.

2 THE SECOND CONCERN THAT I HAVE IS THAT THE
3 DEFINITION OF DISCOVERY, AS I USED TO UNDERSTAND IT,
4 IS NOW REALLY INCEPTION. THE REST, THE QUEST AND
5 CHALLENGE, ARE REALLY WHAT WE CALL EARLY
6 TRANSLATIONAL WORK. AND WHAT IS NOW DEFINED AS
7 TRANSLATION IN LATER INITIATIVES ARE WHAT WE USED TO
8 CALL PRECLINICAL WORK THAT'S HEADED TOWARDS IND,
9 WHICH MEANS THAT ONLY INCEPTION GRANTS WILL BE THE
10 GROUND FOR GROWING UP BRAND-NEW IDEAS. AND REALLY
11 THIS IS APPROPRIATE GIVEN HOW LITTLE TIME WE HAVE
12 LEFT IN CIRM TO MOVE REALLY BASIC IDEAS FORWARD, AND
13 THAT'S TOTALLY UNDERSTANDABLE, BUT IT IS STILL A
14 CONCERN.

15 THE LAST POINT I'D LIKE TO MAKE IS THAT
16 THE REVIEW CRITERIA FOR PRESELECTION IS NOT TOTALLY
17 CLEAR TO ME. AND SO WHILST I CAN TOTALLY UNDERSTAND
18 IF YOU GET 300 PROPOSALS COMING IN, HOW YOU SCREEN
19 THOSE 300 USING WHAT CRITERIA IS NOT TOTALLY CLEAR.

20 CHAIRMAN THOMAS: SOMEBODY ON THE PHONE IS
21 COMING OVER. IF YOU COULD ALL MUTE YOUR PHONES
22 PLEASE.

23 MR. BERGER: MY NAME IS GERALD BERGER. I
24 HAVE PARKINSON'S, AND THIS IS MY DOG ZOE, WHO HELPS
25 ME. SHE HAS PARKINSON'S SOMETIMES. BUT THANK YOU

BARRISTERS' REPORTING SERVICE

1 FOR YOUR INDULGENCE.

2 I JUST WANTED TO REMIND YOU THAT
3 PARKINSON'S IS THE SECOND MOST COMMON AFFLICTION,
4 AND I REALLY APPRECIATE THE WORK THAT YOU'RE DOING.
5 AS I UNDERSTAND IT, WITH THE TWO BILLION THAT HAS
6 BEEN SPENT, APPROXIMATELY, SO FAR, ONLY ABOUT 2.3
7 PERCENT HAS BEEN SPENT ON PARKINSON'S RESEARCH. AND
8 WE REALLY WANT TO ENCOURAGE YOU TO CONSIDER
9 CAREFULLY THE VAST NUMBERS OF PEOPLE THAT COULD
10 BENEFIT FROM FURTHER RESEARCH WITH STEM CELL THERAPY
11 FOR PARKINSON'S. THANK YOU.

12 (APPLAUSE.)

13 MR. FITZPATRICK: MY NAME IS EDWARD
14 FITZPATRICK. I HAVE PARKINSON'S. I'M ONE OF THE
15 EIGHT THAT ARE PART OF THE WORK BEING DONE BY DR.
16 LORING AND DR. HOUSER. YOU HAVE A VERY IMPORTANT
17 JOB, AND I'M IMPRESSED WITH THE EXPERTISE AND THE
18 PROFESSIONALISM AND INTELLIGENCE THAT YOU ALL HAVE,
19 AND YOU UNDERSTAND THE CONCEPT OF TIME. THE
20 ELEMENTS OF MEDICAL RESEARCH INCLUDE VERY
21 INTELLIGENT PEOPLE, SUPPORT, AND THEN MONEY AND
22 TIME. UNFORTUNATELY THERE'S NOT ENOUGH OF SOME OF
23 IT AND THE OTHER.

24 IT REMINDS ME OF A LITTLE MAN BY THE NAME
25 OF JOHN WHO'S VERY RELIGIOUS AND HE GOES INTO CHURCH

BARRISTERS' REPORTING SERVICE

1 WITH A PRAYER AND SAYS HIS PRAYER. AND GOD ANSWERS
2 HIM AND SAYS, "JOHN, THANK YOU FOR THE PRAYER. NOW
3 YOU HAVE A QUESTION?" AND HE SAYS, "YES, GOD, I
4 HAVE A QUESTION. I'D LIKE TO KNOW IN YOUR TIME
5 FRAME WHAT DOES A SECOND MEAN TO YOU IN TERMS OF
6 WHAT TIME IS ON EARTH?" GOD SAYS, "WELL, A SECOND
7 TO ME IN MY TIME FRAME IS ABOUT A HUNDRED YEARS ON
8 EARTH." JOHN SAYS, "THAT'S INTERESTING. HOW ABOUT
9 AN EXCHANGE RATE WITH MONEY? HOW MUCH IS A DOLLAR
10 IN YOUR REFERENCE EQUAL TO U.S. DOLLARS?" HE SAID,
11 "AROUND A MILLION DOLLARS. \$1 OF MINE IS ABOUT A
12 MILLION DOLLARS OF YOURS." HE SAYS, "YOU HAVE ANY
13 OTHER QUESTIONS?" HE SAID, "YES, GOD. CAN I HAVE
14 ONE OF YOUR DOLLARS?" GOD SAYS, "LET ME THINK ABOUT
15 IT. GIVE ME A SECOND."

16 TIME IS RUNNING. WE'RE RUNNING OUT OF IT,
17 AND WE APPRECIATE ALL YOU DO, AND WE'RE VERY HAPPY
18 THAT THERE IS A CIRM. THANK YOU.

19 MR. MADDOX: HI. I'M BILL MADDOX. I'M
20 FROM SAN DIEGO, AND I WAS DIAGNOSED WITH PARKINSON'S
21 EIGHT YEARS AGO, ACTUALLY NINE. I RAN THROUGH A
22 GAUNTLET OF EMOTIONS: DEPRESSION, ANGER, AND
23 DENIAL, HOPING IT WASN'T TRUE. WENT TO FOUR
24 DIFFERENT NEUROLOGISTS HOPING THAT I HAD BEEN
25 MISDIAGNOSED.

BARRISTERS' REPORTING SERVICE

1 THE MEDICINE THAT MY NEUROLOGIST, MELISSA
2 HOUSER, THE NURSE PRACTITIONER SHERRIE GOULD HAS
3 COME UP WITH HAS WORKED TO HELP ME THROUGH MY
4 JOURNEY WITH PARKINSON'S. MORE IMPORTANTLY, I
5 BELIEVE THAT THIS MEDICINE CAN TAKE US HOME.

6 (INAUDIBLE) CLIMB MT. EVEREST TO RAISE
7 FUNDS AND RAISE HOPE, BOTH OUR RESEARCH WITH YOU, A
8 HIGHLY EFFECTIVE THERAPY. NOW OUR RATS ARE IN THE
9 LAB AND BEHAVING IN THE LAB AS PREDICTED, AND WE'RE
10 GOING FULL SPEED AHEAD WITH THIS AMAZING RESEARCH
11 THAT'S HAPPENING RIGHT NOW IN SAN DIEGO.

12 CIRM HAS AN INCREDIBLE OPPORTUNITY TO TAKE
13 THE MOMENTUM WE ALREADY HAVE AND ACCELERATE IT.
14 HELP US GET OUR RESEARCH THROUGH FDA AND PRECLINICAL
15 TRIALS. A GRANT FROM CIRM COULD BRING MORE HOPE,
16 AND WE LOOK FORWARD TO A FUTURE TO GET RID OF
17 PARKINSON'S AND HELP BRING OUR LIVES BACK. THANK
18 YOU SO MUCH FOR LETTING ME SPEAKING AT THIS MEETING
19 TODAY. WE REALLY APPRECIATE IT.

20 DR. CASHMAN: THANK YOU FOR THAT. I THINK
21 ALL PATIENTS SHOULD BE CONGRATULATED FOR COMING HERE
22 AND SPEAKING. I WANT TO TALK ABOUT A SLIGHTLY
23 DIFFERENT --

24 CHAIRMAN THOMAS: COULD WE HAVE YOUR NAME,
25 PLEASE.

BARRISTERS' REPORTING SERVICE

1 DR. CASHMAN: JOHN CASHMAN. I RUN THE
2 HUMAN BIOMOLECULAR RESEARCH INSTITUTE IN SAN DIEGO.
3 AND I CONGRATULATE CIRM FOR THIS PROGRAM BECAUSE
4 IT'S A GREAT IDEA. IT'S ANALOGOUS TO THE R201-RO3
5 PROGRAM AT THE NIH.

6 JUST TO GIVE YOU A LITTLE PERSPECTIVE, I
7 REVIEWED ABOUT A HUNDRED FIFTY OF THOSE GRANTS IN
8 THE LAST YEAR OR SO FOR NIH THROUGH THREE DIFFERENT
9 STUDY SECTIONS. JUST TO GIVE YOU A LITTLE BIT OF
10 FEEDBACK, PROBABLY ONLY ONE OF THOSE GRANTS THAT I
11 REVIEWED OUT OF THE HUNDRED FIFTY OR LESS THAN 1
12 PERCENT HAD ANY LIKELIHOOD OF GETTING INTO A PROOF
13 OF -- NOT PROOF OF CONCEPT, BUT AN ANIMAL MODEL
14 VALIDATION STUDY. I THINK DR. SHEPARD MENTIONED
15 THAT THE REQUIREMENT WOULD BE PROOF OF CONCEPT AND
16 ANIMAL VALIDATION; IS THAT RIGHT? IS THAT WHAT I
17 HEARD? BECAUSE FOR \$150,000 THAT'S REALLY --

18 DR. SHEPARD: WHAT YOU'RE DESCRIBING IS
19 FOR THE QUEST AWARDS, WHICH IS TO BE READY FOR
20 TRANSLATION BY THE END OF AWARD. THE INCEPTION, THE
21 \$150,000 ONES, IS FOR COMPLETELY NEW EXPLORATION.

22 DR. CASHMAN: SO THAT'S PROOF OF CONCEPT.

23 DR. SHEPARD: PROOF OF CONCEPT IS SHOWING
24 THAT A CANDIDATE, A PARTICULAR CELL POPULATION, A
25 PARTICULAR MOLECULE HAS SOME ABILITY TO MODIFY A

BARRISTERS' REPORTING SERVICE

1 DISEASE PHENOTYPE.

2 DR. CASHMAN: TO ME THAT SUGGESTS AN
3 ANIMAL VALIDATION STUDY. I THINK SOMEHOW YOU HAVE
4 TO, AT LEAST TO ME ANYWAY, MAYBE I WAS UNFAIR,
5 BECAUSE IT'S A VERY HIGH HURDLE FOR \$150,000. IN
6 FACT, I THINK NIH'S MONEY IS A LITTLE BIT MORE THAN
7 150,000 IN SOME OF THEIR R201 PROGRAMS. SO JUST
8 SPEAKING ON BEHALF OF RESEARCH SCIENTISTS LOOKING AT
9 A BUDGET AND TRYING TO GET THAT KIND OF MONEY IS
10 EXTREMELY CHALLENGING.

11 OTHERWISE, AS I SAY, CONGRATULATIONS.
12 IT'S A REALLY GOOD IDEA. I THINK YOU SHOULD BE
13 CONGRATULATED.

14 CHAIRMAN THOMAS: OTHER COMMENTS FROM
15 MEMBERS OF THE PUBLIC? THANK YOU. IF NO FURTHER
16 COMMENTS FROM THE BOARD, I GUESS WE CAN PROCEED.
17 MR. HARRISON, IF YOU JUST RESTATE THE MOTION,
18 PLEASE.

19 MR. HARRISON: THE MOTION IS TO APPROVE
20 THE DISCOVERY STAGE PROGRAM CONCEPT PROPOSAL WITH
21 THE TWO CLARIFICATIONS REQUESTED BY THE BOARD
22 RELATING TO THE 25 PERCENT PULL-BACK AND THE ONE
23 APPLICATION PER CYCLE LIMIT.

24 CHAIRMAN THOMAS: OKAY. MARIA, WILL YOU
25 CALL THE ROLL, PLEASE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: DAVID BRENNER. KEN
2 BURTIS.
3 DR. BURTIS: YES.
4 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
5 DR. DULIEGE: YES.
6 MS. BONNEVILLE: LEON FINE.
7 DR. FINE: YES.
8 MS. BONNEVILLE: ELIZABETH FINI.
9 DR. FINI: YES.
10 MS. BONNEVILLE: MICHAEL FRIEDMAN. JUDY
11 GASSON.
12 DR. GASSON: YES.
13 MS. BONNEVILLE: SAM HAWGOOD. DAVID
14 HIGGINS.
15 DR. HIGGINS: YES.
16 MS. BONNEVILLE: STEPHEN JUELSGAARD.
17 SHERRY LANSING. KATHY LAPORTE.
18 MS. LAPORTE: YES.
19 MS. BONNEVILLE: JACOB LEVIN.
20 DR. LEVIN: YES.
21 MS. BONNEVILLE: BERT LUBIN. LAUREN
22 MILLER.
23 MS. MILLER: YES.
24 MS. BONNEVILLE: LLOYD MINER. ADRIANA
25 PADILLA.

BARRISTERS' REPORTING SERVICE

1 DR. PADILLA: YES.
2 MS. BONNEVILLE: JOE PANETTA.
3 MR. PANETTA: YES.
4 MS. BONNEVILLE: ROBERT PRICE.
5 DR. PRICE: YES.
6 MS. BONNEVILLE: FRANCISCO PRIETO.
7 DR. PRIETO: AYE.
8 MS. BONNEVILLE: ROBERT QUINT. AL
9 ROWLETT.
10 MR. ROWLETT: YES.
11 MS. BONNEVILLE: JEFF SHEEHY.
12 MR. SHEEHY: YES.
13 MS. BONNEVILLE: OSWALD STEWARD.
14 DR. STEWARD: YES.
15 MS. BONNEVILLE: JONATHAN THOMAS.
16 CHAIRMAN THOMAS: YES.
17 MS. BONNEVILLE: ART TORRES.
18 MR. TORRES: AYE.
19 MS. BONNEVILLE: KRISTINA VUORI.
20 DR. VUORI: YES.
21 MS. BONNEVILLE: DONNA WESTON.
22 DR. WESTON: YES.
23 MS. BONNEVILLE: DIANE WINOKUR.
24 MS. WINOKUR: YES.
25 CHAIRMAN THOMAS: MOTION PASSES.

BARRISTERS' REPORTING SERVICE

1 BETH, I HAVE A QUESTION FOR YOU. DO YOU
2 NEED -- WE'RE COMING CLOSE TO THE NOON HOUR. WOULD
3 LOVE TO GET BIT MORE OF THIS. CAN YOU STAY WITH US
4 HERE.

5 THE REPORTER: YES.

6 CHAIRMAN THOMAS: OKAY. DR. SHEPARD, WILL
7 YOU PROCEED TO THE NEXT CONCEPT PLAN?

8 DR. SHEPARD: THANK YOU, MR. CHAIR. NOW,
9 I'M NEXT GOING TO BEGIN TO DESCRIBE THE TRANSLATION
10 STAGE CONCEPT PLAN FOR YOU, AND I THINK THIS WILL GO
11 A LITTLE BIT MORE QUICKLY SIMPLY BECAUSE IT'S A BIT
12 MORE STRAIGHTFORWARD FOR ME TO EXPLAIN.

13 IF YOU LOOK AT THIS IMAGE BEFORE YOU OF
14 THE TRACK THAT WE'VE LAID OUT, WHAT YOU'LL NOTICE
15 ARE THESE BRANCHES. THIS IS TO CAPTURE THE MULTIPLE
16 DIFFERENT TYPES OF CANDIDATES THAT CAN EMERGE FROM
17 THE QUEST AWARDS. SO WHETHER A CANDIDATE COULD
18 BECOME A TOOL FOR TRANSLATION OR A DIAGNOSTIC TEST
19 OR A STEM CELL-BASED THERAPEUTIC OR A DEVICE FOR USE
20 WITH STEM CELLS, THERE'S A TRANSLATIONAL PROGRAM TO
21 COVER EACH OF THESE DIFFERENT PATHWAYS. SO THERE
22 ARE FOUR DIFFERENT TRANSLATIONAL PROGRAMS TO TELL
23 YOU ABOUT.

24 THEY ALL LINK FROM THE QUEST AWARDS AS WE
25 JUST DISCUSSED. AND THE OUTCOMES OF TRANSLATION FOR

BARRISTERS' REPORTING SERVICE

1 THESE DIFFERENT PATHWAYS IS A LITTLE BIT DIFFERENT
2 DEPENDING ON THE PATH, AND THE ACTIVITIES ASSOCIATED
3 WITH THEM ARE A LITTLE BIT DIFFERENT. SO A
4 SUCCESSFUL RECIPIENT OF A CIRM TRANSLATION AWARD,
5 THESE ARE REALLY TO SUPPORT EARLY DEVELOPMENT OF THE
6 CANDIDATES, AND THEY DON'T HAVE TO COME IN THROUGH
7 THE QUEST AWARDS. THEY CAN COME IN FROM OTHER
8 PROJECTS OUTSIDE OF THE CIRM PIPELINE. ANYTHING
9 THAT'S READY TO MOVE INTO TRANSLATION WE'RE READY TO
10 SUPPORT TO ADVANCE OUR MISSION.

11 SO THE THERAPEUTIC PROGRAM, THE
12 DELIVERABLE OF THAT WOULD LEAD DIRECTLY INTO THE
13 CIRM CLINICAL PROGRAM, WHICH DR. JORGENSON TALKED
14 ABOUT EARLIER TODAY. THAT WAS ALREADY IMPLEMENTED
15 AND HAS BEEN RUNNING SUCCESSFULLY FOR SEVERAL MONTHS
16 NOW.

17 SAME IS TRUE FOR A DEVICE. SUCCESSFUL
18 OUTCOME OF THE TRANSLATION AWARD FOR THE DEVICE
19 PATHWAY WOULD LINK INTO CIRM'S CLINICAL PROGRAM, OR
20 DEPENDING ON THE TYPE OF DEVICE, READINESS FOR FINAL
21 STUDIES FOR A REGULATORY FILING.

22 THE TRANSLATIONAL PATHWAY IS A LITTLE BIT
23 DIFFERENT FOR DIAGNOSTIC AND TOOLS. DIAGNOSTICS CAN
24 COME IN A COUPLE OF DIFFERENT TYPES. ONE OUTCOME IS
25 READINESS FOR CLINICAL OR OTHER STUDIES FOR A

BARRISTERS' REPORTING SERVICE

1 REGULATORY FILING, OR ANOTHER POTENTIAL OUTCOME IS
2 FILING FOR REFERENCE LAB COMMERCIAL USE. FOR TOOLS,
3 WHICH DON'T NECESSARILY HAVE TO GO THROUGH CLINICAL
4 TESTING, THE OUTCOME OF TRANSLATION IS READINESS FOR
5 FINAL STUDIES FOR MANUFACTURING AND
6 COMMERCIALIZATION.

7 SO THE SPECIFIC DETAILS OF THESE FOUR
8 PROGRAMS ARE AS FOLLOWS. FOR THE THERAPEUTICS
9 PROGRAM, THE LEVEL OF SUPPORT FOR DIRECT PROJECT
10 COSTS WOULD BE UP TO \$5 MILLION FOR A CELL THERAPY
11 CANDIDATE OR \$2.5 MILLION TO CONDUCT EARLY
12 DEVELOPMENT ON A SMALL MOLECULE CANDIDATE. THE
13 PROJECT TERM IS UP TO 30 MONTHS. AGAIN, ALL THESE
14 NUMBERS I'M GIVING YOU NEED TO BE JUSTIFIED BY THE
15 APPLICANT AND MAKE SENSE FOR THE SPECIFIC PROJECT
16 BEING PROPOSED.

17 THE PROJECT TERM FOR THE OTHER THREE
18 PATHWAYS IS UP TO 24 MONTHS, AND THE LEVEL OF
19 SUPPORT FOR THE DEVICE TRANSLATION PROGRAM WOULD BE
20 UP TO \$2 MILLION; FOR DIAGNOSTIC TESTS, UP TO \$1.2
21 MILLION; AND FOR THE TOOL PROGRAM, UP TO \$1 MILLION.
22 AND THE DIFFERENCES YOU SEE HERE REFLECT MERELY THE
23 DIFFERENT TYPE OF ACTIVITIES THAT ARE ASSOCIATED
24 WITH THE TRANSLATION ALONG THESE DIFFERENT PATHWAYS.

25 SO THAT'S THE DESCRIPTION OF THE PROGRAM.

BARRISTERS' REPORTING SERVICE

1 ARE THERE ANY QUESTIONS BEFORE I MOVE INTO THE
2 PROPOSED ACTION? OKAY.

3 SO THE PROPOSED ACTION ITEMS, THE REQUEST
4 WE HAVE FOR THE BOARD ARE THE FOLLOWING. THE FIRST,
5 DELEGATION OF BOARD AUTHORITY. THIS IS SIMILAR TO
6 WHAT WE ASKED FOR IN THE DISCOVERY STAGE AWARDS. IF
7 WE NEED TO IMPLEMENT A TWO-STAGE REVIEW, WHICH WE
8 WOULD ONLY DO IF WE RECEIVED A VERY LARGE NUMBER OF
9 APPLICATIONS. WE DON'T ACTUALLY EXPECT THAT TO BE
10 THE CASE FOR THIS TYPE OF PROGRAM. THE DEMAND AND
11 THE NUMBER OF PROJECTS OF THIS STAGE IS SIMPLY LOWER
12 THAN WHAT WE WOULD EXPECT TO SEE IN DISCOVERY.
13 HOWEVER, IF WE SHOULD RECEIVE MORE APPLICATIONS THAN
14 WE COULD FEASIBLY REVIEW IN A FACE-TO-FACE GRANTS
15 WORKING GROUP REVIEW MEETING, WE WOULD LIKE TO BE
16 ABLE TO IMPLEMENT THE TWO-STAGE REVIEW PROCESS
17 DESCRIBED PREVIOUSLY TO HELP US PICK THE MOST
18 MERITORIOUS ONES FOR THE SECOND STAGE REVIEW OR TO
19 HELP THE GRANTS WORKING GROUP PICK THE MOST
20 MERITORIOUS FOR THE SECOND STAGE. AND THE FUNDING
21 REQUEST FOR THE TRANSLATIONAL CONCEPT AS A WHOLE
22 WOULD BE \$40 MILLION.

23 CHAIRMAN THOMAS: DO I HEAR A MOTION TO
24 THIS EFFECT?

25 MR. SHEEHY: SO MOVED.

BARRISTERS' REPORTING SERVICE

1 DR. PRIETO: SECOND.

2 CHAIRMAN THOMAS: MOVED BY MR. SHEEHY,
3 SECONDED BY DR. PRIETO.

4 COMMENTS, QUESTIONS FROM MEMBERS OF THE
5 BOARD? PARTICULARLY WELCOME ANY THOUGHTS FROM
6 MEMBERS OF THE SCIENCE SUBCOMMITTEE WHO HAD BENEFIT
7 OF THE LENGTHIER DISCUSSION ON THIS PARTICULAR ITEM
8 AS WELL.

9 MR. SHEEHY: SUPPORTED UNANIMOUSLY BY THE
10 SCIENCE SUBCOMMITTEE. I THINK THIS IS PRETTY
11 STRAIGHTFORWARD. IT'S IN LINE WITH WHAT WE'VE BEEN
12 DOING IN THE PAST WITH TRANSLATION WITHIN THE CIRM
13 2.0 CONTEXT.

14 DR. STEWARD: AGREEING WITH JEFF. WE WENT
15 OVER THIS QUITE A LOT, AND IT IS STRAIGHTFORWARD.

16 CHAIRMAN THOMAS: ANY COMMENTS, QUESTIONS
17 FROM THE MEMBERS ON THE PHONE? COMMENTS FROM
18 MEMBERS OF THE PUBLIC?

19 MR. EVANS: I HAVE A QUESTION. I'M RON
20 EVANS. I'M AN OPHTHALMOLOGIST FROM PLACERVILLE, AND
21 MY WIFE HAS PARKINSON'S DISEASE. SPECIFICALLY I WAS
22 NOTICING IN AN EARLIER TALK, I THINK DR. MILLS
23 PRESENTED SOME OF THE FUNDING SCHEDULES, AND FOR
24 20 -- WELL, FOR THIS YEAR AND UP TO, I THINK, 2016,
25 THEY HAD ZERO DOLLARS SLATED TO FUND TRANSLATIONAL

BARRISTERS' REPORTING SERVICE

1 PROJECTS. IS THERE A REASON WHY THERE'S A DELAY IN
2 THAT AND NOT MOVING OF THAT \$40 MILLION FORWARD?

3 DR. MILLS: YES. SO THE FUNDING FOR THE
4 \$40 MILLION HERE IS ON A -- STARTING AS SOON AS IT'S
5 APPROVED BY THE BOARD TODAY. THE NUMBERS I PUT UP
6 ON THAT SLIDE WERE FOR THE FISCAL YEAR 2016. SO OUR
7 FISCAL YEAR STARTED JULY 1ST AND WILL END JUNE 30TH
8 OF NEXT YEAR. BETWEEN NOW AND JUNE 30TH OF NEXT
9 YEAR, WE WILL -- THIS PROGRAM WILL BE STARTED, BUT
10 WE WON'T BE THROUGH AN ENTIRE CYCLE. MEANING WE
11 HAVE TO ISSUE THE PROGRAM ANNOUNCEMENT, THEN THERE
12 HAS TO BE TIME TO COMPLETE THE APPLICATIONS, AND THE
13 APPLICATIONS COME IN AND THEY GO THROUGH THE REVIEW
14 PROCESS, AND THEN AFTER THE REVIEW PROCESS, THEY
15 COME BACK TO THE BOARD AND THE BOARD APPROVES THEM.
16 WE WILL NOT HAVE GONE THROUGH ALL OF THAT CYCLE YET
17 BY JUNE 30TH. SO THE ACTUAL FIRST AWARDS THAT WILL
18 COME OUT OF THIS WILL BE IN FISCAL YEAR 2017.

19 MR. EVANS: SO ESSENTIALLY THERE HAS TO BE
20 A CERTAIN LEGAL PROCESS THAT IT GOES THROUGH BEFORE
21 THE FUNDS ARE AVAILABLE OR PROCEDURAL IF LEGAL IS
22 NOT A GOOD TERM.

23 DR. MILLS: CORRECT.

24 MR. EVANS: AND MAYBE AN AMENDMENT SOMEONE
25 MIGHT EVEN THINK OF IS THE PRESIDENT, IF HE SEES AN

BARRISTERS' REPORTING SERVICE

1 EXCEPTIONAL PROJECT, COULD SEEK TO SIDESTEP THAT OR
2 MAKE AN EXCEPTION. THANK YOU.

3 CHAIRMAN THOMAS: OTHER COMMENTS FROM
4 MEMBERS OF THE PUBLIC? PLEASE STATE YOUR NAME.

5 MR. ROOSE: MY NAME IS BEN ROOS. I'M A
6 YOUNG ONSET PARKINSON'S AT AGE 31. I THINK I WANT
7 TO SEE SOME ACTION. I UNDERSTAND THE PROCEDURES AND
8 POLICIES, BUT THIS IS A BILLION DOLLARS OF MONEY
9 THAT I VOTED FOR AND THE PUBLIC VOTED FOR, AND I'D
10 LIKE TO SEE TRANSLATION PUT INTO EFFECT ASAP.

11 AND I'VE WAITED 15 YEARS. I'M TIRED OF
12 WAITING. THIS IS A GOLDEN OPPORTUNITY. I THINK YOU
13 GUYS SHOULD -- THE PEOPLE AT SCRIPPS HERE HAVE A
14 PROGRAM WHICH IS UNDER WAY. TEN MILLION, FOR
15 EXAMPLE, WOULD HELP THEM GET INTO THE NEXT STAGE OF
16 TRANSLATION. AND I WOULD GIVE IT TO THEM THIS YEAR,
17 NOT IN 2016.

18 ALSO I WOULD URGE MY FELLOW PARKIES TO
19 SPEAK UP. THIS TRANSLATION THING IS WHERE THE
20 RUBBER HITS THE ROAD. SO WE'VE ALL COME A LONG WAY.
21 SPEAK UP.

22 (APPLAUSE.)

23 MR. HOOVER: CHRIS HOOVER. I'M A
24 PARKINSON'S PATIENT. I'VE ADDRESSED THE BOARD TWICE
25 BEFORE, BUT THE LAST ONE WAS WITH DR. LORING AT THE

BARRISTERS' REPORTING SERVICE

1 CLAREMONT, AND WE WERE THE ONLY ONES THERE BECAUSE
2 THERE WAS A RAINSTORM OF THE YEAR. WE CALL THAT
3 DIVINE INTERVENTION. BUT I THINK WHAT I WANT TO DO
4 IS SUMMARIZE.

5 WE KIND OF FEEL LIKE WE'RE A ROUND PEG IN
6 A SQUARE HOLE. WE CAME TO YOU AND WE HAD OUR
7 DISCOVERY STAGE PRETTY MUCH DONE BY OURSELVES.
8 WE'VE RAISED THE MONEY, WE'VE DONE THE RESEARCH,
9 WE'VE GOT THE SCIENCE. SO CLEARLY WE'RE IN THE
10 TRANSLATIONAL STAGE, AND THAT'S WHERE WE'RE AT.
11 THEY SUGGESTED THAT WE PULL OUR OLD APPLICATION
12 BECAUSE WHERE WE'RE AT DIDN'T FIT THE OLD CIRM AND
13 THAT IT WOULD FIT THE NEW CIRM 2.0 BETTER.

14 I WAS HERE ALMOST EVERY MEETING, AND CIRM
15 TALKED ABOUT DOING A 60-DAY TURNAROUND ON
16 APPLICATIONS UNDER THE 2.0. SO I'M NOT HEARING
17 ANYTHING ABOUT THAT NOW. WE'RE TALKING NOW JUNE OF
18 THE FOLLOWING YEAR. AND THAT'S KIND OF -- WE'VE
19 BEEN WAITING A WHILE HERE. WE'VE ATTENDED EVERY
20 MEETING. SO I'M WONDERING IF THERE'S ANY WAY, WHEN
21 YOU APPROVE THE TRANSLATIONAL, THAT WE CAN SPEED
22 THAT PROCESS UP. AND MY QUESTION IS WHAT HAPPENED
23 TO THE 60-DAY TURNAROUND THAT YOU TALKED ABOUT
24 INITIALLY WITH THE 2.0 PRESENTATION.

25 CHAIRMAN THOMAS: DR. MILLS.

BARRISTERS' REPORTING SERVICE

1 DR. MILLS: SO THE 60-DAY FUNDING DECISION
2 IS FOR THE CLINICAL STAGE PROGRAMS, WHICH INCLUDES
3 THE LAST PART OF TRANSLATIONAL AND THE ENABLING
4 STUDIES THAT ARE DONE. THERE WOULD BE NO WAY TO DO
5 IT FOR THE HIGH VOLUME APPLICATIONS THOUGH.

6 MR. HOOVER: WHERE DO WE FIT IN YOUR
7 PROCESS BECAUSE WE DIDN'T TO COME TO YOU IN THE
8 DISCOVERY STAGE? WE'RE WHERE WE ARE NOW. OUR
9 SCIENCE IS DONE. WE'RE NEED FUNDING TO GET FDA
10 APPROVAL. I GUESS MY QUESTION TO THE BOARD IS IS
11 THERE ANY WAY TO ACCELERATE THE PROCESS? THEN YOU'D
12 HAVE US OUT OF YOUR HAIR. THANK YOU.

13 CHAIRMAN THOMAS: MR. SHEEHY.

14 MR. SHEEHY: I THINK THAT'S A QUESTION FOR
15 DR. LORING. I'M NOT SURE WHERE YOU WOULD BE IN THE
16 SCIENCE IN TERMS -- WE HAD OUR TRAIN ANALOGY. I
17 DON'T KNOW. I DON'T KNOW WHAT PIECES NEED TO BE
18 DONE AND HOW THAT FITS.

19 MR. HOOVER: I GUESS WHAT I MEANT WAS WHEN
20 CAN WE GET OUR APPLICATION IN? WE JUST WANT OUR
21 APPLICATION IN TO GET REVIEWED. THAT'S WHAT WE'RE
22 LOOKING TO DO. AND WE'VE BEEN AT THIS FOR ABOUT A
23 YEAR. THANKS.

24 DR. LORING: SO, JEFF, WHAT'S THE
25 QUESTION?

BARRISTERS' REPORTING SERVICE

1 MR. SHEEHY: YOU DON'T QUALIFY FOR THE
2 PRECLINICAL THAT'S CURRENTLY OPEN?

3 DR. LORING: IT'S NOT OPEN NOW. THERE
4 ISN'T ANOTHER ROUND OPEN RIGHT NOW.

5 I'M SORRY. I'M CONFUSED. THERE'S NO RFA
6 THAT I KNOW OF THAT IS OPEN RIGHT NOW THAT WOULD BE
7 APPROPRIATE FOR US. IF THERE IS, I'LL APPLY IT.

8 MR. SHEEHY: SO THERE'S NOT AN RFA. SO
9 YOU'RE REALLY IN THE MIDDLE OF THE TRANSLATION
10 STAGE.

11 DR. LORING: THAT'S RIGHT. WE ARE. WE
12 CALL IT PRECLINICAL, BUT IT REALLY IS TRANSLATION AS
13 YOU DEFINE IT.

14 CHAIRMAN THOMAS: ADDITIONAL PUBLIC
15 COMMENT?

16 MR. ROBB: I'M RAY ROBB. MY WIFE HAS
17 PARKINSON'S, AND WE'VE BEEN INVOLVED WITH DR. HOUSER
18 AND SHERRIE. AT ANY RATE, HERE'S WHERE WE ARE. AND
19 IF THERE'S AN EXCEPTION THAT CAN BE MADE, HERE'S WHY
20 WE NEED IT. WE HAVE SCRAPED TOGETHER ALMOST \$2
21 MILLION. WE'VE DONE IT OURSELVES. WE'VE DONE IT ON
22 THE BACKS OF OUR FRIENDS. WE DON'T HAVE A LOT OF
23 THOSE LEFT. THEY DON'T ANSWER THE PHONE ANYMORE
24 WHEN WE CALL BECAUSE THEY KNOW WHY WE'RE CALLING.
25 BUT WE'VE DONE THIS AND WE'VE GOTTEN AWFULLY FAR.

BARRISTERS' REPORTING SERVICE

1 WE'VE ACCELERATED WHAT WE'RE DOING. WE'RE TRYING TO
2 GET THROUGH THE FDA. WE'VE GOT FUNCTIONING SETS OF
3 DOPAMINERGIC NEURONS. WE'RE READY TO PUT THEM INTO
4 A LOT OF THE PEOPLE THAT YOU'VE HEARD FROM TODAY.

5 WE WON'T BE ABLE TO DO IT WITHOUT YOUR
6 HELP. WE'RE TAPPED. AND WE'VE ACCELERATED WHAT
7 WE'VE BEEN TRYING TO GET THROUGH THE FDA. WE'VE
8 PROBABLY GOT ABOUT THREE MONTHS MORE OF FUNDING
9 LEFT. WE NEED HELP, AND WE CAN'T WAIT TILL THE END
10 OF THE FISCAL YEAR 2016, TILL NEXT YEAR. WE'LL FIND
11 A WAY TO DO IT. IF YOU CAN'T HELP, WE'LL FIND A WAY
12 SOMEHOW. ANYTHING YOU CAN DO. AND AS I SAID, IF
13 THERE WAS EVER A SITUATION WHEN EXCEPTION WAS
14 WARRANTED, I SWEAR THIS IS IT. THANKS.

15 DR. DULIEGE: I JUST WANT TO CLARIFY.
16 FIRST OF ALL, I JUST WANT TO SAY HOW MOVED WE ARE
17 WITH ALL OF YOUR COMING AND YOUR TESTIMONY ABOUT
18 WHAT YOU ARE GOING THROUGH AND WHAT YOU'VE DONE ON
19 YOUR SIDE TO ACCELERATE THE PROCESS. BUT I WANT
20 JUST TO CLARIFY ONE SIMPLE THING THAT I DIDN'T GET
21 CLEAR ANSWER. IS THERE CURRENTLY AN OPPORTUNITY TO
22 APPLY FOR A GRANT FOR THE RESEARCH THAT DR. LORING
23 IS TRYING TO DO, OR IS THERE NOT? IT'S A VERY
24 SIMPLE ANSWER. IN WHICH COURT IS THE BALL?

25 DR. MILLS: FOR TRANSLATIONAL ACTIVITIES,

BARRISTERS' REPORTING SERVICE

1 THAT'S WHAT WE'RE VOTING ON NOW.

2 DR. DULIEGE: I'D LIKE FOR EVERYBODY. IS
3 THERE AN OPPORTUNITY FOR DR. LORING TO APPLY FOR A
4 GRANT FOR THE RESEARCH THAT SHE'S TRYING TO DO?

5 DR. MILLS: IF WE APPROVE THIS, THEN THERE
6 WILL BE A PROGRAM ANNOUNCEMENT ISSUED, AND THAT'S
7 WHAT THIS FUNDING IS FOR.

8 DR. DULIEGE: THANK YOU VERY MUCH.

9 CHAIRMAN THOMAS: ADDITIONAL COMMENTS FROM
10 MEMBERS OF THE PUBLIC?

11 MR. RODUNSKY: MY NAME IS MIKE RODUNSKY,
12 AND I'M INVOLVED IN DR. LORING'S PROGRAM. YOU'VE
13 HEARD FROM ME SEVERAL TIMES. AND I FEEL A LITTLE
14 BIT LIKE THE COUNSEL MEMBERS' STATEMENTS ARE A WAY
15 TO SAY, WELL, WE GAVE YOU A CHANCE TO APPLY, BUT
16 YOU'RE TELLING US THAT WE HAVE TO WAIT ANOTHER YEAR
17 BEFORE THE FUNDING COMES IN. THAT'S WHAT WE SAW, A
18 BIG ZERO IN THE 2016 FUNDING. AND THERE WERE THREE
19 DIGITS IN ALL THE COLUMNS FOR EVERYTHING ELSE. AND
20 THE FACT THAT IT'S GOING TO TAKE NINE MONTHS TO
21 REVIEW A GRANT THAT WE'VE BEEN DISCUSSING WITH YOU
22 FOR A LONG PERIOD OF TIME IS A LITTLE BIT ONEROUS.

23 I THINK, AGAIN, AS RAY ROBB ASKED, IF
24 THERE'S EVER A TIME FOR AN EXCEPTION, THIS IS IT. I
25 HAVE TWO SMALL CHILDREN THAT I'M TAKING CARE OF WITH

BARRISTERS' REPORTING SERVICE

1 PARKINSON'S DISEASE. AND IF I DON'T FIND SOMETHING
2 THAT'S GOING TO HELP ME WITH THIS, I DON'T KNOW IF
3 I'M GOING TO GET TO THE END OF THIS WITHOUT SEVERE
4 FINANCIAL HARDSHIP. AND I'M EXTREMELY LUCKY TO BE
5 INVOLVED IN THIS PROGRAM, BUT I WOULD LIKE TO ASK
6 YOU GUYS TO HELP ME STAY LUCKY BY GETTING THERE,
7 HELPING US GET THE MONEY FASTER SO THAT I CAN
8 CONTINUE TO WORK AND SUPPLY FOR MY FAMILY.

9 CHAIRMAN THOMAS: ADDITIONAL COMMENTS FROM
10 MEMBERS OF THE PUBLIC?

11 MS. ROBB: HELLO. MY NAME IS JENNIFER
12 ROBB, AND MY HUSBAND IS GOING TO MAKE ME CRY. I
13 JUST ASK YOU TO PLEASE SPEED THIS UP. TELL US WHEN
14 WE CAN APPLY, NOT SEPTEMBER.

15 CHAIRMAN THOMAS: DR. MILLS.

16 DR. MILLS: FOR THE SCHEDULING, SO
17 EVERYONE KNOWS, THE CONCEPT PLAN THAT'S BEFORE YOU
18 FOR TRANSLATION HAS THE FIRST APPLICATION DEADLINE,
19 MEANING THE APPLICATION WOULD HAVE TO BE IN, IS IN
20 MARCH, WHICH MEANS THE APPLICATION WOULD POST THIS
21 YEAR. THERE WOULD BE TIME TO OBVIOUSLY BE
22 RESPONSIVE TO THE APPLICATION AND THE APPLICATION
23 AVAILABLE IN MARCH.

24 CHAIRMAN THOMAS: ANY OTHER COMMENTS FROM
25 MEMBERS OF THE PUBLIC?

BARRISTERS' REPORTING SERVICE

1 MS. ROBB: ONLY ME. MY NAME IS JENNIFER
2 ROBB, AND THAT'S OUTRAGEOUS.

3 MR. BURKES: MY NAME IS DENNIS BURKES.
4 I'M A PATIENT, PARKINSON'S PATIENT. AND THIS
5 REMINDS ME OF THE OLD SAYING, "WATER WATER
6 EVERYWHERE AND NOT A DROP TO DRINK." DOWN IN SAN
7 DIEGO WE SIT AMONGST OTHER RESEARCH INSTITUTES THAT
8 ARE SITTING ON HUNDREDS OF MILLIONS OF DOLLARS.
9 GUESS WHAT THEY'RE DOING. THEIR TRYING TO FIGURE
10 OUT HOW THEY'RE GOING TO DISPENSE THAT MONEY, AND
11 THEY'RE JUST DRAGGING THAT OUT AND DRAGGING THAT
12 OUT. AND IT'S SO FRUSTRATING TO ALL OF US.

13 IF THERE'S SOMETHING WRONG WITH THE
14 SCIENCE HERE, IF YOU KNOW SOMETHING OR SOME REASON
15 THIS SHOULDN'T PROCEED, THEN TELL US. DON'T LET
16 BUREAUCRACY AND POLICY AND PROCEDURE STOP THIS
17 PROJECT FROM MOVING FORWARD AND TAKING ANOTHER YEAR
18 BECAUSE WE'RE GOING TO RUN OUT OF MONEY VERY SOON.
19 RAY IS RIGHT. MAYBE WE CAN COME UP WITH MORE MONEY,
20 BUT WE'RE NOT THE MOST WELL-HEALED GROUP. AND OUR A
21 LIST IN OUR ROLLADEX HAS BEEN USED UP.

22 AND IT'S GOING TO BE TOUGH. AND WE'VE
23 HIRED NEW PEOPLE, WE HAVE NEW RESEARCHERS AT WORK
24 NOW, AND IT WOULD JUST BE TRAGIC TO SEE THAT COME TO
25 AN END WITH ALL THE FUNDS THAT ARE THERE AND WITH

BARRISTERS' REPORTING SERVICE

1 SUCH A PROMISING PROJECT AS THIS ONE. SO I JUST ASK
2 THAT YOU PLEASE TAKE THAT INTO CONSIDERATION. THANK
3 YOU.

4 CHAIRMAN THOMAS: OTHER COMMENTS FROM
5 MEMBERS OF THE PUBLIC?

6 MR. ROOS: THIS -- I DON'T KNOW WHICH OF
7 YOU THIS IS ADDRESSED TO, BUT WHY WAS THERE ZERO
8 DOLLARS IN THIS YEAR'S BUDGET FOR TRANSLATION?

9 CHAIRMAN THOMAS: DR. MILLS.

10 DR. MILLS: SO THE SCHEDULE WAS SET UP
11 BECAUSE WE WERE GOING TO BE LAUNCHING ALL OF THESE
12 INITIATIVES, NOT JUST THE TRANSLATIONAL PHASE. SO
13 WE HAVE MULTIPLE DISCOVERY REVIEWS TO DO, WE HAVE
14 THE TRANSLATIONAL REVIEW TO DO, WE HAVE THE
15 EDUCATIONAL REVIEWS TO DO, AND WE HAVE ALL THE
16 CLINICAL REVIEWS TO DO. SO WE JUST HAVE SLOTS THAT
17 WE CAN HAVE THESE THINGS FALL INTO.

18 THE REASON THAT MARCH WAS PICKED AS THE
19 FIRST APPLICATION DEADLINE FOR THE TRANSLATION PHASE
20 WAS BECAUSE WE JUST DID AN AWARD REVIEW IN FEBRUARY.
21 IT WAS THE MOST RECENT AWARD THAT WE HAD. WE HADN'T
22 DONE A DISCOVERY AWARD IN A WHILE. SO WHEN WE WERE
23 ORDERING THEM BETWEEN DISCOVERY AND TRANSLATION,
24 BECAUSE WE HAD JUST COMPLETED THE TRANSLATIONAL
25 PHASE AWARD IN FEBRUARY, WE SLOTTED DISCOVERY FIRST.

BARRISTERS' REPORTING SERVICE

1 MR. ROOS: AND THE FOLLOW-UP QUESTION IS
2 WHY CAN'T YOU APPROVE A PROJECT LIKE THIS NOW? IS
3 THIS PROCEDURE REALLY NECESSARY, TO WAIT A YEAR?

4 DR. MILLS: I WOULD JUST -- JAMES IS LEGAL
5 COUNSEL HERE.

6 MR. HARRISON: SO PROP 71 REQUIRES THAT WE
7 GO THROUGH A COMPETITIVE SELECTION PROCESS WHICH
8 ENTAILS REVIEW BY THE GRANTS WORKING GROUP. AND
9 BACKING UP, THAT INVOLVES RELEASING A PROGRAM
10 ANNOUNCEMENT, WHICH WILL BE DONE EXPEDITIOUSLY
11 ASSUMING THE BOARD APPROVES THE CONCEPT PROPOSAL.
12 WE THEN NEED TIME TO PROCESS THE APPLICATIONS,
13 SCHEDULE A GWG MEETING FOR THE REVIEW, AND THEN
14 BRING THOSE RECOMMENDATIONS TO THE BOARD FOR ITS
15 FINAL CONSIDERATION.

16 MR. ROOS: YOU GUYS (UNINTELLIGIBLE). CAN
17 YOU DO IT IN THREE MONTHS? I JUST DON'T UNDERSTAND
18 WHY IT HAS TO WAIT A YEAR. THANK YOU.

19 MR. REED: DON REED, PATIENT ADVOCATE.
20 WHENEVER I WORK WITH OTHER STATE EFFORTS, I ALWAYS
21 FIRST GO TO THE PARKINSON'S GROUPS WHEREVER THEY ARE
22 BECAUSE THEY ARE TREMENDOUS FIGHTERS, PERHAPS
23 BECAUSE THEIR CONDITION IS PROGRESSIVE. THE AGONY
24 YOU FELT YESTERDAY AND BE WORSE TOMORROW. BUT I
25 ALSO KNOW THAT EVERYBODY IN THIS ROOM FEELS THAT

BARRISTERS' REPORTING SERVICE

1 AGONY. EVERYBODY IN THIS ROOM IS DEDICATED. YOU'VE
2 ALL GIVEN YOUR LIVES TO THIS EFFORT. SO WE KNOW
3 THAT.

4 CHAIRMAN THOMAS: I THINK THAT CONCLUDES
5 ALL THE COMMENT. MARIA, WILL YOU NOW TAKE THE ROLL
6 ON THE MOTION?

7 MR. HARRISON: AS A REMINDER, THE MOTION
8 IS TO APPROVE THE TRANSLATION STAGE PROGRAM CONCEPT
9 PROPOSAL.

10 MS. BONNEVILLE: DAVID BRENNER. KEN
11 BURTIS.

12 DR. BURTIS: YES.

13 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

14 DR. DULIEGE: YES.

15 MS. BONNEVILLE: LEON FINE.

16 DR. FINE: YES.

17 MS. BONNEVILLE: ELIZABETH FINI.

18 DR. FINI: YES.

19 MS. BONNEVILLE: MICHAEL FRIEDMAN. JUDY
20 GASSON.

21 DR. GASSON: YES.

22 MS. BONNEVILLE: SAM HAWGOOD. DAVID
23 HIGGINS.

24 DR. HIGGINS: YES.

25 MS. BONNEVILLE: STEPHEN JUELSGAARD.

BARRISTERS' REPORTING SERVICE

1 SHERRY LANSING. KATHY LAPORTE. JACOB LEVIN.
2 DR. LEVIN: YES.
3 MS. BONNEVILLE: BERT LUBIN. LAUREN
4 MILLER.
5 MS. MILLER: YES.
6 MS. BONNEVILLE: LLOYD MINER. ADRIANA
7 PADILLA.
8 DR. PADILLA: YES.
9 MS. BONNEVILLE: JOE PANETTA.
10 MR. PANETTA: YES.
11 MS. BONNEVILLE: ROBERT PRICE.
12 DR. PRICE: YES.
13 MS. BONNEVILLE: FRANCISCO PRIETO.
14 DR. PRIETO: AYE.
15 MS. BONNEVILLE: ROBERT QUINT. AL
16 ROWLETT.
17 MR. ROWLETT: YES.
18 MS. BONNEVILLE: JEFF SHEEHY.
19 MR. SHEEHY: YES.
20 MS. BONNEVILLE: OSWALD STEWARD.
21 DR. STEWARD: YES.
22 MS. BONNEVILLE: JONATHAN THOMAS.
23 CHAIRMAN THOMAS: YES.
24 MS. BONNEVILLE: ART TORRES.
25 MR. TORRES: AYE.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: KRISTINA VUORI.

2 DR. VUORI: YES.

3 MS. BONNEVILLE: DONNA WESTON.

4 DR. WESTON: YES.

5 MS. BONNEVILLE: DIANE WINOKUR.

6 MS. WINOKUR: YES.

7 MR. HARRISON: MOTION PASSES WITH 20

8 VOTES.

9 CHAIRMAN THOMAS: THANK YOU VERY MUCH.

10 WE'RE GOING TO TRY TO GET TWO MORE AGENDA TOPICS
11 BEFORE WE BREAK FOR LUNCH, ASSUMING BETH, AGAIN, CAN
12 HANG IN THERE JUST A FEW MORE MINUTES. THANK YOU
13 VERY MUCH, AGAIN, FOR EVERYBODY WHO CAME TO GIVE
14 PUBLIC COMMENT. WE APPRECIATE YOUR TIME AND EFFORT
15 AND COMMENTS.

16 SO WE'RE GOING TO PROCEED NOW TO THE NEXT
17 ITEM -- BY THE WAY, DR. KELLY SHEPARD, THANK YOU SO
18 MUCH FOR THAT PRESENTATION. DR. OLSON AND DR. YAFFE
19 AND TEAM, FANTASTIC WORK. THIS HAS REALLY TAKEN
20 THESE STAGES OF OUR FUNDING CONTINUUM TO A NEW LEVEL
21 AND COMPLETES THE CIRM 2.0 PROTOCOL. SO THANKS TO
22 EVERYBODY FOR YOUR GREAT DEDICATION AND MANY, MANY
23 HOURS OF WORK.

24 WE'RE GOING TO GO ON NOW TO ITEM 14, WHICH
25 IS ESSENTIALLY A REUP OF THE BRIDGES PROGRAM WITH

BARRISTERS' REPORTING SERVICE

1 SOME NEW ADDITIONAL ITEMS ATTACHED. DR. YAFFE.

2 DR. YAFFE: MR. CHAIRMAN, MEMBERS OF THE
3 BOARD, MEMBERS OF THE PUBLIC, AND TEAM CIRM,
4 EDUCATION PLAYS A KEY ROLE IN CIRM'S ENDEAVOR TO
5 TURN DISCOVERIES INTO THERAPIES AND SERVES CIRM'S
6 MISSION TO ACCELERATE THE DEVELOPMENT OF TREATMENTS
7 TO PATIENTS WITH UNMET MEDICAL NEEDS.

8 TODAY I BRING FOR YOUR CONSIDERATION
9 CONCEPT PROPOSALS FOR TWO EDUCATIONAL PROGRAMS,
10 BRIDGES, OUR COLLEGE INTERNSHIP AND TRAINING
11 PROGRAM, AND SPARK, OUR REIMAGINED SUMMER HIGH
12 SCHOOL PROGRAM.

13 THE CIRM, AS MANY OF YOU KNOW OR MOST OF
14 YOU PROBABLY KNOW, THE CIRM BRIDGES TO STEM CELL
15 RESEARCH PROGRAM SUPPORTS RESEARCH INTERNSHIPS AND
16 TRAINING IN STEM CELL SCIENCE FOR UNDERGRADUATE AND
17 MASTER'S LEVEL STUDENTS FROM DIVERSE CALIFORNIA
18 COMMUNITIES. THE FIRST VERSION OF THIS PROGRAM,
19 WHICH WE REFER TO AS BRIDGES 1.0, IS NOW IN ITS
20 SEVENTH YEAR. OVER 700 STUDENTS HAVE COMPLETED THIS
21 PROGRAM AT 13 CALIFORNIA STATE UNIVERSITIES AND
22 THREE COMMUNITY COLLEGES.

23 OF FORMER BRIDGES TRAINEES WE KNOW FROM
24 OUTCOME SURVEYS THAT APPROXIMATELY 50 PERCENT ARE
25 CURRENTLY WORKING IN LAB JOBS. ABOUT 30 PERCENT ARE

BARRISTERS' REPORTING SERVICE

1 ENROLLED IN GRADUATE OR PROFESSIONAL SCHOOLS, AND
2 ANOTHER 15 PERCENT ARE IN THE PROCESS OF COMPLETING
3 THEIR INITIAL EDUCATIONAL PROGRAM OR ARE CURRENTLY
4 APPLYING TO GRADUATE SCHOOL.

5 ALSO, THERE ARE BRIDGES ALUMNI NOW
6 EMPLOYED FULL TIME IN LABORATORIES AT MORE THAN 20
7 CALIFORNIA UNIVERSITIES AND RESEARCH INSTITUTES AND
8 AT MORE THAN 50 BIOTECH AND PHARMACEUTICAL COMPANIES
9 THAT A VAST MAJORITY OF THESE ARE IN CALIFORNIA.

10 WE NOW BRING TO YOU A REIMAGINED
11 INITIATIVE BETTER ALIGNED WITH CIRM'S MISSION,
12 BRIDGES 2.0. OUR OBJECTIVE REMAINS TO PREPARE
13 CALIFORNIA'S UNDERGRADUATE AND MASTER'S LEVEL
14 STUDENTS FOR HIGHLY PRODUCTIVE CAREERS IN STEM CELL
15 RESEARCH AND THERAPY DEVELOPMENT. WE'RE KEEPING A
16 NUMBER OF ACTIVITIES THAT WE FEEL ARE BENEFICIAL AND
17 HAVE PROVEN TO BE SUCCESSFUL IN PREPARING THESE
18 YOUNG PEOPLE FOR CAREERS OR HIGHER EDUCATION FOCUSED
19 ON STEM CELL RESEARCH AND THERAPY DEVELOPMENT.

20 WE'RE KEEPING HANDS-ON RESEARCH
21 INTERNSHIPS AT RESEARCH INSTITUTES, COMPANIES, AND
22 RESEARCH UNIVERSITIES IN CALIFORNIA. WE'RE ALSO
23 KEEPING A STEM CELL TECHNIQUES TRAINING COURSE TO
24 PREPARE ALL STUDENTS WITH A BASIC LEVEL OF
25 EXPERIENCE IN HANDLING HUMAN STEM CELLS.

BARRISTERS' REPORTING SERVICE

1 ADDITIONALLY, WE ARE CONTINUING EDUCATIONAL
2 ENHANCEMENT ACTIVITIES SUCH AS ADDITIONAL COURSES,
3 SEMINARS, CLUBS, AND OTHER ACTIVITIES OF THIS SORT
4 RELATED TO STEM CELL RESEARCH AND TRAINING. AND WE
5 ARE MAKING A RENEWED COMMITMENT TO BROADENING THE
6 PARTICIPATION IN THIS PROGRAM OF STUDENTS FROM
7 UNDERREPRESENTED POPULATIONS.

8 IN ORDER TO BETTER ALIGN THIS PROGRAM WITH
9 CIRM'S MISSION, WE ARE BRINGING A NUMBER OF NEW
10 FEATURES AND ACTIVITIES. THESE INCLUDE DIRECT
11 PATIENT ENGAGEMENT ACTIVITIES WHERE TRAINEES WILL
12 HAVE THE OPPORTUNITY TO MEET AND DISCUSS THE
13 CHALLENGES FACED BY PATIENTS AND HAVE AN OPPORTUNITY
14 TO UNDERSTAND DISEASE FROM THE PATIENT'S
15 PERSPECTIVE.

16 ADDITIONALLY, WE WILL BE ADDING TRAINING
17 IN THE REGULATORY PROCESS AND THE PROCESS FOR
18 DEVELOPMENT OF DRUGS AND THERAPIES TO PROVIDE
19 TRAINEES WITH AN UNDERSTANDING OF WHAT IT TAKES TO
20 MOVE SOMETHING FROM A LAB DISCOVERY INTO A CLINICAL
21 REALITY.

22 THIRD, WE'RE ADDING COMMUNITY OUTREACH AND
23 EDUCATION ACTIVITIES TO ENGAGE DIVERSE CALIFORNIA
24 COMMUNITIES IN SUPPORTING HEALTHCARE INITIATIVES AND
25 TO UNDERSTAND MORE BROADLY THE POTENTIAL OF THIS

BARRISTERS' REPORTING SERVICE

1 POWERFUL TECHNOLOGY.

2 AND FINALLY, WE'RE ADDING DYNAMIC AND
3 CAREER COUNSELING FOR BOTH TRAINEES AND PROGRAM
4 ALUMNI TO HELP THESE INDIVIDUALS FIND JOBS AND HELP
5 ALSO GUIDE THEM TO HIGHER EDUCATIONAL OPPORTUNITIES.

6 HERE ARE A FEW KEY FEATURES OF THE
7 PROGRAM. IT'S SPELLED OUT MORE ELABORATELY AND IN
8 MORE DETAIL IN THE CONCEPT PROPOSAL DOCUMENT. THIS
9 PROGRAM WILL BE OPEN TO CALIFORNIA UNIVERSITIES OR
10 COLLEGES THAT DO NOT HAVE A MAJOR STEM CELL RESEARCH
11 PROGRAM. IN PARTICULAR, WE EXPECT APPLICANTS FROM
12 THE STATE UNIVERSITY SYSTEM AND COMMUNITY COLLEGES
13 AND ALSO PRIVATE COLLEGES IN CALIFORNIA.

14 THERE WILL BE ONE FUNDING AND APPLICATION
15 OPPORTUNITY, AND ALL THE APPLICATIONS WILL BE
16 CONSIDERED IN A SINGLE REVIEW CYCLE. AND WE ARE
17 REQUESTING THAT CIRM COMMIT 45.7 MILLION TO SUPPORT
18 UP TO 15 AWARDS. EACH AWARD WILL BE SUPPORTED FOR
19 UP TO TEN TRAINEES PER YEAR, AND PROGRAMS WILL BE
20 SUPPORTED FOR UP TO FIVE YEARS.

21 AND NOW I'D LIKE TO TAKE ANY QUESTIONS
22 THAT YOU MAY HAVE ABOUT THIS PROGRAM AND THIS
23 PROPOSAL.

24 CHAIRMAN THOMAS: DR. YAFFE, HOW MANY
25 INSTITUTIONS DO WE CURRENTLY HAVE AWARDS OUT TO

BARRISTERS' REPORTING SERVICE

1 UNDER BRIDGES 1.0?

2 DR. YAFFE: WE CURRENTLY HAVE 16 AWARDS.
3 WE'RE ASKING FOR 15. IT WILL BE, OF COURSE, THE
4 BOARD'S DISCRETION TO ADD AN ADDITIONAL. WE'RE
5 ASKING ALL THE PROGRAMS TO RECOMPETE. WILL THEY ALL
6 RECOMPETE AS SUCCESSFULLY? WE DON'T KNOW THAT. THE
7 GRANTS WORKING GROUP WILL LOOK AT THE PROPOSALS AND
8 THEY WILL BRING THEIR RECOMMENDATION TO YOU. IT IS
9 POSSIBLE THAT YOU MAY FUND 14 AWARDS OR 10 AWARDS OR
10 16 AWARDS, AND THAT, I THINK, WILL BE A RESULT OF
11 THE GRANTS WORKING GROUP REVIEW, THE RECOMMENDATION,
12 AND YOUR ASSESSMENT OF THE VALUE OF THESE PROGRAMS.

13 CHAIRMAN THOMAS: DR. FINE.

14 DR. FINE: THIS IS VERY COMMENDABLE
15 INITIATIVE. IN THE INITIAL WORDING OR THE WORDING
16 THAT ACCOMPANIED THIS, THERE WAS AN INDICATION THAT
17 ONLY THOSE PROGRAMS THAT HAD NOT RECEIVED ORIGINAL
18 INFRASTRUCTURE MONEY FROM CIRM WOULD BE ELIGIBLE FOR
19 THIS BECAUSE THE DEFINITION OF WHAT IS A MAJOR STEM
20 CELL PROGRAM IS OBVIOUSLY IN THE EYES OF THE
21 BEHOLDER. SO I'M SUGGESTING THAT THERE ARE MANY
22 PROGRAMS IN CALIFORNIA THAT DID NOT RECEIVE THAT
23 INITIAL START-UP INFRASTRUCTURE FUNDING. THE
24 QUESTION IS ARE ALL OF THE OTHER PROGRAMS ELIGIBLE
25 FOR THIS AWARD?

BARRISTERS' REPORTING SERVICE

1 DR. YAFFE: ALL PROGRAMS ARE ELIGIBLE IF
2 THEY MEET THE OTHER REQUIREMENTS. ONE REQUIREMENT
3 IS THAT THE PROGRAM HAVE AN UNDERGRADUATE OR
4 MASTER'S LEVEL EDUCATIONAL PROGRAM. SO THIS IS A
5 BUILD-ON ON TOP OF AN ESTABLISHED PROGRAM THAT'S
6 ACCREDITED, AND THAT WILL PROVIDE STUDENTS,
7 QUALIFIED STUDENTS, FOR SUCH A PROGRAM.

8 THE IDEA THAT WE WERE EXCLUDING CERTAIN
9 INSTITUTIONS SUCH AS THE BIG RESEARCH UNIVERSITIES
10 HERE IN CALIFORNIA IS THE UNDERSTANDING THAT
11 STUDENTS AT THOSE INSTITUTIONS HAVE AN OPPORTUNITY
12 TO PARTICIPATE IN AND LEARN ABOUT STEM CELL
13 RESEARCH. THEY CAN VOLUNTEER IN LABS. THEY ARE
14 EXPOSED TO PROFESSORS AND MEDICAL SCHOOL
15 OPPORTUNITIES. SO THERE ARE MECHANISMS FOR STUDENTS
16 AT STANFORD OR UCSD WHERE I USED TO BE ON THE
17 FACULTY OR MANY OTHER RESEARCH UNIVERSITIES HERE IN
18 CALIFORNIA FOR THOSE STUDENTS TO GAIN THESE
19 EXPERIENCES. STUDENTS AT THE STATE UNIVERSITIES,
20 SMALLER COLLEGES, COMMUNITY COLLEGES OFTEN AND
21 GENERALLY DO NOT HAVE THAT OPPORTUNITY.

22 CHAIRMAN THOMAS: DO I HEAR A MOTION TO
23 ADOPT THIS PROGRAM?

24 MR. TORRES: SO MOVED.

25 DR. PRIETO: SECOND.

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: MOVED BY SENATOR TORRES,
2 SECONDED BY DR. PRIETO. OTHER QUESTIONS, COMMENTS
3 FROM MEMBERS OF THE BOARD? ANY COMMENTS FROM
4 MEMBERS ON THE PHONE? ANY COMMENTS ON THIS TOPIC
5 FROM MEMBERS OF THE PUBLIC?

6 MR. CASHMAN: THANK YOU, MR. CHAIRMAN.
7 THIS IS JOHN CASHMAN FROM HUMAN BIOMOLECULAR
8 RESEARCH INSTITUTE. IT LOOKS LIKE YOUR DEFINITION
9 EXCLUDES RESEARCH INSTITUTES, WHICH I THINK IS A
10 POTENTIAL OPPORTUNITY FOR REALLY EXCELLENT RESEARCH
11 PROSPECTS FOR UNDERGRADUATES AND HIGH SCHOOL
12 STUDENTS. WE'VE HAD OVER A HUNDRED STUDENTS GO
13 THROUGH OUR INSTITUTE OVER THE YEARS AND HAVE HAD A
14 TREMENDOUS EXPERIENCE. IN FACT, THOSE PERCENTAGES
15 THAT YOU LISTED IN TERMS OF HOW MANY STUDENTS GO TO
16 COLLEGE, WE'RE VIRTUALLY CLOSE TO A HUNDRED PERCENT,
17 MUCH HIGHER THAN THE NUMBERS I SAW IN THE
18 PRESENTATION.

19 SO I THINK EXCLUDING RESEARCH INSTITUTES,
20 ESPECIALLY SMALL RESEARCH INSTITUTES LIKE OURSELVES
21 THAT DON'T HAVE MAJOR STEM CELL PROGRAMS, BUT THEY
22 DON'T HAVE MASTER'S OR PH.D. PROGRAMS IS CUTTING OUT
23 AN IMPORTANT ELEMENT OF RESEARCH OPPORTUNITY. AND I
24 ASK THAT THAT BE REVISITED OR REVISED. SMALL
25 INSTITUTES CAN ALSO PARTNER WITH LARGER

BARRISTERS' REPORTING SERVICE

1 INSTITUTES THAT DO OFFER MASTER'S AND PH.D.
2 PROGRAMS, AND WE'VE DONE THAT EFFECTIVELY IN THE
3 PAST. JUST A SUGGESTION TO BROADEN THE SCOPE A
4 LITTLE BIT.

5 DR. YAFFE: I MAY NOT HAVE BEEN CLEAR.
6 THERE ARE TWO TYPES OF INSTITUTIONS INVOLVED. THERE
7 ARE APPLICANT INSTITUTIONS. THOSE ARE THE ONES THAT
8 PROPOSE THE PROGRAM, RECRUIT THE STUDENTS, PROVIDE
9 BASIC EDUCATIONAL ACTIVITIES. THEN THERE ARE POST
10 INSTITUTIONS WHERE THE RESEARCH INTERNSHIPS ACTUALLY
11 TAKE PLACE. THESE ARE RESEARCH UNIVERSITIES,
12 RESEARCH INSTITUTES SUCH AS WE JUST HEARD ABOUT, AND
13 BIOTECH AND PHARMACEUTICAL COMPANIES IN CALIFORNIA.
14 SO THERE'S NO EXCLUSION THERE IN TERMS OF WHERE THE
15 RESEARCH ACTIVITIES ACTUALLY OCCUR.

16 THE APPLICANT OR HOME INSTITUTIONS, THOSE
17 ARE THE ONES WHERE THERE'S A RESTRICTION BECAUSE WE
18 WANT TO TRY AND BRING IN STUDENTS WHO WOULDN'T
19 OTHERWISE HAVE THE OPPORTUNITY TO PARTICIPATE IN
20 THIS TYPE OF RESEARCH AND ACTIVITY.

21 DR. CHIU: ARLENE CHIU, CITY OF HOPE. I
22 AGREE WITH THE PREVIOUS COMMENT. WE HAVE A PH.D.
23 PROGRAM, BUT NOT AN UNDERGRADUATE PROGRAM. AND,
24 THEREFORE, BY THAT DEFINITION, WE'D BE EXCLUDED.
25 HOWEVER, WE CAN PROVIDE EDUCATIONAL ENHANCEMENT

BARRISTERS' REPORTING SERVICE

1 ACTIVITIES, COMMUNITY OUTREACH IN PARTICULAR, AND
2 ADVISING CAREER DEVELOPMENT, AND PARTICULARLY
3 PATIENT AND HEALTHCARE ENGAGEMENT ACTIVITIES.

4 NOW, I UNDERSTAND WE HAVE ALSO HOSTED A
5 NUMBER OF THESE BRIDGES FELLOWS AT CITY OF HOPE TO
6 THEIR BENEFIT. BUT IT SEEMS LIKE WE WOULD BE
7 OFFERING A LOT AND NOT ALLOWED TO INITIATE SUCH A
8 PROGRAM EVEN THOUGH WE DID NOT GET THE FACILITIES
9 GRANT AND WE DID NOT GET A SHARED LABS GRANT. SO IN
10 THOSE TWO CRITERIA, WE ACTUALLY FULFILL THE CRITERIA
11 STATED HERE; HOWEVER, WE'RE EXCLUDED AS IT STANDS
12 NOW. THANK YOU.

13 DR. YAFFE: WE ENCOURAGE INSTITUTIONS TO
14 JOIN FORCES TO COLLABORATE, TO FORM PARTNERSHIPS.
15 WE SAW THAT IN BRIDGES 1.0 WHERE A NUMBER OF SMALLER
16 STATE UNIVERSITIES AND COMMUNITY COLLEGES JOINED IN
17 WITH LARGER ONES. SO I THINK THERE ARE
18 OPPORTUNITIES FOR PARTICIPATION BY INSTITUTIONS
19 WHICH MIGHT NOT COMPLETELY QUALIFY AS AN APPLICANT,
20 BUT THEY COULD PARTNER WITH ANOTHER INSTITUTION AND
21 BECOME INVOLVED IN THIS ACTIVITY.

22 CHAIRMAN THOMAS: ANY OTHER COMMENTS FROM
23 MEMBERS OF THE PUBLIC? MARIA, PLEASE TAKE THE ROLL.

24 MS. BONNEVILLE: DAVID BRENNER. KEN
25 BURTIS.

BARRISTERS' REPORTING SERVICE

1 DR. BURTIS: YES.
2 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
3 DR. DULIEGE: YES.
4 MS. BONNEVILLE: LEON FINE.
5 DR. FINE: YES.
6 MS. BONNEVILLE: ELIZABETH FINI.
7 DR. FINI: YES.
8 MS. BONNEVILLE: MICHAEL FRIEDMAN. JUDY
9 GASSON.
10 DR. GASSON: YES.
11 MS. BONNEVILLE: SAM HAWGOOD. DAVID
12 HIGGINS.
13 DR. HIGGINS: YES.
14 MS. BONNEVILLE: STEPHEN JUELSGAARD.
15 SHERRY LANSING. KATHY LAPORTE. JACOB LEVIN.
16 DR. LEVIN: YES.
17 MS. BONNEVILLE: BERT LUBIN. LAUREN
18 MILLER.
19 MS. MILLER: YES.
20 MS. BONNEVILLE: LLOYD MINER. ADRIANA
21 PADILLA.
22 DR. PADILLA: YES.
23 MS. BONNEVILLE: JOE PANETTA.
24 MR. PANETTA: YES.
25 MS. BONNEVILLE: ROBERT PRICE.

BARRISTERS' REPORTING SERVICE

1 DR. PRICE: YES.
2 MS. BONNEVILLE: FRANCISCO PRIETO.
3 DR. PRIETO: AYE.
4 MS. BONNEVILLE: ROBERT QUINT. AL
5 ROWLETT.
6 MR. ROWLETT: YES.
7 MS. BONNEVILLE: JEFF SHEEHY.
8 MR. SHEEHY: YES.
9 MS. BONNEVILLE: OSWALD STEWARD.
10 DR. STEWARD: YES.
11 MS. BONNEVILLE: JONATHAN THOMAS.
12 CHAIRMAN THOMAS: YES.
13 MS. BONNEVILLE: ART TORRES.
14 MR. TORRES: AYE.
15 MS. BONNEVILLE: KRISTINA VUORI.
16 DR. VUORI: YES.
17 MS. BONNEVILLE: DONNA WESTON.
18 DR. WESTON: YES.
19 MS. BONNEVILLE: DIANE WINOKUR.
20 MS. WINOKUR: YES.
21 MR. HARRISON: MOTION PASSES WITH 20
22 VOTES.
23 CHAIRMAN THOMAS: THANK YOU. ONE ITEM TO
24 GO SEPARATING YOU FROM LUNCH. DRS. YAFFE AND
25 VESSAL.

BARRISTERS' REPORTING SERVICE

1 DR. VESSAL: THANK YOU, MR. CHAIRMAN.
2 GOOD AFTERNOON, MEMBERS OF THE BOARD. I WOULD LIKE
3 TO INTRODUCE THE NEW CONCEPT WHICH WOULD BE THE
4 CREATIVITY AWARDS AS YOU MAY KNOW IT AS WE ALREADY
5 ARE FUNDING. WE'RE CALLING IT SPARK THIS TIME
6 AROUND, KNOWN AS SUMMER PROGRAM TO ACCELERATE
7 REGENERATIVE MEDICINE KNOWLEDGE. THE OBJECTIVE OF
8 THE PROGRAM, AS YOU ALREADY KNOW, IS TO INTRODUCE
9 AND INSPIRE CALIFORNIA'S HIGH SCHOOL STUDENTS TO THE
10 FIELD OF REGENERATIVE MEDICINE AS IT RELATES TO
11 HUMAN DISEASES. AND IT HAS BEEN A VERY SUCCESSFUL
12 PROGRAM IN THE PAST THREE YEARS IN OUR PREVIOUS RFA.

13 THE ITEMS THAT WE ARE ACTUALLY KEEPING
14 HERE WITH THE NEW CIRM PROGRAM WOULD BE THE
15 FULL-TIME, HANDS-ON SUMMER INTERNSHIP PROGRAM AT THE
16 CALIFORNIA INSTITUTES THAT CARRY ON STEM CELL
17 RESEARCH AND ALSO ENCOURAGING THE ENROLLMENT OF
18 STUDENTS THAT COME FROM UNDERREPRESENTED
19 POPULATIONS. AND, OF COURSE, ALL CULMINATING AT THE
20 END OF THE SUMMER POSTER DAY.

21 WE'RE ALSO ADDING CIRM COMPONENTS TO THIS
22 NEW RFA, AND THAT WOULD BE DIRECT PATIENT ENGAGEMENT
23 ACTIVITIES, A PREP COURSE TRAINING BEFORE THE
24 INTERNS ARE ACTUALLY HOSTED IN THE HOST LABORATORIES
25 FOR THEIR SUMMER RESEARCH, AS WELL AS COMMUNITY

BARRISTERS' REPORTING SERVICE

1 OUTREACH ACTIVITIES WHICH WOULD BE ENGAGING WITH
2 THEIR COMMUNITY AND DIVERSE COMMUNITIES IN
3 CALIFORNIA THROUGH SOCIAL MEDIA.

4 WE'VE ALREADY DONE THE SOCIAL MEDIA ASPECT
5 OF THIS NEW ADDITION IN THE PAST TWO YEARS IN THE
6 CREATIVITY PROGRAM, AND IT HAS SHOWN TO BE QUITE
7 SUCCESSFUL, AND THE ENTRANTS ACTUALLY ARE PRETTY
8 COMFORTABLE WITH IT AND HAVE WELCOMED IT.

9 THE INSTITUTIONS THAT CAN APPLY ARE FROM
10 THE CALIFORNIA UNIVERSITIES, COLLEGES, OR RESEARCH
11 INSTITUTES THAT ALREADY HAVE AN ESTABLISHED HIGH
12 SCHOOL SUMMER INTERNSHIP PROGRAM IN PLACE. AND THE
13 APPLICATIONS, OF COURSE, WILL BE CONSIDERED UNDER A
14 SINGLE REVIEW CYCLE.

15 CIRM IS ASKING FOR UP TO \$4 MILLION TO
16 SUPPORT UP TO TEN AWARDS, AND EACH AWARD WILL
17 SUPPORT A MINIMUM OF FIVE AND UP TO TEN TRAINEES PER
18 YEAR. AND WE ARE ASKING TO SUPPORT THESE PROGRAMS
19 FOR UP TO FIVE YEARS. IF THERE'S ANY QUESTIONS, I'D
20 BE HAPPY TO ANSWER. THANK YOU.

21 CHAIRMAN THOMAS: DR. VESSAL, ON THE WHO
22 MAY APPLY BULLET POINT WHERE YOU SAY ESTABLISHED
23 HIGH SCHOOL SUMMER INTERNSHIP PROGRAM, THAT DOESN'T
24 MEAN ESTABLISHED HIGH SCHOOL STEM CELL INTERNSHIP
25 PROGRAM THAT WE'RE CURRENTLY FUNDING, CORRECT?

BARRISTERS' REPORTING SERVICE

1 DR. VESSAL: THIS WOULD BE A NEW
2 APPLICATION. SO ANYBODY THAT WE'RE CURRENTLY
3 ACTUALLY FUNDING WILL HAVE TO REAPPLY, AND THAT
4 WOULD BE TAKEN INTO CONSIDERATION.

5 CHAIRMAN THOMAS: SUMMER INTERNSHIP
6 DOESN'T MEAN STEM CELL. IT MEANS THEY HAVE A SUMMER
7 INTERNSHIP PROGRAM.

8 DR. VESSAL: A HIGH SCHOOL SUMMER
9 INTERNSHIP PROGRAM DOES NOT HAVE TO BE STEM CELL
10 BASED.

11 CHAIRMAN THOMAS: JUST WANTED TO CLARIFY.
12 IT'S A LITTLE CONFUSING.

13 DR. VESSAL: SO THIS WOULD ACTUALLY BE
14 ASSOCIATED TO THE EXISTING PROGRAMS.

15 CHAIRMAN THOMAS: AS WITH BRIDGES, HOW
16 MANY CURRENT AWARDS DO WE HAVE OUTSTANDING FOR
17 CREATIVITY?

18 DR. VESSAL: WE HAVE NINE INSTITUTIONS
19 THAT HAVE BEEN AWARDED AND FUNDED.

20 CHAIRMAN THOMAS: OTHER QUESTIONS FROM
21 MEMBERS OF THE BOARD? FIRST, DO I HAVE A MOTION TO
22 APPROVE?

23 DR. BURTIS: SO MOVED.

24 CHAIRMAN THOMAS: MOVED BY DR. BURTIS.

25 DR. GASSON: SECOND.

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: SECOND BY DR. GASSON.
2 OTHER COMMENTS, QUESTIONS FROM MEMBERS ON THE PHONE?
3 ANY PUBLIC COMMENT? MARIA, PLEASE TAKE THE ROLL.
4 MS. BONNEVILLE: DAVID BRENNER. KEN
5 BURTIS.
6 DR. BURTIS: YES.
7 MS. BONNEVILLE: ANNE-MARIE DULIEGE.
8 DR. DULIEGE: YES.
9 MS. BONNEVILLE: LEON FINE.
10 DR. FINE: YES.
11 MS. BONNEVILLE: ELIZABETH FINI.
12 DR. FINI: YES.
13 MS. BONNEVILLE: MICHAEL FRIEDMAN. JUDY
14 GASSON.
15 DR. GASSON: YES.
16 MS. BONNEVILLE: SAM HAWGOOD. DAVID
17 HIGGINS.
18 DR. HIGGINS: YES.
19 MS. BONNEVILLE: STEPHEN JUELSGAARD.
20 SHERRY LANSING. KATHY LAPORTE. JACOB LEVIN.
21 DR. LEVIN: YES.
22 MS. BONNEVILLE: BERT LUBIN. LAUREN
23 MILLER.
24 MS. MILLER: YES.
25 MS. BONNEVILLE: LLOYD MINER. ADRIANA

BARRISTERS' REPORTING SERVICE

1 PADILLA.

2 DR. PADILLA: YES.

3 MS. BONNEVILLE: JOE PANETTA.

4 MR. PANETTA: YES.

5 MS. BONNEVILLE: ROBERT PRICE.

6 DR. PRICE: AYE.

7 MS. BONNEVILLE: FRANCISCO PRIETO.

8 DR. PRIETO: AYE.

9 MS. BONNEVILLE: ROBERT QUINT. AL

10 ROWLETT.

11 MR. ROWLETT: YES.

12 MS. BONNEVILLE: JEFF SHEEHY.

13 MR. SHEEHY: YES.

14 MS. BONNEVILLE: OSWALD STEWARD.

15 DR. STEWARD: YES.

16 MS. BONNEVILLE: JONATHAN THOMAS.

17 CHAIRMAN THOMAS: YES.

18 MS. BONNEVILLE: ART TORRES.

19 MR. TORRES: AYE.

20 MS. BONNEVILLE: KRISTINA VUORI.

21 DR. VUORI: YES.

22 MS. BONNEVILLE: DONNA WESTON.

23 DR. WESTON: YES.

24 MS. BONNEVILLE: DIANE WINOKUR.

25 MS. WINOKUR: YES.

BARRISTERS' REPORTING SERVICE

1 MR. HARRISON: MOTION PASSES WITH 20
2 VOTES.

3 CHAIRMAN THOMAS: OKAY. THANK YOU. I'VE
4 BEEN INFORMED WE HAVE A VERY SHORT YET VERY
5 IMPORTANT ADDITIONAL ITEM. THANK YOU, DR. VESSAL.

6 DR. VESSAL: I JUST WANT TO REMIND THE
7 BOARD MEMBERS THAT THE CREATIVITY AWARDS POSTER DAY
8 FOR THIS YEAR WILL BE HELD ON AUGUST 7TH IN CASE
9 ANYBODY WOULD BE INTERESTED TO ATTEND.

10 CHAIRMAN THOMAS: THANK YOU, DR. VESSAL.
11 THANK YOU FOR ALL YOU DO FOR THE PROGRAM. THIS IS,
12 AS WITH BRIDGES, IS A TRULY WINNER PROGRAM THAT JUST
13 GENERATES SO MUCH INTEREST, ENTHUSIASM, AND PRODUCT
14 AND IS REALLY PRIMING THE WORKFORCE FOR FUTURE
15 PEOPLE TO TAKE OVER ALL OF THESE WONDERFUL STEM CELL
16 PROGRAMS THAT WE ARE FUNDING AND OTHERS. SO THANK
17 YOU FOR YOUR HARD WORK.

18 DR. VESSAL: MY PLEASURE.

19 CHAIRMAN THOMAS: SO THE FINAL ITEM IS THE
20 AUGMENTATION OF THE REMCHO, JOHANSEN LEGAL CONTRACT
21 DUE TO EXPANDED DUTIES OF THE PAST YEAR AND GOING
22 FORWARD FOR MR. HARRISON.

23 DR. MILLS: THIS IS, I THINK, JUST TO
24 RENEW THE CONTRACT OF REMCHO, JOHANSEN & PURCELL AND
25 JAMES HARRISON AS OUR COUNSEL TO THE BOARD AND

BARRISTERS' REPORTING SERVICE

1 GENERAL COUNSEL TO CIRM FOR \$575,000. I'LL REMIND
2 THE BOARD THAT IN JULY OF 2014, IN ADDITION TO HIS
3 DUTIES AS COUNSEL TO THE BOARD, MR. HARRISON ALSO
4 TOOK OVER THE RESPONSIBILITIES FROM OUR PREVIOUS
5 GENERAL COUNSEL AND FROM AN ADDITIONAL IN-HOUSE
6 ATTORNEY WHICH ACTUALLY REDUCED OUR SALARY RATE BY
7 HALF A MILLION DOLLARS.

8 MR. TORRES: SO MOVED.

9 MS. WINOKUR: SECOND.

10 CHAIRMAN THOMAS: SECONDED BY MS. WINOKUR.

11 ALWAYS FEEL THE NEED WHEN THIS COMES UP EVERY YEAR
12 JUST TO POINT OUT WHAT AN OUTSTANDING JOB MR.
13 HARRISON DOES FOR THE AGENCY IN EVERY RESPECT AND
14 HOW FORTUNATE WE ARE TO HAVE HIM IN EACH AND EVERY
15 CAPACITY FOR WHICH HE SERVES. SO, MR. HARRISON,
16 THANK YOU VERY MUCH FOR YOUR GREAT WORK.

17 (APPLAUSE.)

18 CHAIRMAN THOMAS: ANY FURTHER COMMENT FROM
19 MEMBERS OF THE BOARD? ANY COMMENT FROM MEMBERS ON
20 THE PHONE? ANY COMMENT FROM MEMBERS OF THE PUBLIC?
21 WITHOUT FURTHER ADO, A VOICE VOTE, I AM INFORMED,
22 WILL DO ON THIS ONE. ALL THOSE IN FAVOR PLEASE SAY
23 AYE. MARIA, PLEASE POLL THOSE ON THE PHONE.

24 MS. BONNEVILLE: LAUREN MILLER.

25 MS. MILLER: YES.

BARRISTERS' REPORTING SERVICE

1 MS. BONNEVILLE: JOE PANETTA.

2 MR. PANETTA: YES.

3 MS. BONNEVILLE: KRISTINA VUORI.

4 DR. VUORI: YES.

5 MS. BONNEVILLE: DONNA WESTON.

6 DR. WESTON: YES.

7 CHAIRMAN THOMAS: MR. HARRISON, DID WE
8 APPROVE YOUR OWN MOTION?

9 MR. TOCHER: MOTION CARRIES.

10 CHAIRMAN THOMAS: THANK YOU, MR. TOCHER.
11 BY THE WAY, MR. TOCHER AND OTHER MEMBERS OF THE
12 LEGAL STAFF, WE APPLAUD YOU AS WELL. WE'RE IN VERY
13 CAPABLE HANDS WITH OUR ENTIRE LEGAL TEAM HERE AND
14 ARE VERY FORTUNATE INDEED. SO THANK YOU.

15 THAT CONCLUDES THE ACTION ITEMS ON THE
16 AGENDA. WE CAN NOW GO GET LUNCH AND COME BACK HERE
17 FOR THE SPOTLIGHT ON DISEASE AND CONCLUDING ITEMS ON
18 THE AGENDA AFTER THAT. SO, BETH, YOU HAVE A NICE
19 BREAK HERE. THANK YOU FOR HANGING IN THERE.
20 EVERYBODY PLEASE GET LUNCH AND COME RIGHT BACK TO
21 THIS ROOM. THANK YOU.

22 (A RECESS WAS TAKEN FOLLOWED BY THE
23 SPOTLIGHT ON DISEASE, NOT REPORTED NOR HEREIN
24 TRANSCRIBED. THE FOLLOWING WAS THEN HEARD IN OPEN
25 SESSION:)

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: OKAY. THANK YOU VERY
2 MUCH TO BOTH OF OUR SPEAKERS.

3 LAST ITEM ON THE AGENDA, LAST BUT, OF
4 COURSE, NEVER LEAST, KEVIN AND OUR COMMUNICATION
5 REPORT.

6 MR. MC CORMACK: CHAIRMAN THOMAS, MEMBERS
7 OF THE BOARD, COLLEAGUES, AND MEMBERS OF THE PUBLIC,
8 IT'S ALWAYS A PLEASURE TO COME AND TALK TO YOU,
9 WELL, ALMOST ALWAYS A PLEASURE BECAUSE THE PROBLEM
10 ABOUT GOING LAST IS THAT YOU HAVE TO FOLLOW SPEECHES
11 LIKE THAT AND THE PRESENTATIONS AND THE COMMENTS
12 THAT CAME EARLIER IN THE DAY FROM THE PARKINSON'S
13 PATIENTS, AND I ALWAYS FEEL TERRIBLY INADEQUATE TO
14 FOLLOW SOMETHING LIKE THAT. AND THEN, OF COURSE,
15 THE PEOPLE WHO WENT BEFORE ME, CHAIRMAN THOMAS AND
16 DR. MILLS, STILL THE BEST MINDS, AND SO I'M LEFT
17 WITH THE SCRAB ENDS. I FEEL AS THOUGH I MIGHT BE
18 THE ROYAL FOOTMAN WHO FOLLOWS THE COACH, HAVING TO
19 SWEEP UP BEHIND.

20 HAVING SAID THAT, THERE'S SOME GOOD STUFF
21 TO BE SWEEP UP. AND I WANT TO BEGIN WITH OUR ANNUAL
22 REPORT, COPIES OF WHICH WERE ON YOUR SEATS AS YOU
23 CAME IN TODAY IN BOTH ENGLISH AND SPANISH. AND I
24 WANT TO THANK DR. TODD DUBNICOFF FOR REALLY KIND OF
25 MASTERMINDING AND SHEPHERDING THIS WHOLE PROCESS

BARRISTERS' REPORTING SERVICE

1 THROUGH. HE DID A WONDERFUL JOB OF MAKING IT VERY
2 CIRM 2.0-Y IN BOTH ENGLISH AND SPANISH, WHICH IS NOT
3 EASY TO DO, AND ALSO THE PHOTOGRAPHY. IN THE PAST
4 WE'VE ALWAYS GONE OUT WITH A PROFESSIONAL
5 PHOTOGRAPHER TO TAKE SOME OF THE PHOTOGRAPHS. THIS
6 YEAR TODD DID IT HIMSELF AND DID AN EXTRAORDINARY
7 JOB. SO WE CAN SAVE MONEY THERE IN THE FUTURE. SO
8 THANK YOU, TODD.

9 MR. TORRES: I WOULDN'T DO THAT, TODD,
10 UNLESS YOU GET PAID.

11 MR. MC CORMACK: HE GETS SEVEN FIFTY AN
12 HOUR.

13 AS BOTH DR. THOMAS AND DR. MILLS BOTH
14 TALKED ABOUT, WE HAD A NUMBER OF PATIENT ADVOCATE
15 MEETINGS AROUND THE STATE IN SAN DIEGO, LOS ANGELES,
16 AND IN SAN FRANCISCO LAST WEEK TO REALLY LISTEN TO
17 THE PATIENT ADVOCATES AND GET THEIR IDEAS ON THE
18 STRATEGIC PLAN. THIS IS THE AUDIENCE AT USC IN LOS
19 ANGELES, AND WE HAD AN EVEN BIGGER CROWD IN SAN
20 DIEGO. SO IT WAS A REALLY INTERESTING TURNOUT, SOME
21 REALLY THOUGHTFUL COMMENTS. AND WE'VE BEEN GETTING
22 COMMENTS SINCE THEN AS WELL. PEOPLE ARE E-MAILING
23 AND LETTING US KNOW THEIR THOUGHTS.

24 IT'S REALLY IMPORTANT WHEN WE TALK ABOUT
25 THE PATIENT ADVOCATES BECAUSE THEY'RE THE ONES

BARRISTERS' REPORTING SERVICE

1 REALLY WHO HAVE MOST SKIN IN THIS GAME. AND SO IT'S
2 IMPORTANT FOR US TO GET THEIR THOUGHTS ON WHAT WE
3 SHOULD BE DOING, THE GOALS THAT WE HAVE, AND HOW WE
4 GET THERE OVER THE NEXT FIVE YEARS WITH THIS
5 STRATEGIC PLAN. SO I THINK WE'RE GOING TO GET A LOT
6 OF REALLY USEFUL INFORMATION OUT OF THOSE VISITS.

7 MR. SHEEHY AND I HAVE ALSO BEEN WORKING ON
8 A COUPLE OF ITEMS TO ENGAGE THE PUBLIC IN OTHER
9 WAYS. WE'RE HOLDING AN HIV/AIDS CURE TOWN HALL
10 MEETING IN LOS ANGELES NEXT WEEK, JULY 30TH TO BE
11 PRECISE. WE HELD A SIMILAR EVENT ABOUT 18 MONTHS
12 AGO, AND AT THAT TIME WE REALLY ONLY HAD CAL-IMMUNE
13 AND THE CLINICAL TRIAL THEY WERE DOING TO TALK
14 ABOUT. NOW WE HAVE NOT JUST THE CAL-IMMUNE, BUT THE
15 CITY OF HOPE AND SANGAMO TRIAL, THE PROJECT THAT YOU
16 APPROVED TODAY, THE AIDS AND LYMPHOMA TRIAL OUT OF
17 UC DAVIS. AND DR. PAULA CANNON AT USC IS ALSO DOING
18 SOME OTHER REALLY INTERESTING WORK. SO THERE'S AN
19 AWFUL LOT OF THINGS TO TALK ABOUT. IT'S A REALLY
20 GOOD OPPORTUNITY TO BRING OUR MESSAGE ABOUT THE WORK
21 THAT WE'RE FUNDING AND THE PROGRESS THAT'S BEING
22 MADE TO THE COMMUNITY.

23 THIS IS GOING TO BE TAKING PLACE AT
24 PLUMBER PARK IN WEST HOLLYWOOD, SO IT'S A GREAT
25 OPPORTUNITY TO REACH OUT TO THAT PARTICULAR

BARRISTERS' REPORTING SERVICE

1 COMMUNITY. IT'S ALSO A REALLY GOOD TIME FOR THIS
2 EVENT. WE'VE BEEN PLANNING IT FOR SEVERAL MONTHS,
3 BUT THE TIMING IS REALLY GOOD BECAUSE THERE WAS A
4 STORY IN THE NEWS RECENTLY ABOUT A FRENCH TEENAGER
5 WHO WAS BORN HIV POSITIVE, BUT STOPPED TAKING HER
6 MEDICATIONS ABOUT 12 YEARS AGO AND IS NOW VIRUS
7 FREE. SO IT'S BROUGHT BACK THE WHOLE NOTION OF CURE
8 INTO THE CONVERSATION, INTO THE NEWS, AND IT'S A
9 GREAT OPPORTUNITY FOR US TO BUILD ON THAT TO SHOW
10 THAT YOU DON'T HAVE TO GO TO FRANCE, YOU DON'T HAVE
11 TO GO TO VANCOUVER WHERE THE NEWS CONFERENCE WHERE
12 THEY RELEASED THIS INFORMATION WAS HELD. YOU CAN
13 FIND IT IN LOS ANGELES, YOU CAN FIND IT IN
14 CALIFORNIA, AND THAT WE'RE THE DRIVING FORCE BEHIND
15 AN AWFUL LOT OF THIS.

16 AND MR. SHEEHY, DR. SHEEHY, IF YOU LIKE,
17 AN HONORABLE DOCTORATE. MR. SHEEHY AND I ARE ALSO
18 ORGANIZING A SIMILAR EVENT TO BE HELD IN PALM
19 SPRINGS IN THE FALL.

20 ONE OF THE OTHER THINGS WE'VE BEEN WORKING
21 ON IS A NUMBER OF US HAVE BEEN WORKING WITH THE
22 FOLKS AT CORYELL CELLULAR DYNAMICS AND ALSO AT THE
23 BUCK PREPARING FOR THE OPENING OF OUR STEM CELL
24 BANK. IT'S GOING TO OPEN EARLY IN THE FALL. AND SO
25 WE REALLY WANT TO BE ABLE TO PUT TOGETHER A

BARRISTERS' REPORTING SERVICE

1 MARKETING AND PROMOTIONAL PACK SO THAT THE
2 RESEARCHERS AROUND THE WORLD KNOW THAT THIS RESOURCE
3 IS AVAILABLE. ULTIMATELY THE GOAL OF THE BANK IS TO
4 BE SELF-SUSTAINABLE WHEN OUR FUNDING ENDS. SO THIS
5 IS A VERY IMPORTANT FIRST STEP IN DOING THAT.

6 AND WE'VE BEEN, IN OUR SPARE TIME, PUTTING
7 TOGETHER SOME VIDEOS. DR. DUBNICOFF AND I HAVE BEEN
8 CONTRIBUTING A NUMBER OF VIDEOS. A NUMBER OF THEM
9 BEING FROM WHAT WE CALL OUR STEM CELLS IN YOUR FACE
10 SERIES. AND THE IDEA BEHIND THAT IS THAT WE BLEND
11 BOTH HUMOR AND SCIENCE, TALK ABOUT THE RESEARCH THAT
12 WE'RE FUNDING. THE MOST RECENT ONE THAT WE SHOT WAS
13 ABOUT GENE THERAPY AND ABOUT DR. KOHN'S WORK AT UCLA
14 IN HELPING THERAPY THAT NOT ONLY CURED SKIN, BUT NOW
15 WE'RE WORKING WITH HIM, WE'RE FUNDING A CLINICAL
16 TRIAL FOR SICKLE CELL DISEASE. SO THIS VIDEO HAS
17 ACTUALLY BEEN GETTING A NUMBER OF LEASES OF LIFE.
18 IT SEEMS THAT EVERY TIME WE THINK THAT IT'S DIED
19 DOWN, SOMEONE ELSE CIRCULATES IT AND IT POPS UP
20 SOMEWHERE ELSE. SO WE'RE GETTING A REALLY GOOD
21 RESPONSE, WHICH IS GOOD. IT TOOK A LOT OF WORK AND
22 FUN TO DO, BUT IT TAKES A WHILE.

23 IN FACT, WE SHOT ANOTHER JUST LAST FRIDAY
24 PROMOTING THE WORK THAT WE DO IN VISION LOSS. DR.
25 HUMAYAN'S WORK AT USC FOR MACULAR DEGENERATION AND

BARRISTERS' REPORTING SERVICE

1 DR. CLASSEN'S WORK AT UC IRVINE FOR RETINITIS
2 PIGMENTOSA. IN THAT VIDEO WE'RE ALSO INCORPORATING
3 AN IDEA THAT CAME FROM ONE OF OUR OTHER BOARD
4 MEMBERS, MS. MILLER, IN TERMS OF ADDING ANIMATION TO
5 THE VIDEO. SO WE'RE GOING TO BE DOING THAT.

6 I ACTUALLY JUST WANTED TO FOLLOW UP ON
7 SOMETHING THAT DR. YAFFE SAID EARLIER ABOUT MS.
8 MILLER'S SPEECH AT THE BRIDGES EVENT, WHICH I
9 THOUGHT WAS WONDERFUL. IT'S AN AMAZING EXAMPLE OF
10 WHAT YOU CAN DO WITHOUT ANY VISUALS, WITHOUT ANY
11 POWERPOINT, WITHOUT ANY PROPS. IT WAS JUST HER OWN
12 VOICE AND HER OWN STORY, AND IT WAS AN AMAZINGLY
13 POWERFUL THING TO BE PART OF, TO HEAR.

14 I THINK FOR THE STUDENTS IN THE ROOM IN
15 PARTICULAR IT'S REALLY IMPORTANT BECAUSE IT CUT
16 THROUGH AN AWFUL LOT OF THE CLUTTER AROUND THESE
17 EVENTS AND FOCUSED ON WHAT'S REALLY IMPORTANT, WHICH
18 IS THIS IS WHY WE DO THIS WORK, WHICH IS WHY YOU GET
19 INVOLVED IN STEM CELL RESEARCH IS TO FIND CURES,
20 FIND TREATMENTS FOR DISEASES WHERE CURRENTLY WE HAVE
21 NONE.

22 THE OTHER VIDEO THAT WE'VE BEEN WORKING ON
23 QUITE RECENTLY WAS FOR OUR ALPHA STEM CELL CLINIC
24 NETWORK, AND WE WORKED WITH DR. MILAN AND THE FOLKS
25 AT CITY OF HOPE, UCLA, AND UC IRVINE, AND UC SAN

BARRISTERS' REPORTING SERVICE

1 DIEGO ON THIS. AND THE OTHER THING IS JUST TO LET
2 PEOPLE KNOW WHAT THE ALPHA STEM CELL CLINIC NETWORK
3 IS AND WHY YOU NEED A SERIES OF SPECIALIST CLINICS
4 TO ADMINISTER STEM CELLS AND THE ADVANTAGE OF HAVING
5 A NETWORK TO SUPPORT THAT AND TO EXPAND BEYOND JUST
6 WHAT EACH INDIVIDUAL CLINIC IS DOING. HOPEFULLY
7 THIS IS SOMETHING -- THIS IS JUST A FIRST STEP IN
8 WHAT WILL BE A MUCH BIGGER NETWORK AS THE VIDEO
9 HELPS TO, I THINK, EXPLAIN THAT.

10 AND THEN FINALLY, THIS IS THE NEWEST
11 MEMBER OF OUR COMMUNICATIONS TEAM OF THE CIRM TEAM.
12 IT'S DR. KAREN RING. SHE'S GOING TO BE OUR NEW
13 WEBSITE AND SOCIAL MEDIA MANAGER. THE T-SHIRT SHE'S
14 WEARING IS SAGE. AND THAT'S THE GROUP SHE HELPED
15 FOUND AT THE BUCK INSTITUTE FOR RESEARCH ON AGING
16 WHERE SHE CURRENTLY WORKS. DR. RING COMES TO US
17 FROM -- SHE HAS A PH.D. IN NEURODEVELOPMENT AND STEM
18 CELL RESEARCH AT UCSF, AND SHE'S DOING A FELLOWSHIP
19 AT THE BUCK AT THE MOMENT, AND SHE'S FINISHING THAT
20 UP. BUT SHE'S ALSO BEEN AN AVID BLOGGER AND
21 COMMUNICATIONS PERSON, AND I THINK SHE'S GOING TO BE
22 A TERRIFIC ADDITION TO THE TEAM, AND WE'RE LOOKING
23 FORWARD TO HAVING HER JOIN US EARLY NEXT MONTH.

24 WITH THAT, I'M HAPPY TO TAKE ANY
25 QUESTIONS.

BARRISTERS' REPORTING SERVICE

1 CHAIRMAN THOMAS: ANY QUESTIONS FOR
2 MR. MCCORMACK?

3 DR. BURTIS: WILL MS. MILLER'S
4 PRESENTATION BE AVAILABLE?

5 MR. MC CORMACK: YES. THANK YOU FOR
6 REMINDING ME. YES, WE DID ACTUALLY VIDEOTAPE IT,
7 AND WE'RE GOING TO BE POSTING IT ON OUR WEBSITE
8 FAIRLY SOON. IT WAS A WONDERFUL PRESENTATION, AND
9 IT'S WORTH SHARING WITH AS MANY PEOPLE AS WE CAN.

10 CHAIRMAN THOMAS: I WOULD ECHO THAT ON ALL
11 SORTS OF LEVELS. IT RESONATED A LOT WITH THE
12 STUDENTS BECAUSE THEY'RE FAIRLY CLOSE IN AGE AND
13 RELATED TO LAUREN AND, OF COURSE, THE WORK SHE'S
14 DOING WITH HILARITY FOR CHARITY TO RAISE MONEY FOR
15 ALZHEIMER'S RESEARCH WITH HER HUSBAND SETH RHOGAN.
16 HER STYLE, THE WAY SHE PRESENTED WAS SO GOOD, AND
17 JUST IT WAS VERY MUCH HER AND HER OWN WORDS AND JUST
18 IT WAS GREAT IN EVERY RESPECT. AND EVERYBODY IN THE
19 ROOM JUST RESPONDED TO IT WITH GENUINE SORT OF
20 HEARTFELT APPRECIATION FOR WHAT SHE WAS SAYING. SO
21 I RECOMMENDED THAT SHE BE MADE A PERMANENT MEMBER OF
22 THE PRESENTERS AT THE BRIDGES CONFERENCE EVERY YEAR.
23 IT WAS WONDERFUL.

24 MR. MC CORMACK: WHAT WAS SO GREAT ABOUT
25 IT WAS THAT SHE STARTED OUT TALKING ABOUT HER

BARRISTERS' REPORTING SERVICE

1 GRANDFATHER AND HOW AS A SIX-YEAR-OLD SHE THOUGHT
2 THAT HIS INABILITY TO REMEMBER ANYTHING, HIS
3 TENDENCY TO SAY THE SAME THING OVER AND OVER AGAIN
4 WAS FUNNY. AND PEOPLE WERE LAUGHING ALONG WITH HER.
5 IT WAS AMAZING. AND THEN WHEN SHE TALKED ABOUT WHAT
6 HAPPENED TO HER GRANDMOTHER AND THEN HER MOTHER, THE
7 ROOM GOT QUIETER AND QUIETER UNTIL THE POINT WHERE
8 YOU COULD HEAR THE AIR CONDITIONING BECAUSE THE
9 PEOPLE WERE SO RAPT AND SO ATTENTIVE. IT WAS JUST A
10 WONDERFUL WAY OF DRAWING THEM IN, INTRODUCING THEM
11 TO THE KIND OF COMPLEXITY OF A DISEASE LIKE
12 ALZHEIMER'S AND THE NEED FOR RESEARCH TO FIND
13 TREATMENTS. IT WAS JUST WONDERFUL.

14 DR. BURTIS: NICE TO BE ABLE TO SHARE THAT
15 WITH STUDENTS ACROSS THE STATE.

16 CHAIRMAN THOMAS: YES. ABSOLUTELY. VERY
17 GOOD IDEA.

18 MR. ROWLETT: ONE QUICK COMMENT ON THE
19 ANNUAL REPORT. THIS IS ACTUALLY VERY USEFUL. THIS
20 PARTICULAR REPORT, FORGIVE THE SARCASTIC
21 INTRODUCTION, THIS ONE I'LL ACTUALLY READ AND HAND
22 OUT TO PEOPLE. AND THE FACT THAT YOU WERE VERY
23 SENSITIVE TO THE CONSTITUENTS IN OUR STATE AND
24 PREPARED IT IN SPANISH I THINK IS EVEN MORE
25 EQUIPMENT FOR A BOARD MEMBER. SO WELL DONE ON THE

BARRISTERS' REPORTING SERVICE

1 ANNUAL REPORT, DR. MILLS. GOOD WORK BY THE TEAM.

2 GOOD WORK.

3 MR. MC CORMACK: WE USED TO HAVE THEM THAT
4 WERE MUCH LONGER, FAIRLY THICK VOLUMES.

5 MR. ROWLETT: SARCASTIC INTRODUCTION.

6 MR. MC CORMACK: THOSE WERE THE KIND OF
7 BOOKS THAT WE HAVE BOXES AND BOXES IN THE STORAGE
8 CUBBY. NO ONE WANTS TO READ A TEN-PAGE LETTER FROM
9 THE PRESIDENT. DR. MILLS PERFORMS GOOD WORK. SO
10 THE IDEA WAS TO PRODUCE SOMETHING THAT SOMEONE WOULD
11 ACTUALLY READ RATHER THAN KIND OF LOOK AT AND SAY
12 OH, THANKS. WE'LL RECYCLE.

13 CHAIRMAN THOMAS: ANY OTHER COMMENTS FOR
14 MR. MCCORMACK? WELL, WITH THAT, WE STAND ADJOURNED.
15 WE'LL LOOK FORWARD TO SEEING EVERYBODY IN SEPTEMBER.
16 AND EVERYONE HAVE A WONDERFUL REST OF YOUR SUMMER.
17 THANK YOU VERY MUCH.

18 (THE MEETING WAS THEN CONCLUDED AT
19 02:04 P.M.)

20

21

22

23

24

25

BARRISTERS' REPORTING SERVICE

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

OAKLAND MARRIOTT CITY CENTER
1001 BROADWAY
OAKLAND, CALIFORNIA
ON
JULY 23, 2015

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152
BARRISTERS' REPORTING SERVICE
160 S. OLD SPRINGS ROAD
SUITE 270
ANAHEIM, CALIFORNIA
(714) 444-4100